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Abstract
With the rising incidence of diabetic retinopathy (DR), there is an urgent need for
novel therapies. Presently, several altered metabolic pathways have been implicated in
the pathogenesis of DR. Recent advances in genomic technologies have identified
considerable epigenetic alterations that also contribute to DR progression. Long noncoding RNAs (lncRNAs; >200 nucleotides), critical regulators of gene expression, are
aberrantly expressed in DR and have not been comprehensively characterized. Our
microarray analyses using human retinal endothelial cells (HRECs) revealed
thousands of differentially expressed lncRNAs following high glucose (HG) exposure,
with profound increases in the lncRNAs MALAT1 and HOTAIR. Using multiple
techniques, I sought to elucidate the roles of these two molecules in inflammation and
angiogenesis during DR. My findings demonstrated that MALAT1 is upregulated in
HG and in diabetic animals, and regulates inflammatory transcripts (IL-6 and TNF-α)
through its association with polycomb repressive complex 2 (PRC2). Vitreous humors
from diabetic patients revealed parallel findings. DNA methylation array analyses did
not demonstrate significant alterations at CpG sites across the MALAT1 gene, but
inhibition of DNA methyltransferases significantly increased MALAT1 and associated
inflammatory transcripts. Furthermore, HG upregulated HOTAIR and angiogenic
transcripts (VEGF-A and ET-1) in HRECs and promoted an association with RNAbinding proteins, P300 and EZH2. HOTAIR knockdown reduced the expressions of
angiogenic cytokines, EZH2 and P300. HG did not induce significant hypomethylation
in HOTAIR CpG regions, while inhibitors for histone methylation, DNA methylation
and HOTAIR significantly impacted VEGF-A and ET-1 expressions. HOTAIR
expressions were elevated in the vitreous of DR patients and in the retinas of diabetic
rodents. HOTAIR knockdown reduced HG-induced oxidative DNA and mitochondrial
damage. The studies were further extended to delineate how these epigenetic
mechanisms influence the regulation of a specific vasoactive factor, ET-1, in DR.
DNA methylation array demonstrated hypomethylation in the ET1 promoter in HG.
Blocking DNA methylation or histone methylation significantly increased ET-1
mRNA expressions in control and HG-treated HRECs; while, knocking down
pathogenetic lncRNAs (MALAT1 and HOTAIR) subsequently prevented glucoseii

induced ET-1 upregulation. Collectively, I uncovered a novel epigenetic paradigm that
demonstrates a complex web of epigenetic mechanisms that regulate glucose-induced
transcription of molecules in important pathological processes (inflammation and
angiogenesis) during DR.
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Summary for Lay Audience
Background: Diabetic retinopathy (DR) is a serious eye complication that arises from
both type 1 and 2 diabetes and is the leading cause of blindness among working-age
adults in North America. To develop a better understanding of the processes involved
in the advancement of DR, researchers are currently focusing on the ‘epigenetic
phenomena’, which include any process that changes gene activity without making
changes to the DNA sequence. In recent years, the field of epigenetics has shown that
a special group of RNA molecules called long non-coding RNAs (lncRNAs) may be
controlling many processes in cancer and heart disease. Although the expressions of
several lncRNAs have been shown to increase in diabetes, the exact mechanisms of
how certain lncRNAs contribute to the progression of DR are not known.
Hypothesis: In this study, we will test the hypothesis that two unique lncRNAs,
known as MALAT1 and HOTAIR, control inflammation and abnormal blood vessel
growth that take place in diabetic retinopathy.
Methods: We will investigate the expressions of MALAT1 and HOTAIR using the
vitreous fluid from the eyes of diabetic patients (type 1 and type 2) and study the
functions of these lncRNAs in different cell culture and animal models.
Expected Results and Significance: Results from this study will provide a better
understanding on how lncRNAs can control inflammation and blood vessel growth in
DR. We may use our findings to develop better therapies that can specifically target
these disease-causing lncRNAs and ultimately reduce inflammation and abnormal
blood vessel growth from happening, which are associated with severe diabetic eye
damage.
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Chapter 1 i

1

Diabetic retinopathy

With nearly 642 million people projected to live with diabetes in the year 2040, the
risk for developing diabetes-related complications will drastically increase [1].
Diabetes mellitus (DM) is a chronic degenerative metabolic disease that is
characterized by sustained hyperglycemia. Hyperglycemia correlates with a number of
DM-related complications and is one of the preeminent factors for causing vascular
damage in the human body [2, 3, 4]. The majority of diabetic complications can be
viewed as either microvascular disease (small vascular injury) or macrovascular
disease (large vessel injury) [4, 5]. Diabetic retinopathy (DR) remains the most
prevalent chronic microvascular complication of DM [6, 7]. This debilitating ocular
condition is also the leading cause of blindness in the working-age population in
industrialized countries [7, 8]. The relationship between DR and diabetes has been
reported in several studies with the majority of type 1 diabetic patients and over 60%
of patients with type 2 DM developing evidence of DR within 20 years of diagnosis
[9-14]. With the incidence of visual impairment due to DR strongly related to the
duration of diabetes, DR remains asymptomatic to patients until the pathology
significantly progresses [14, 15]. In this chapter, I will first highlight both clinical and
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pathological features of DR and then discuss our current understanding of the
mechanisms involved in the pathogenesis of DR in diabetes.

1.1 Clinical features
To impede the progression of non-vision threatening DR to vision-threatening DR,
distinct clinical features must be noted in the early stages of DR in order to implement
appropriate treatments plans.

1.1.1

Non-proliferative diabetic retinopathy (NPDR)

The earliest stage of disease progression in DR is known as non-proliferative DR
(NPDR). Although hyperglycemia-induced damage to endothelial cells and capillary
pericytes in the retinal microvasculature are associated with the preclinical stages of
DR, the loss of these cells underlies a number of clinical features in NPDR. These
clinical features are characterized by microvascular abnormalities that consist of
microaneurysms, intraretinal hemorrhages (dot and blot), increased retinal vascular
permeability, nerve fiber layer infarcts (cotton wool spots), greater presence of
intraretinal lipid deposits (hard exudates), and venous beading [16-19]. NPDR can be
categorized into mild, moderate, severe, or very severe stages based upon the absence
or presence of the aforementioned clinical features (Figure 1.1). In the natural course
of DR, the severity of retinal vascular occlusion increases, which in turn leads to
impaired perfusion and retinal ischemia [19, 20]. The sequelae of increasing ischemia
include various venous abnormalities and considerable retinal vascular leakage that is
markedly distinguished by the increased presence of hard lipid exudates and retinal
hemorrhages [20]. Once the progression of these features surpasses clinically defined
thresholds, severe NPDR is diagnosed. During this stage, the risk of progression to
proliferative diabetic retinopathy heightens. Among the severe NPDR patients, nearly
50% will develop proliferative diabetic retinopathy (PDR) within one year and 15%
will develop high-risk PDR [21, 22, 23]. Whereas, 75% of patients classified with very
severe NPDR are at risk of developing PDR within one year and 45% will become
high-risk PDR during this period [22, 23].
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Figure 1.1. Respective clinical features of the various stages in diabetic retinopathy.
Diabetic macular edema, not depicted, can occur at any point during DR progression, which is
characterized by retinal thickening or hard intraretinal lipid exudates near the macula.
Reproduced from Pathogenetic Mechanisms in Diabetic Retinopathy: From Molecules to
Cells to Tissues (p. 213) by S. Biswas and S. Chakrabarti, 2017, Springer International
Publishing.

1.1.2

Proliferative diabetic retinopathy (PDR)

Once diabetic retinopathy advances to the proliferative stage, visual loss becomes
imminent if left untreated. In order to compensate for the sustained retinal ischemia,
one of the distinguishing clinical hallmarks of PDR is the presence of
neovascularization. The formation of abnormal vessels in the retinal circulation may
occur through both endothelial cell migration and proliferation on or near the optic
disc (neovascularization of the disk) or elsewhere in the retina (neovascularization
elsewhere), on the iris (neovascularization of the iris), or into the vitreous cavity of the
eye [24, 25]. Due to the fragility of the new vessels, the vessels become more
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susceptible to bleeding, leakage, fibrosis, and contraction, which can result in vitreous
hemorrhaging, retinal tears, and retinal detachment—crippling ocular complications
that inevitably lead to vision loss [26-29]. Further, neovascularization of the iris, also
known as rubeosis iridis, and neovascularization of the anterior chamber angle can
lead to neovascular glaucoma, a painful ocular disease that may even necessitate
enucleation of the affected eye [30].

1.1.3

Diabetic macular edema (DME)

Diabetic macular edema (DME) represents a common vision-threatening complication
of DR that is defined as retinal thickening in the macular area [31-34]. Although DME
has three severity levels, DME can occur at any point during DR progression and
promotes the breakdown of the blood-retinal barrier via microaneurysms and
hyperpermeability of capillaries—causing lipids and plasma to be leaked into the
macula [31, 32, 33]. The increased presence of hard lipid exudates in close proximity
or at the center of the macula is associated with clinically significant macular edema
[34].

1.2 Pathological features of DR
There are five distinct vascular lesions underlying the DR response: dysfunctional
pericytes and endothelial cells, basement membrane thickening, retinal capillary nonperfusion, retinal neovascularization, and breakdown of the blood retinal barrier. Each
vascular disorder associated with DR is initiated by the microangiopathic properties of
the diabetic process, which mainly occurs through numerous growth factors that are
altered by the changing ocular environment [35]. In this section, we will discuss the
pathological features of DR in detail as the presence of one or more of these vascular
disorders will help us understand the pathogenetic mechanisms associated with DR.

1.2.1

Dysfunctional endothelial cells and pericytes

One of the earliest pathological features that occur in DR are alterations in the
microvasculature, which consist of modifications in cellular structure [35, 36]. Two
essential cell types in the microvasculature are pericytes and endothelial cells, and the
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interaction between these cells is pivotal in the proper regulation of retinal
hemodynamics and vascular function [36, 37]. With endothelial cells comprising the
endothelium, which is the thin monolayer covering found in the interior surface of all
blood vessels, retinal endothelial cells must ensure that proper nutritional requirements
and protection of the ocular tissues, critical to vision are met [38, 39]. The general
structure of the endothelium in the retinal microvasculature consists of adjoining
endothelial cells that are linked by adherens junctions and tight junctions, which
constitute much of the blood-retinal barrier (BRB) [40, 41, 42]. An essential
prerequisite in the development of diabetic retinopathy is the loss of endothelium
integrity caused by chronic hyperglycemic exposure. Following endothelial cell
damage, the interendothelial junctions are unable to maintain the precise permeable
properties that necessitate proper BRB function [43]. Therefore, the presence of
dysregulated endothelial cell-to-cell junctions in the BRB allows for the extravasation
of plasma constituents into the retina. Moreover, diabetic animal models have
demonstrated that the apoptosis of retinal endothelial cells is enhanced by the
activation of the Fas/Fas ligand (FasL) pathway upon leukocyte adhesion to the
vascular endothelium [44].
In the context of maintaining vascular homeostasis, pericytes are important
multifunctional cells that serve to stabilize blood vessels, form the BRB, regulate
blood flow, and are involved in angiogenesis, endothelial proliferation, and leukocyte
recruitment [45, 46]. Pericytes are situated on the abluminal surface of blood
capillaries and are morphologically characterized as cells that possess finger-like
projections, which extend along the capillary wall and wrap around endothelial cells
[47, 48, 49]. While there are several intricate signalling pathways involved in the
interaction between pericytes, astrocytes, and endothelial cells, the intercellular
communication between endothelial cells and pericytes appears to determine the
presence of pericytes on retinal microvessels [50]. One prominent signal transduction
pathway utilized between pericytes and endothelial cells is the platelet-derived growth
factor-BB-platelet-derived growth factor receptor subunit B pathway (PDGF-BBPDGFRß) [50, 51]. During angiogenic or hypoxic stress, endothelial cells secrete
PDGF-BB, which binds to the pericyte-specific PDGFRß with a strong affinity [52,

6

53]. Upon binding, the receptor is dimerized, autophosphorylated, and activated,
which then further initiates the downstream cascade of PDGF-BB signalling, leading
to pericyte survival, migration, proliferation, attachment, as well as leukocyte
trafficking [54, 55]. In the case of diabetic retinopathy, both in vitro and in vivo studies
have shown that hyperglycemic stress induces dysfunctional PDGF-BB-PDGFRß
signalling, consequently leading to pericyte apoptosis and failure of proper pericyte
recruitment [55, 56, 57]. The inability to replace damaged retinal pericytes will
ultimately lead to aberrant retinal vascular morphologies, increased development of
microaneurysms, endothelial cell hyperplasia, and blood-retinal barrier breakdown
[58, 59]. Nevertheless, the loss of pericytes coupled with endothelial cell apoptosis
contributes to the formation of acellular, nonperfused capillaries, which are tubes of
basement membranes devoid of cell nuclei [44].

1.2.2

Basement membrane thickening

The vascular basement membrane (BM) is a thin extracellular sheet-like structure,
comprised of numerous components (including types IV and V collagen, laminin,
fibronectin (FN), nidogen, heparan and chondroitin sulfate proteoglycans), that exists
between pericytes and endothelial cells [60]. The methodical arrangement of the BM
components and molecular interactions between them manages cell survival and
provides both a selective permeability barrier and physical support for cell attachment
[61-64]. Early induction of hyperglycemia can provoke BM thickening in retinal
capillaries through accelerated synthesis and decreased degradation of BM
components, which can contribute to the occlusion of capillaries [64, 65]. More
specifically, hyperglycemic conditions heighten the mRNA expression of FN, laminin
(subunits beta-1 and gamma-1), and types IV (alpha-1 and alpha-2), and V collagen in
the retinal BM of both diabetic animals and patients, which can be detected long
before the onset of morphological lesions due to DR [65-68]. Further, any alterations
in the vascular BM structure or its components may have detrimental effects on its
ability to prevent vascular permeability, consequently leading to the development of
macular edema [69, 70]. Since the careful balance between synthesis and degradation
of BM components to sustain proper BM turnover is disrupted in DR, an
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understanding of the mechanisms perpetuating BM thickening and accumulation of
BM components is essential and will be later described in this chapter. The underlying
mechanisms possibly include increases in protein kinase C (PKC) activity, polyol
pathway flux, inflammation, advanced glycation end-product (AGE) accumulation,
endothelin activity, and growth factor activity [71-78].

1.2.3

Breakdown of the blood-retinal barrier

The preservation of the blood-retinal barrier (BRB) is a mandatory requirement for
proper vision. Compromised BRB integrity can result in numerous ocular pathologies
that can have irreparable damage to one’s visual perception; therefore, elucidation of
the BRB structure is required. The BRB consists of both an inner and outer retinal
barrier that serves to maintain a specialized environment for the neural retina [79]. In
the inner BRB, retinal capillary endothelial cells form the inner lining of microvessels
and are accompanied by pericytes, astrocytes, and glial cells (Müller cells) (shown in
Figure 1.2) [80]. These endothelial cells are linked together via junctional complexes
that facilitate the transport of highly selective molecules between the circulating blood
and the neural retina through either transcellular or paracellular routes [81]. Retinal
pericytes and astrocytes also interact with the endothelial cells to provide vascular
integrity [82]. On the contrary, the outer BRB is comprised of retinal pigment
epithelial cells that are connected by tight junctions; the primary role of the outer BRB
is to sustain homeostasis in the outer retina [83]. During DR, however, hyperglycemic
conditions result in both structural and functional alterations to the barrier, which
subsequently leads to both inner and outer BRB breakdown (Figure 1.3). Following
BRB damage, large amounts of plasma protein begin to extravasate into the neural
interstitium, producing high oncotic pressures that will eventually contribute to
macular edema [84]. As a result of chronic hyperglycemia, several known factors are
implicated in BRB disruption: dysfunctional endothelial cells, pericytes, Müller cells,
and astrocytes, increased levels of VEGF, hypoxia, oxygen-free radicals,
inflammatory mediators, advanced glycated end products, and protein kinase C
activity [85].
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1.2.4

Retinal capillary non-perfusion

Satisfying the high metabolic demands of the retina requires the maintenance of
adequate tissue perfusion, which ultimately preserves retinal function. The cessation of
blood flow to certain areas of the retina is known as capillary non-perfusion (CNP)
and this phenomenon is associated with occluded vessels, a consequence of glucoseinduced retinal vascular damage [86]. Chronic retinal ischemia is manifested as large
areas of CNP, which is the underlying cause of retinal neovascularization [87]. In the
severe stages of non-proliferative DR (NPDR), the considerable presence of hypoxic
regions resulting from retinal microvascular abnormalities can stimulate the retinal
endothelial cells to release proinflammatory cytokines [88]. The subsequent release of
cytokines perpetuates retinal hypoxia by recruiting and activating leukocytes, which
adhere to the vascular endothelium—contributing to retinal capillary impedance [89,
90]. In the case of chronic retinal hypoxia, the heightened activation of several
abnormal biochemical pathways induces the expression of numerous vasoactive
factors [91]. These factors are instrumental in capillary dropout and the development
of retinal neovascularization—a distinctive clinical feature of proliferative DR (PDR)
[92]. Although the exact mechanisms of how retinal ischemia elevates the expression
of vasoactive factors still require further elucidation, studies within the past decade
have revealed that the activation of specific transcription factors increase a variety of
vasoactive mediators implicated in the progression of DR [93-98].
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Figure 1.2. An illustration depicting a stable inner blood-retinal barrier in a healthy
patient. The integrity of the endothelium is maintained by the presence of functional adherens
junctions and tight junctions. Gap junctions authorize the passage of small molecules, and are
predominantly located between pericytes and endothelial cells. Furthermore, Müller cells
provide mechanistic support to the neural retina and also sustain balance of the extracellular
environment in the retina. While, retinal astrocytes are involved in neuronal signaling and
assist in managing the barrier properties of endothelial cells. Reproduced from Pathogenetic
Mechanisms in Diabetic Retinopathy: From Molecules to Cells to Tissues (p. 217) by S.
Biswas and S. Chakrabarti, 2017, Springer International Publishing.
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Figure 1.3. An illustration depicting an unstable inner blood-retinal barrier in a patient
with advanced proliferative diabetic retinopathy. Chronic hyperglycemia compromises
BRB integrity through numerous factors, which are depicted by letters in this figure: (A)
Endothelial dysfunction, (B) Pericyte degeneration/apoptosis, (C) Basement membrane
thickening, (D) Retinal capillary non-perfusion, (E) Neural inflammation and dysfunctional
astrocytes, and (F) Retinal neovascularization. Reproduced from Pathogenetic Mechanisms in
Diabetic Retinopathy: From Molecules to Cells to Tissues (p. 218) by S. Biswas and S.
Chakrabarti, 2017, Springer International Publishing.

1.2.5

Retinal neovascularization

Angiogenesis is a critical physiological process in growth, development, and wound
repair that induces the neogenesis of blood vessels from pre-existing vessels.
However,

in

the

case

of

DR,

pathological

retinal

angiogenesis

(retinal

neovascularization) is a detrimental complication to vision. As observed in the mid-to
late-1900s, retinal neovascularization (NV) transpires parallel to areas of CNP
supporting the notion that vasoactive factors released from ischemic tissues are pivotal

11

in the development of pathological angiogenesis [99, 100, 101]. The discovery of
hypoxia-related transcription factors and their role in mediating angiogenesis has shed
more insight into the complicated pathogenesis of DR. The hypoxia-inducible factor
(HIF)-1α protein is one such transcription factor that is significantly accumulated in
the presence of low oxygen levels and subsequently upregulates numerous hypoxiaregulated gene products [102, 103]. Under normoxia, the tumor suppressor protein,
von Hippel-Lindau (VHL) binds to HIF-1α, targeting it for degradation through the
ubiquitin-proteasome pathway [104, 105]. In contrast, hypoxic conditions prevent
HIF-1α and VHL interaction, which subsequently results in HIF-1α to cumulate,
dimerise with HIF-1β, and translocate into the nucleus where it binds to the hypoxiaresponse elements in the promoters of vasoactive genes [106]. Following the
activation of transcription, multiple pro-angiogenic factors are then upregulated
including vascular endothelial growth factor (VEGF), placental growth factor (PLGF),
stromal derived growth factor (SDF-1), platelet-derived growth factor (PDGF-B), and
their receptors, and angiopoietin-2 (Ang-2) [107, 108]. In particular, VEGF not only
stimulates the development of endothelial cells, but it also induces both the
disassembly of endothelial cell-to-cell junctions, which drives vascular permeability,
and the sprouting of new vessels in combination with Ang-2 [108, 109]. Before
sprouting vessels develop, specific subsets of endothelial cells differentiate into either
tip or stalk cells [110]. The sprouting process is controlled through the antagonistic
actions of delta-like ligand 4 (Dll4) and Jagged1 ligands in the hypoxia-induced Notch
signalling pathway [111-114]. As Notch-Dll4 and VEGF-induced signalling increases,
the specialized endothelial tip cells direct the sprout vessel growth along a specific
VEGF gradient, comprised of VEGF-A that is detected by VEGF receptor-2 expressed
on the filopodia of these cells [115]. Although tip cells do not proliferate, the
proliferative activity of stalk cells is driven by the availability of VEGF, Ang-2, and
additional growth factors [116]. Together, the interaction between tip and stalk cells
and the surrounding pro-angiogenic factors stimulate the growth of new blood vessels
in the retina. It is important to note that within the retina, several cell types can
produce VEGF: endothelial cells, pericytes, Müller cells, astrocytes, and retinal
pigment epithelial cells [150]. To further emphasize the role of VEGF in DR, current
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treatment of DME using intravitreal injections of anti-VEGF agents have met with
success.

1.3 Biochemical and molecular mechanisms involved in
the pathogenesis of DR
Hyperglycemic insult gives rise to a diverse number of biochemical pathways that are
implicated in the pathogenesis of DR. As our knowledge over the years has
significantly developed in regard to the molecular mechanisms attributed to DR, more
theories begin to emerge and therefore expand and enrich our knowledge of
preexisting DR mechanisms. Currently, as shown in Figure 1.4, several
mechanisms/pathways that have an involvement in hyperglycemia-induced DR
progression have been proposed: polyol pathway, protein kinase C pathway,
hexosamine pathway, advanced glycation end-products formation, retinal reninangiotensin system, and inflammatory mechanisms that include neural-and-immunoinflammatory responses.

1.3.1

Polyol Pathway

Under normal glucose concentrations in non-diabetic patients, glucose metabolism
utilizing the polyol pathway comprises only a small portion of total glucose use [117].
However, the elevation of intracellular glucose concentrations under diabetic
conditions activates increased glucose flux through this pathway [118, 119]. Aldose
reductase, the initial and NAPDH-dependent enzyme present in the polyol pathway,
plays a critical role in the reduction of glucose to sorbitol [117, 118, 119]. Further
metabolization of sorbitol is completed by sorbitol dehydrogenase, using NAD+ as a
cofactor, which allows for the formation of fructose [120]. Hyperglycemic conditions
serve as a catalyst for enhancing aldose reductase activity, subsequently leading to
sorbitol agglomeration [119, 120]. Although the polyol pathway and its exact
mechanism in DR pathogenesis still remains inconclusive, several hypotheses have
been reported that can ultimately commence and augment cellular damage
mechanisms after the activation of the polyol pathway: changes in intracellular
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tonicity (osmotic stress) via the accumulation of sorbitol and fructose, development of
advanced glycation end-product precursors (methylglyoxal, fructose-3-phosphate, and
3-deoxyglucosone), decreased Na+/K+ ATPase activity, diminished cellular antioxidant defense mechanisms as a consequence of reduced glutathione levels, protein
kinase C (PKC) activation by elevated diacylglycerol (DAG) formation, and increased
generation of reactive oxidant species (ROS) through the hyperglycemic activations of
poly (ADP-ribose) polymerase and NADH oxidase [121-127].

Figure 1.4. Chronic hyperglycemia in DR gives rise to abnormalities in diverse
biochemical pathways, which ultimately contribute to and advance DR pathogenesis. The
application of a large initial stimulus, such as increased glucose levels, can activate a chain of
reactions that incorporate unique pathways: polyol, hexosamine, neural-and-immunoinflammatory, retinal renin-angiotensin, advanced glycation end-products, and protein kinase
C. The “*” in this figure signifies that reactive oxygen species (ROS) may regulate these
pathways to some extent. Reproduced from Pathogenetic Mechanisms in Diabetic
Retinopathy: From Molecules to Cells to Tissues (p. 221) by S. Biswas and S. Chakrabarti,
2017, Springer International Publishing.
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1.3.2

Protein Kinase C (PKC) Pathway

As hyperglycemia elevates DAG levels via the de novo pathway, the subsequent
elevation of this intracellular messenger activates several isoforms in the PKC family
that consists of serine/threonine kinases. More specifically, both in vitro and in vivo
experiments have shown that the hyperglycemic activation of PKC-β can mediate
VEGF-A levels and increase vascular permeability by phosphorylating endothelial cell
tight junction proteins. These tight junction proteins are then targeted for ubiquitinmediated protein degradation—contributing to blood-retinal barrier breakdown [128,
129]. PKC-β is also involved in altering nitric oxide (NO) production, endothelial
nitric oxide synthase (eNOS) expression, and endothelin-1 (ET-1) that consequently
supports abnormal retinal hemodynamics [130, 131]. While, on the other hand,
hyperglycemic activation of PKC-δ and Src homology-2-domain-containing
phosphatase-1 (SHP-1) has been reported to induce retinal pericyte apoptosis through
the nuclear factor-kappa B (NF-κB) signalling pathway [132]. The combined effects of
hyperglycemic stimulus and PKC-δ activation can additionally provoke increased
ROS generation, which will have detrimental consequences on retinal function [130133]. Furthermore, the link between PKC activation and increased mitogen-activated
protein kinase (MAPK) activity has been established—suggesting that the interplay
between several PKC isoforms and MAPK activity can lead to subsequent
phosphorylation of numerous transcription factors that heighten the expression of
multiple stress-related genes associated with DR pathogenesis [134].

1.3.3

Hexosamine Pathway

During intracellular glucose metabolism, the redirection of fructose-6-phosphate from
the glycolytic pathway to the hexosamine pathway (HSP) can ultimately induce
increased transcription of pro-inflammatory cytokines, insulin desensitization, and
oxidative stress—all of which are prominent features contributing to retinal neuronal
apoptosis [135-138]. Glutamine:fructose-6-phosphate amidotransferase (GFAT) is the
first and rate-limiting enzyme present in the HSP that catalyzes the conversion of
fructose-6-phosphate and glutamine to glucosamine-6-phosphate and glutamate,
respectively—preparing their entry into the HSP [139]. After a series of conversions,
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the major HSP end product is uridine diphosphate-N-acetylglucosamine, which
allosterically inhibits GFAT and serves as an important substrate for O-linked Nacetylglucosamine transferase to facilitate the process of O-linked glycosylation on the
serine and threonine residues of nucleocytoplasmic proteins [139-142]. In the context
of diabetes, hyperglycemia elevates both HSP flux and GFAT activity, which leads to
post-translational over modifications and subsequently alters the expression of
numerous genes implicated in DR pathogenesis. After all, O-linked glycosylation can
target transcription factors, signalling molecules, cofactors, and even RNA polymerase
II [143, 144, 145]. Although O-linked glycosylation may compete with
phosphorylation for the specific serine and threonine sites on a protein,
hyperglycemia-induced HSP activation has shown to elevate O-linked glycosylation
and reduce serine and threonine phosphorylation of the transcription factor Sp1 [146].
The successive glycosylation of Sp1 additionally increases the transcription of
transforming growth factor-beta1 (TGF-β1) and plasminogen activator inhibitor-1
(PAI-1)—assisting DR development [146, 147].

1.3.4 Formation of Advanced Glycation End-Products
(AGEs)
The perpetual exposure of hyperglycemia to the retina can cause the formation and
build-up of advanced glycation end-products (AGEs), which participate in endothelial
dysfunction, chronic inflammation, BRB breakdown and retinal neuronal degeneration
through a variety of mechanisms [148, 149]. The formation of AGEs is accomplished
in a series of sequential chemical reactions that initially begins with the non-enzymatic
interaction between carbonyl groups of intracellular glucose molecules (and other
reducing sugars) and the free amino groups of intracellular proteins [150]. As a result
of this interaction, an unstable compound known as a Schiff base is formed and then
by molecular rearrangement, a more stable compound (an Amadori product) is
constructed that later metabolizes to AGEs (an irreversible compound) [150, 151,
152]. Not only can the generation of AGEs modify and alter the function of
intracellular proteins, but AGE precursors can also diffuse out of a cell and modify
extracellular matrix components and their matrix receptors such as integrins, and
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circulating plasma proteins that greatly contribute to retinal microvascular leukostasis
[153-157]. The receptor for AGEs (RAGE) is ubiquitously expressed on multiple cell
types and the activation of RAGE, upon the binding of AGE precursors, activates and
enhances pro-inflammatory and pro-oxidant signal cascades involving MAPK, NF-κB,
activator protein-1 (AP-1), Janus kinase/signal transducers and activators of
transcription (JAK-STAT), phosphatidylinositol-3 kinase (PI3K), PKC, VEGF, and
tumor necrosis factor- alpha (TNF-α) [158-163].

1.3.5

Retinal Renin-Angiotensin System

The systemic renin-angiotensin system (RAS) is responsible for regulating blood
pressure and maintaining the balance of electrolytes. Within the last 30 years, research
has revealed that local RAS exists in various tissues (including the retina) that are
independent from the systemic RAS and play a role in sustaining local equilibrium
[164]. In the eye, the localization of RAS components are found to be predominantly
expressed on retinal microvessels (endothelial cells and pericytes), various glial cells
(Müller cells, astrocytes, and microglia), neurons (ganglion cells), and in other
structures, such as the choroid and ciliary epithelium [165]. In addition to their cellular
localization, distinct local RAS components have been implicated in ocular
pathogenesis. For example, studies have reported that DR patients have elevated
plasma and intraocular concentrations of prorenin, renin, angiotensin II, and
angiotensin-converting enzyme (ACE)—these levels additionally correlate with DR
severity [166-169]. Furthermore, in vivo experiments have reported that DR may have
an association with local RAS imbalances through the activation of the proinflammatory RAS axis (comprised of ACE, renin, the renin receptor, and angiotensin
II receptor type I) that promotes vasoconstriction and a subsequent reduction in the
vasoprotective axis (comprised of ACE2, angiotensin-(1-7), and Mas) of RAS [170].
Although the retinal RAS signalling mechanisms in DR still require further
elucidation, several studies have demonstrated that the activation of angiotensin II
receptor type I by angiotensin II facilitates the upregulation of VEGF/VEGFR-2
signalling [171, 172, 173]. This upregulation induces vascular permeability and retinal
neovascularization that assists in BRB breakdown [171, 172, 173].

17

1.3.6

Inflammatory Mechanisms

Although acute inflammation is generally the body’s natural way of protecting tissues
from physiological stress or pathological stimuli, chronic inflammation, however, can
mediate tissue destruction, enhance fibrosis, and drive angiogenesis. The persistence
of low-grade inflammation is a prominent feature of DR that is mediated by several
inflammatory mechanisms that can facilitate retinal vascular damage and
neovascularization. Nevertheless, insight into the mechanisms regulating immune-andneural-inflammation in DR pathogenesis is integral.

1.3.6.1

Immuno-Inflammatory Response

The immuno-inflammatory mechanisms involved in the ocular microenvironment
remain ambiguous, as recent findings only allude to the complex interplay between the
eye and the inflammatory system [174]. With the eye being an immune-privileged
tissue, the presence of the inner and outer BRB allow the eye to create its own
specialized microenvironment to suppress active inflammation and strictly regulate the
activity of resident intraocular immune cells [174, 175]. The unique composition of
the ocular immune microenvironment includes various immunosuppressive factors
such as TGF-β2, alpha-melanocyte-stimulating hormone (α-MSH), neuropeptides,
macrophage migration inhibitory factor (MIF), and vasoactive intestinal peptide (VIP),
which restrict the actions of immune-competent cells (macrophages, microglial cells,
dendritic cells, T-cells, and monocytes) [174-178]. During early NPDR stages, the
chronic activation of pattern recognition receptors, such as RAGE and toll-like
receptors expressed on immune-competent cells, can lead to the production of
abnormal pro-inflammatory cytokines, upregulation of adhesion molecules, activation
of other ocular resident immune cells, and increased retinal microvascular leukostasis
[179]. More specifically, DR increases the production of several key ligands (includes
high-mobility group box-1 (HMGB1) and AGEs) that greatly enhance RAGE
activation in the retina [180]. Following activation, RAGE can stimulate MAPK and
p38 signalling which in turn can trigger NF-κB transcription—contributing to proinflammatory cytokine production and ROS generation [181]. Heightened levels of
inflammatory cytokines can then recruit additional leukocytes (i.e., monocyte
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chemoattractant protein-1 (MCP-1)) and stimulate VEGF-A activation, which
upregulates the expression of adhesion molecules [182, 183]. Intercellular adhesion
molecule-1 is one of the upregulated adhesion molecules expressed on the surface of
retinal endothelial cells that facilitates the binding of leukocytes to the vascular
endothelium [183]. Upon binding, leukocytes generate ROS and additional
inflammatory cytokines that promote retinal vascular permeability—consequently
jeopardizing BRB integrity [184]. After all, maintenance of BRB integrity is critical
for the preservation of the intraocular anti-inflammatory immune environment.

1.3.6.2

Neural Inflammation

Neural inflammation plays a critical role in DR pathogenesis. The neural retina is
separated from retinal blood supply by the inner and outer BRBs and is an extremely
delicate nerve tissue that is mainly comprised of Müller cells, astrocytes, microglia,
and retinal ganglion cells [185]. Macroglial cells, which include Müller cells and
astrocytes, have critical functions in maintaining normal retinal physiology: ensuring
appropriate neuronal functioning by contributing metabolic and physical support
forming and maintaining BRB integrity, maintaining homeostasis in the extracellular
environment, and regulating retinal blood flow, metabolic waste product removal,
local immune responses, and retinal glucose metabolism [186]. In addition to
macroglial cells providing a local immune response, microglial cells also play an
important role in initiating and mediating appropriate intraocular immune responses.
Microglial cells are mononuclear phagocytes that are derived from the bone marrow
and represent the retinal innate immune cells as they use cytotoxic and phagocytic
mechanisms to eliminate foreign materials in the eye and lack specificity and memory
[187, 188]. On the other hand, retinal ganglion cells are involved in transmitting visual
information to pertinent brain centers that constructs our vision [189]. DR ultimately
alters the morphology and function of neural retinal components. For example, in the
early stages of DR, Müller cells can become extremely responsive to the
hyperglycemia-induced

retinal

changes

and

significantly

contribute

to

the

inflammatory environment by releasing VEGF and decreasing anti-angiogenic factors
(such as pigment epithelium derived factor (PEDF)) to promote retinal vascular
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permeability [190, 191]. Müller cells have also shown to induce RAGE activation,
interleukin-1β (IL-1β), interleukin-6 (IL-6), nitric oxide (NO), prostaglandin E2
(PGE2), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2)
levels by numerous signalling pathways (including MAPK/NF-κB signalling) when
exposed to high glucose in vitro—suggesting its roles in driving angiogenesis and
furthering inflammation implicated in DR [190-194]. In regard to astrocytes, in vivo
experiments have reported that astrocyte densities are significantly decreased in the
retinas of diabetic rats and astrocytes can potentially excrete various inflammatory
mediators (including TGF-α, COX-2, PGE2, and IL-1β) during hyperglycemic stress
[195-199]. DR can also alter microglial morphology and induce microglial
hyperactivity by RAGE activation—adding to the pro-inflammatory environment by
releasing key inflammatory mediators [200, 201, 202]. Moreover, chronic
hyperglycemia and accumulating levels of neurotoxic metabolites in the neuronal
environment can induce apoptosis in retinal neurons by compromising the function of
retinal ganglion cells [203].

1.4 Interconnection of the Pathways: Oxidative Stress
Although chronic hyperglycemia can provoke the involvement of multiple abnormal
biochemical pathways, research has revealed that these pathways are interconnected
by mitochondrial-derived ROS [153,154]. In aerobic cellular respiration, NADH and
FADH2 from the tricarboxylic acid (TCA) cycle are generated to donate electrons to
specific complexes in the electron transport chain (ETC)—NADH provides electrons
to complex I, while FADH2 supplies electrons to complex II [204]. The electrons from
both of these complexes are then shuttled through coenzyme Q, complex III,
cytochrome-C, and finally complex IV, where oxygen is reduced to water [205]. The
transfer of electrons through these complexes generates energy that is utilized to build
an electrochemical proton gradient across the inner mitochondrial membrane [206].
Energy acquired from the electrochemical gradient regulates the generation of ATP
through ATP synthase [206]. In the case of diabetes, however, elevated intracellular
glucose levels lead to increased glucose oxidation in the TCA cycle; therefore,
producing a substantial amount of electron donors that are then transported to the ETC
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[154]. Following the increase of electron donors, the voltage across the proton gradient
rises until a critical threshold is attained, which subsequently impedes the electron
transfer properties of complex III [207, 208] As a result of the complex III blockade,
superoxides are constructed at an elevated rate; since, coenzyme Q donates the
accumulated electrons to molecular oxygen [209]. The build-up of mitochondrialderived superoxides then creates breaks in the DNA strands that signals the activation
for PARP [210, 211]. Consequently, activated PARP inhibits the activity of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a critical enzyme present in the
cytosol and in the nucleus where it has a role in glycolysis and DNA repair,
respectively [211, 212, 213]. The reduced capability of cytosolic GAPDH prevents
glycolysis from completing, causing an aggregation of upstream glycolytic metabolites
such as glucose, fructose-6 phosphate, fructose 1,6-biphosphate, and glyceraldehyde
3-phosphate [154]. Depending on the biochemical pathway and its respective
glycolytic metabolite, the metabolites are subjected to additional modifications by
pathway-specific enzymes that ultimately activate the major biochemical pathways
previously mentioned in section 3 (shown in Figure 1.5). Nevertheless, although
experimental data supports that hyperglycemia activates several downstream
biochemical pathways and cellular aberrations that contribute to the pathogenesis of
DR, accumulating research within the last three decades is beginning to demonstrate a
strong role of epigenetics in such processes [214].
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Figure 1.5. Effects of reactive oxygen species (ROS) on a retinal endothelial cell and the
association of ROS with other biochemical pathways implicated in the pathogenesis of
diabetic retinopathy. To summarize, the presence of high glucose stimulates the increased
production of mitochondrial ROS, which induces breaks in DNA strands and activates poly
(ADP-ribose) polymerase (PARP). As a consequence of PARP activation, glyceraldehyde 3phosphate dehydrogenase activity is significantly reduced due to its interactions with PARP.
Dysfunctional glyceraldehyde 3-phosphate dehydrogenase results in the accumulation of
glycolytic metabolites upstream of this enzyme, which ultimately activates several
biochemical pathways. Note, the endothelial junctional complexes, the retinal reninangiotensin system, and the neural-and-immuno-inflammatory mechanisms are not shown in
this figure. Furthermore, there are additional mechanisms of ROS generation that can
subsequently contribute to cellular dysfunction. This figure only illustrates one of the ROS
mechanisms in retinal endothelial cells. Reproduced from Pathogenetic Mechanisms in
Diabetic Retinopathy: From Molecules to Cells to Tissues (p. 222) by S. Biswas and S.
Chakrabarti, 2017, Springer International Publishing.
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1.5 ‘Metabolic Memory’ and the Rise of Epigenetics
Despite improving glycemic control, the early exposure of hyperglycemia can still be
implicated in late complications and disease progression [215, 216, 217]. This
phenomenon is known as “metabolic memory” or “legacy effect” and was documented
in the Diabetes Control and Complications-Epidemiology of Diabetes Interventions
and Complications Trial (DCCT-EDIC), and the United Kingdom Prospective
Diabetes Study (UKPDS), respectively [215, 216, 217]. When diabetic patients are
transiently exposed to hyperglycemia, metabolic abnormalities such as ROS
generation, PKC activation, increased activation of the hexosamine pathway, AGEs
formation, and RAGE activation can affect epigenetic mechanisms by altering the
expression of target-specific genes in cells without modifying the DNA sequence [218,
219]. These heritable epigenetic alterations can still facilitate DR pathogenesis despite
the achievement of normoglycemia as epigenetic modifications can sustain constant
activation of pro-inflammatory genes [220, 221]. The involvement of epigenetic
changes in diabetes, cancer, and heart disease stresses the importance of understanding
how epigenetic modifications lead to the manifestation of these diseases [221, 222,
223]. Major epigenetic modifications that are being explored in depth include DNA
methylation, histone modifications, and the activity of non-coding RNAs [224, 225].

1.5.1

DNA Methylation

Although the epigenetic modifications of DNA remain elusive, studies have reported
that DNA methylation is typically associated with the silencing of gene transcription
through the covalent addition of a methyl group on the fifth position of cytosine
residues within CpG dinucleotide clusters (CpG Islands) [226, 227]. Moreover, the
DNA methylation reaction involves the interaction between two enzymes that oppose
each other: DNA methyltransferases (DMNTs) that create and sustain methylated
DNA patterns, and DNA demethylases that remove methyl groups, such as the teneleven translocase (TET) enzyme [228]. In the context of diabetes, increases in DMNT
have been reported with DMNT1, a maintenance enzyme among the three major types
of DMNT, activity heightened in retinal capillary cells [229]. Further, new research
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has shown that TET2 is activated in diabetes and its activation demonstrates increased
binding at the promoter region of matrix metalloproteinase-9 (MMP-9)—establishing
a hypomethylated state in the MMP-9 promoter [230]. Due to the novelty of DNA
methylation, the exact mechanisms of how the DNA methylation machinery assists
DR pathogenesis remains unclear.

1.5.2

Histone Modifications

Histone modifications are one of the better-characterized epigenetic mechanisms in
DR. The nucleosome is the fundamental subunit that allows for the composition of
chromatin, a tightly packaged structure that contributes to the final structure of
eukaryotic chromosomes. Individual nucleosomes consist of an octamer of histones,
two molecules of each histone protein (H2A, H2B, H3, and H4), encased by
approximately 147 base pairs of DNA [231, 232]. Nucleosomes are prone to rapid
adjustments from external stimuli [231, 232, 233]. More specifically, the core histones
possess N-terminal tails where a large number of post-translational modifications can
occur by targeting the amino acid residues in this area [233, 234]. Below, we will
focus on the most common covalent histone modifications associated with gene
expression and transcription in DR: histone acetylation and histone methylation [235].

1.5.2.1

Histone Methylation

In order for histone methylation to occur, histone methyltransferases (HMTs) are
required to facilitate the transfer of methyl groups to amino acid residues including
arginine and lysine residing in the N-terminal tails of histones [235, 236]. While, on
the other hand, histone demethylases (HDMCs) possess the capacity to remove methyl
groups from this area [237]. It is important to note that select amino acid residues
(such as lysine) can be methylated using one, two, or three methyl groups [220, 237].
Depending on the type of stimulus present, the over-modifications performed by either
HMTs or HDMCs on these amino acid residues will dictate chromatin accessibility to
transcriptional factors that subsequently regulates the expression of specific genes and
their respective translated products [231]. For example, studies have reported that the
methylation of specific lysine residues, such as lysines 9 and 27 in histone H3 and
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lysine 20 in histone H4 are associated with suppressed gene activity [236-239]. In
contrast, methylation of lysines 4, 36, and 79 in histone H3 are associated with active
gene regulation [236-239]. Moreover, epigenetic-related in vitro and in vivo
experiments have demonstrated that diabetic conditions elevate the activity of lysinespecific demethylase 1 (LSD1), a type of HDMC, that hypomethylates lysine 9 in
histone H3 at the promoter region of the MMP-9 gene [240]. Following
hypomethylation of lysine 9, this amino acid residue is then subjected to increased
acetylation that promotes NF-κB transcription—contributing to elevated MMP-9
activity that evokes retinal mitochondrial damage and apoptosis in retinal capillary
cells [240]. Other hyperglycemic studies have also reported decreased activity of the
manganese superoxide dismutase gene (SOD2) by increased methylation of lysine 20
in histone H4, which subsequently increases retinal oxidative stress [241, 242].
Furthermore, a multimeric complex known as polycomb repressive complex 2 (PRC2)
plays a critical role in epigenetic regulation as it is associated with gene suppression
including microRNAs (miRNAs) by tri-methylating lysine 27 of histone H3 [243,
244]. Previous work completed by our laboratory studied the role between PRC2 and
miR-200b in DR, but we will discuss the detailed findings in the subsection discussing
small non-coding RNAs.

1.5.2.2

Histone Acetylation

In addition to methylation, histones can also be acetylated. The acetylation process
involves the interactions between histone acetyltransferases (HATs) and histone
deacetylases (HDACs) that facilitates either the addition or removal of acetyl groups
to lysine residues, respectively [245, 246]. More specifically, the acetylation of lysines
9, 14, 18, and 56 in histone H3 and lysines 5, 8, 13, and 16 in histone H4 are
speculated to have a role in chromatin relaxation that augments transcription factor
recruitment—subsequently contributing to gene activation [220, 247]. The direct
modification of regulatory proteins and transcription factors can also occur by HATs
and HDACs [247]. To further demonstrate the importance of HATs in DR, previous in
vitro and in vivo work from our laboratory demonstrated that P300, a transcriptional
coactivator that is also a HAT, was markedly expressed in a diabetic environment and
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its increase in activity led to the overexpression of ET-1, VEGF, and FN—molecules
that are upregulated in DR [248, 249]. On the other hand, sirtuin (silent mating type
information regulation 2 homolog) 1 (SIRT1) is an important NAD-dependent
deacetylase that is implicated in a dynamic range of cellular processes [250, 251, 252].
Due to its unique localization in both the nucleus and cytoplasm, SIRT1 is categorized
as a type III HDAC [252]. In vitro and in vivo results from our laboratory
demonstrated that chronic hyperglycemia reduces SIRT1 activity, which consequently
drives ROS formation mediated by the acetylation of forkhead box protein O1
(FOXO1) through increased P300 activity [253].

1.5.3

The Emergence of Non-Coding RNAs

When the sequencing results materialized from the Human Genome Project, it become
evident that the majority of our genome (>98%) is comprised of non-protein coding
DNA, while less than 2% of the total genomic sequence is represented by proteincoding regions (amounts to ~20,000 protein-coding genes) [254, 255]. Furthermore, as
demonstrated through genomic tiling arrays and large-scale cDNA cloning projects
[255, 256], the process of transcription is pervasive throughout the mammalian
genome and is not only restricted to protein-coding regions. In fact, more than 90% of
our genome is transcribed and the resulting output of transcription produces a dynamic
network of transcripts that includes thousands of non-protein-coding RNAs [255, 257].
Due to the breadth of information that can now be found on different classes of noncoding RNAs (ncRNAs), I will provide insight into some of the known functions of
certain small and long ncRNAs, and their implications, in the pathogenesis of DR
below.

1.5.3.1

Small Non-Coding RNAs

Although there are several classes of small non-coding RNAs (sncRNAs), microRNAs
(miRNAs) are an extensively studied class in the context of disease, which will be the
primary focus in this section. Being a class of small, endogenous, single-stranded,
non-coding RNA molecules, active miRNAs typically range from 20 to 25 nucleotides
in length and post-transcriptionally regulate gene expression [258, 259, 260]. The
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initial synthesis of primary miRNA molecules transpires in the nucleus where they are
synthesized by RNA polymerase II and are several kilobases long [260, 261].
Similarly, within the nucleus, RNA polymerase III enzymes, Drosha and DiGeorge
syndrome critical region 8 (DGCR8), further processes these primary miRNA
molecules into precursor miRNAs that are roughly 70 to 100 nucleotides in length and
hairpin-shaped [260-265]. Following processing, exportin 5, a nuclear export factor,
facilitates the transport of precursor miRNAs into the cytoplasm [264, 265]. Once
reaching the cytoplasm, another RNA polymerase III enzyme, DICER, modifies the
precursor miRNAs into their active miRNA forms, where they are then incorporated
into the RNA-induced silencing complex (RISC) with the help of argonaute proteins
[263, 264, 265]. The formation of RISC then binds to the targeted mRNA by
interacting with its 3’ untranslated regions (3’-UTR) [260-265]. As a result of this
binding, the targeted mRNA is subjected to either repressed translation or degradation
[260-265]. Earlier reports from our laboratory identified alterations of several
miRNAs in hyperglycemia-induced endothelial cells and in numerous tissues affected
by chronic diabetes: miR-1, miR-133a, miR-146a, miR-195, miR-200b, and miR-320
[39, 266-272]. Moreover, our recent findings report a novel regulation mechanism
between PRC2 and miRNAs through histone methylation in diabetic complications.
For instance, human retinal microvascular endothelial cells exposed to hyperglycemia
and diabetic mice and rat retinas demonstrated heightened PRC2 activity, which in
turn regulated the repression of miR-200b through tri-methylation of lysine 27 in
histone H3 [270, 271]. Subsequently, reduced miR-200b levels promoted increased
VEGF levels—contributing to vascular permeability and neovascularization [270,
271]. In addition to these findings, previous studies from our laboratory reported that
miR-146a and miR-200b play an integral role in preventing glucose-induced
endothelial-to-mesenchymal

transition

(EndMT),

a

pathogenetic

mechanism

implicated in diabetic complications that induces basement membrane thickening by
accelerating the production and deposition of extracellular matrix proteins [39, 268].
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1.5.3.2

Long Non-Coding RNAs

Long non-coding RNAs (lncRNAs) are a fundamental class of RNA molecules that
are defined by their length (greater than 200 nucleotides) and limited protein-coding
capacities. LncRNAs have putative roles in both biological (i.e. embryonic
development [273] and pathological processes [274] and can take on unique regulatory
capacities when governing the expression of genes (Table 1.1). Moreover, certain
lncRNAs may execute more than one mechanism and present with specific
functionalities depending on their subcellular localization. For instance, lncRNAs that
are localized in the cytoplasm are generally involved in post-transcriptional
modifications that govern the stability and translation potential of mRNAs [275];
whereas, lncRNAs primarily residing in the nucleus have implications in organizing
nuclear architecture [276], alternative splicing [277], and transcriptional regulation
[278]. Interestingly, certain lncRNAs can also be found in both the nucleus and
cytoplasm [279], or other cellular compartments (such as the mitochondria [280]),
where these RNA molecules have versatile roles in shaping the epigenome,
influencing biological processes (such as transcription and translation), and regulating
organelle formation and function [281]. Aside from their subcellular localization, the
site of biogenesis can also classify lncRNAs (Table 1.2). Namely, lncRNAs can be
broadly categorized as either intergenic (not overlapping with any protein-coding loci)
or intragenic/genic (overlapping protein-coding genes), where intragenic lncRNAs are
further classified as ‘antisense’, ‘bidirectional’, ‘intronic’, or ‘sense’ depending on
their transcriptional orientation on the protein-coding loci. When compared to
intragenic lncRNAs, long intergenic ncRNAs (lincRNAs), which arise from the
intergenic regions of the human genome, oftentimes possess greater evolutionary
conservation at both the sequence and RNA secondary structure level [282, 283].
Although particular differences in biogenesis exist between intragenic and intergenic
lncRNAs, it is plausible that a majority of these lncRNAs share similar modes of
action, through cis or trans-regulatory mechanisms, in order to govern fundamental
biochemical and cellular processes.
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Table 1.1. Regulatory capacities of lncRNAs. Reproduced from The multifaceted roles of
lncRNAs in diabetic complications: a promising, yet perplexing paradigm by S. Biswas and S.
Chakrabarti, 2020, Springer Nature.
Type of Mechanism

Description of Mechanism
LncRNAs can serve as adaptors that tether
pertinent protein subunits into distinct

Scaffold

complexes [284].
Once bound to a protein partner (i.e.
chromatin-modifying enzymes), lncRNAs

Guide

can direct enzymes to select regions of the
genome [285].
Certain lncRNAs can directly enhance the
activation of neighbouring genes [286].

Enhancer
LncRNAs

can

sequester

proteins

(i.e.

transcription factors and alternative splicing
factors) and small regulatory RNAs (i.e.
Decoy/Sponge

miRNAs) in order to affect their regulation
of target genes [287, 288].
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Table 1.2. Classification of lncRNAs based on their site of biogenesis. Reproduced from
The multifaceted roles of lncRNAs in diabetic complications: a promising, yet perplexing
paradigm by S. Biswas and S. Chakrabarti, 2020, Springer Nature.
LncRNA

Subcategory

Description of lncRNA subcategory

classification
Transcribed from the intergenic DNA
regions (regardless of orientation) and
Intergenic (does not

Long intervening/

intersect with protein-

intergenic lncRNA

coding genes)

generally

possess

greater

evolutionary

conserved regions compared to intragenic
lncRNAs.
Transcribed from the antisense/opposite

Antisense

strand of a protein-coding gene and may
overlap with coding exons.
Transcribed in the opposite direction from

Intragenic/genic

Bidirectional

the promoter of a protein-coding gene
(generally less than 1 kb away).

(overlaps with proteincoding genes)

Transcribed entirely within the intronic
Intronic

regions of a protein-coding gene, and does
not overlap with coding exons.
Transcribed from the sense/coding strand of

Sense

a protein-coding gene and may overlap
coding exons.

In the context of DR, many aberrant lncRNAs have been identified that are expressed
in the retina during diabetes; however, these lncRNAs have not been comprehensively
characterized [289]. Therefore, defining the specific roles of each lncRNA becomes
critical to understanding the interplay between lncRNAs and the pathogenesis of DR.
Currently, a prominent lncRNA that is upregulated in DR and associated with
increased

inflammatory

cytokine

production

is

metastasis-associated

lung
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adenocarcinoma transcript 1 (MALAT1) [290, 291]. As a matter of fact, both in vitro
and in vivo results from our laboratory identified that hyperglycemia induces an
upregulation of MALAT1 in endothelial cells, which in turn regulates increased
expression of inflammatory mediators, IL-6 and TNF-α, through serum amyloid
antigen three (SAA3) activation [291]. In addition to MALAT1, in vitro and in vivo
experiments from our laboratory revealed another lncRNA, antisense non-coding RNA
in the INK4 locus (ANRIL), that is upregulated in human retinal endothelial cells under
hyperglycemic conditions [292]. High glucose exposure elevated direct ANRIL
binding to P300 and another component of PRC2, enhancer of zeste homolog 2
(EZH2). Furthermore, we demonstrated that VEGF regulation might involve ANRILmediated control of PRC2, P300 and miR-200b, since silencing of ANRIL
simultaneously prevented the glucose-induced expressions of these epigenetic
molecules and VEGF [292]. Moreover, a recent study from our laboratory has
demonstrated the ability of H19 (a lncRNA) to mediate the phenotypic switch of
retinal endothelial cells in diabetic environments (this process is known as endothelialto-mesenchymal transition, EndMT; where endothelial cells lose their endothelial
markers and develop a more mesenchymal phenotype) [293]. More specifically,
human retinal endothelial cells (HRECs) cultured in high glucose (HG) showed
decreases in H19 and endothelial cell markers (VE-cadherin and CD-31), while
mesenchymal markers were significantly upregulated (SM22-α, α-SMA, and FSP-1).
Remarkably, the overexpression of H19 in HRECs drastically prevented the trends
elicited by HG, which suggests that the lncRNA H19 has a protective role in impeding
EndMT in DR. In parallel with our in vitro findings, significant reductions of H19
RNA levels were also observed in the vitreous humors of PDR patients. As well,
retinal tissues from H19 knockout non-diabetic mice revealed an EndMT phenotype
(decreased endothelial markers and increased mesenchymal markers) that was
comparable to retinal tissues from diabetic wild-type and diabetic H19 knockout mice.
Further expanding our findings, H19 was found to suppress glucose-induced EndMT
via the MAPK-ERK1/2 pathway of TGF-β signalling. In addition to H19, another
lncRNA known as HOX anti-sense intergenic RNA (HOTAIR) has been shown to
exert regulatory capabilities that promote oncogenesis [297], while other evidences
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have suggested that aberrant HOTAIR expressions exist in diabetic kidney disease but
its dysregulation may not necessarily contribute to disease pathogenesis [298]. Based
on these reports, it may be possible that disease-specific phenotypes exist for HOTAIR,
however, current work on this lncRNA in other diabetes models are limited and its
implications in DR pathogenesis remain elusive.
Undoubtedly, long non-coding RNAs (lncRNAs) continue to evolve our understanding
of the genomic landscape. The versatility of these non-protein-coding molecules
warrants serious consideration for in-depth investigations of their roles in
pathophysiological mechanisms, as novel information on these critical mediators will
not only add to the existing molecular paradigms, but such knowledge will also
contribute to the development of better-targeted diagnostics and therapies. As such, for
my thesis, I sought to characterize the epigenetic mechanisms of two specific
lncRNAs, MALAT1 and HOTAIR, in the pathogenesis of DR.

1.6 Rationale
In our earlier studies, we performed microarray analyses that examined the global
expression profiles of lncRNAs in HRECs cultured with 5 mM (mimicking
euglycemia; NG) or 25 mM D-glucose (mimicking hyperglycemia; HG) for 48 hours
(GEO: GSE122189; Appendix B, Supplemental Figure 1). Our findings identified
thousands of differentially expressed long non-coding RNAs (lncRNAs) following 48
hours of HG stimulation. Among the transcripts, the lncRNAs MALAT1 and HOTAIR
were profoundly upregulated in HG environments. Based on our previous studies
linking MALAT1 to inflammation in diabetic complications [291, 294] and prior
cancer-based studies demonstrating a relationship between HOTAIR and angiogenesis
[295, 296], my research sought to elucidate for the first time the epigenetic
mechanisms of MALAT1 in inflammation and HOTAIR in angiogenesis during the
pathogenesis of DR.

32

1.7 Central Hypothesis
I hypothesize that the lncRNAs MALAT1 and HOTAIR are intertwined in a complex
network of epigenetic mechanisms that regulate critical pathogenetic processes (such
as inflammation and angiogenesis) in DR. To test this hypothesis, three specific aims
were proposed.

1.7.1

Specific Aims

Aim 1: To investigate the implications of MALAT1 in the epigenetic regulation of
inflammation in DR (Chapter 2).
Synopsis: In this aim (Chapter 2), we investigated a prominent, cancer-related,
intergenic lncRNA in DR known as MALAT1. More specifically, we established a
novel epigenetic paradigm for MALAT1 in DR by employing siRNA-mediated
MALAT1 knockdown in HRECs, a Malat1 knockout animal model, vitreous humor
from diabetic patients, pharmacological inhibitors for histone and DNA methylation,
RNA immunoprecipitation, western blotting, and a unique DNA methylation array to
determine glucose-related alterations in MALAT1. Our findings indicated that
MALAT1 is capable of impacting the expressions of inflammatory transcripts through
its association with components of the PRC2 complex in diabetes. Furthermore, the
vitreous humors from diabetic patients revealed increased expressions of MALAT1,
TNF-α, and IL-6. Intriguingly, our DNA methylation array demonstrated that transient
high glucose exposure in HRECs does not contribute to significant methylation
alterations at CpG sites across the MALAT1 gene. However, global inhibition of DNA
methyltransferases induced significant increases in MALAT1 and associated
inflammatory transcripts in HRECs. Our collective findings demonstrated the
importance of MALAT1 in inflammation and epigenetic regulation in DR.
Aim 2: To examine whether HOTAIR is a critical epigenetic mediator of
angiogenesis in the pathogenesis of DR (Chapter 3).
Synopsis: In Aim 2 (Chapter 3), we identified the lncRNA HOTAIR in HRECs
through microarray screening and further examined its expression using several in
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vitro and in vivo experimental models. As evident by our cellular findings,
hyperglycemic environments can significantly augment HOTAIR expressions and the
subsequent upregulation of HOTAIR can directly promote glucose-induced
angiogenesis, oxidative damage, and mitochondrial aberrations. Similarly, vitreous
fluid and serum samples from PDR patients and retinas from diabetic animals
demonstrated significant HOTAIR expressions when compared to non-diabetic
controls. Furthermore, in vivo knockdown of Hotair prevented early glucose-induced
increases in several angiogenic markers and diabetes-associated molecules in the
diabetic retina. Mechanistically, HOTAIR may be exerting its regulatory capabilities
through its implications in a complex epigenetic axis involving histone methylation
(PRC2), histone acetylation (P300), DNA methylation (DNMTs), and specific
transcription factors (CTCF). Taken together, our findings suggest that the versatile
lncRNA HOTAIR is a critical epigenetic mediator of angiogenesis in the pathogenesis
of DR and HOTAIR may be a highly effective molecule for diagnostic and therapeutic
targeting.
Aim 3: To examine the interrelationships between epigenetic mechanisms
and specific molecular alterations in DR (Chapter 4).
Synopsis: Since endothelial cells (ECs) are primary targets of glucose-induced tissue
damage, in Aim 3 (Chapter 4), we selected a prominent diabetes-related molecule,
known as endothelin-1 (ET-1), for further follow-up. We carried out the investigation
in HRECs using multiple approaches in order to identify novel transcriptional
mechanisms that influence ET-1 regulation in diabetes. ECs were incubated with 5
mM glucose (NG) or 25 mM glucose (HG) and analyses for DNA methylation, histone
methylation, or long non-coding RNA-mediated regulation of ET-1 mRNA were then
performed. DNA methylation array analyses demonstrated the presence of
hypomethylation in the proximal promoter and 5' UTR/first exon regions of EDN1
following HG culture. Further, globally blocking DNA methylation or histone
methylation significantly increased ET-1 mRNA expressions in both NG and HGcultured HRECs, while knocking down pathogenetic lncRNAs (including MALAT1
and HOTAIR) subsequently prevented the glucose-induced upregulation of ET-1
transcripts. Based on our past and present findings, we present a novel paradigm that
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reveals a complex web of epigenetic mechanisms regulating glucose-induced
transcription of ET-1.
Following the discussion of these aims, in Chapter 5, I will examine the significance
of my overall work and discuss potential follow-up experiments that could provide
additional

insights

into

this

perplexing

transcriptional

paradigm.
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Chapter 2 ii

2

MALAT1: An Epigenetic Regulator of Inflammation in

Diabetic Retinopathy
As the global prevalence of diabetes is projected to rise to 642 million by 2040, there is
an urgent need for understanding the pathogenesis of diabetic complications to develop
effective therapeutic agents [1, 2]. Diabetic retinopathy (DR), a debilitating ocular
complication, is the leading cause of blindness among working-aged adults in
industrialized nations [3]. The asymptomatic nature of DR, prior to the development of
vision loss, is concerning, as nearly all type 1 diabetic patients and over 60% of type 2
diabetic patients will develop evidence of retinopathy within the first 20 years of
diagnosis [4, 5]. Despite the presence of management strategies, the rate of DR is still
expected to rise due to the increasing incidence of diabetes, which necessitates the need
for exploration of new molecular aspects of DR to expand the current scope of therapy.
In the last two decades, the rapid advent of high-throughput genomic technology has
made it evident that more than 97% of the human genome is comprised of non-proteincoding elements, such as non-coding RNAs (ncRNAs) [6]. Although significant
research has been conducted in annotating the transcripts that arise from these genomic
regions, a vast amount of information regarding the roles and functions of ncRNAs in
DR remains elusive.
Long non-coding RNAs (lncRNAs) are a class of ncRNAs that are greater than 200
nucleotides in length and have diverse roles in a myriad of cellular processes including
the ability to repress the expression of nearby protein-coding genes [7], X-chromosome
inactivation [8], and the modulation of protein activity [9]. In DR, transcriptomic
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analyses have identified more than 300 lncRNAs that display aberrant expression
profiles in the retina—with over 80 lncRNAs being overexpressed [10]. Among these
upregulated lncRNAs, MALAT1 (metastasis-associated lung adenocarcinoma transcript
1) is a prominent intergenic lncRNA that is known to be associated with metastasis in
non-small cell lung cancer (NSCLC) [11]. Since it is accepted that endothelial cells
(ECs) are main targets of diabetes-induced tissue damage, recent research has also
revealed novel roles for MALAT1 in diabetic complications. Results from our previous
study indicate that MALAT1 knockdown in human umbilical vein endothelial cells
(HUVECs), under hyperglycemic conditions, down-regulates serum amyloid antigen 3
(SAA3) activation, subsequently reducing the RNA and protein expressions of key
inflammatory mediators (IL-6 and TNF-α) implicated in diabetic complications [12].
Further, augmentation of MALAT1 expression by hypoxia promotes a proliferative
response in HUVECs [13].
In order to understand how lncRNAs, such as MALAT1, regulate the inflammatory
processes underpinning these pathologies, the complex molecular interplay between
lncRNAs and other epigenetic events must be examined in an integrated way. Several
cancer-related studies have revealed that MALAT1 is capable of binding to enhancer of
zeste homolog 2 (EZH2), the main catalytic subunit of the histone methyltransferase
polycomb repressive complex 2 (PRC2), and promotes oncogenesis by reprograming
the chromatin state [14-17]. Furthermore, in the context of DNA methylation, it has
been previously reported that lung cancer tissues exhibit reduced methylation in the
MALAT1 promoter, which subsequently enhances MALAT1 expression [18]. However,
in contrast, others have reported minimal methylation alterations at the CpG island in
the MALAT1 promoter of esophageal squamous cell carcinoma tissues and concluded
that CpG island methylation status may not contribute to MALAT1 dysregulation [19].
Nevertheless, despite the recent emergence of these epigenetic roles for MALAT1 in
cancer, the question of whether MALAT1 influences other epigenetic mediator proteins
to regulate inflammation in DR still remains unanswered.
Here, we first determined the expression level of MALAT1 in human retinal
microvascular endothelial cells (HRECs) cultured in high glucose (HG) and
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subsequently analyzed the expressions of common inflammatory markers (IL-6, TNF-α,
MCP-1, and IL-1β) along with components of PRC2 (EZH2, SUZ12, and EED) to
represent histone methyltransferase activity. Following our initial findings, we
employed MALAT1 knockdown and Malat1 knockout (KO) strategies in HRECs and in
a mouse model, respectively, to determine the functional role and significance of
MALAT1 on inflammation and PRC2 activity in DR. Moreover, to substantiate the data
from our in vitro and in vivo animal experiments, we examined MALAT1 and its
associated inflammatory markers in the vitreous humor (VH) of diabetic patients
undergoing vitrectomy. We also examined MALAT1 binding to EZH2 by RNA
immunoprecipitation in HRECs. As well, we further investigated the effects of HG on
CpG island methylation status in the MALAT1 promoter of HRECs using a methylation
array and then explored the impact of specific treatment(s) targeting MALAT1, histone
methyltransferases, and DNA methyltransferases (DNMTs).

2.1 Research Design and Methods
2.1.1

Cell Culture

We utilized HRECs (Olaf Pharmaceuticals, Worcester, MA, USA) for the in vitro
experiments. The experimental and culture conditions for HRECs were mentioned in
our previous studies [44, 58]. Briefly, prior to experimentation, HRECs were plated at a
density of 4.3x105 cells/mL and used between passages 5 and 6 to reduce variability.
Cells were grown to 80-90% confluency post-seeding and subjected to serum starvation
for 24 hours, which was then followed by the administration of specific glucose levels
(normal glucose [NG], 5 mM; high glucose [HG], 25 mM; and osmotic control [LG], 20
mM L-glucose + 5 mM D-glucose) at various time points. These glucose levels are
based on a large volume of previous experiments [12, 32, 44, 58-61]. All cell culture
reagents were purchased from Sigma (Oakville, Ontario, Canada) unless specified and
in vitro experiments were performed with six replicates and independently repeated at
least three times, unless specified.
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2.1.2

Diabetic Mice Model

The Western University Council for Animal Care Committee approved all animals used
in this study and the experiments were performed in accordance with The Guide for the
Care and Use of Laboratory Animals (NIH Publication 85-23, revised in 1996). Malat1
knockout (KO) mice, with a C57/BL6 background, were obtained through collaboration
with Dr. Spector (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York,
USA) [22] and only male mice were randomly organized into control and diabetic
groups. Wild-type (WT) non-diabetic and WT diabetic mice were used as comparators
to Malat1 KO non-diabetic and Malat1 KO diabetic mice. To generate a type 1 diabetic
animal model, we used streptozotocin (STZ). STZ injection methods and monitoring
have been previously described [59]. At two months following diabetes induction,
animals (n= 6/group) were euthanized and the retinal tissues were either snap-frozen for
future RNA or protein analyses or were placed in 10% formalin for paraffin embedding.

2.1.3

Clinical Sample Collection

The Western Research Ethics Board at the University of Western Ontario, London,
Ontario, Canada, approved the clinical component of this study. Prior to the
procurement of surgical specimens, patients provided informed consent and all of the
samples were handled in accordance with the Declaration of Helsinki. VH was collected
from patients undergoing pars plana vitrectomy by an experienced vitreoretinal surgeon.
Specimens were then categorized into two groups: diabetic and non-diabetic. The
diabetic group comprised of patients diagnosed with proliferative DR (PDR; n= 7; 3
males and 4 females; mean age ± SD= 61 ± 6.76 years); whereas, the non-diabetic
group consisted of patients that had no previous history of diabetes mellitus and were
diagnosed with idiopathic macular hole or a separate non-diabetic ocular condition (n=
6; 4 males and 2 females; mean age ± SD= 75 ± 3.52 years). As previously described
[60], VH specimens were centrifuged (12,000g, 10 minutes, 4°C) and the pellet was
used for RNA extraction using the TRIzol reagent (Invitrogen, Burlington, ON, Canada)
and subsequently, real-time quantitative reverse transcription-PCR (RT-qPCR). In order
to avoid contaminating RNA from blood cells, indications of vitreal haemorrhage in the
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VH specimens were immediately excluded from this study.

2.1.4

Immunohistochemistry

To identify blood-retinal barrier (BRB) damage in the eye, paraffin-embedded mouse
retinal sections were applied for immunohistochemical staining of immunoglobulin G
(IgG) using anti-mouse IgG antibody (MP Biomedicals, OH, USA), as previously
specified [44, 61]. Histological slides were evaluated for positive IgG immunoreactivity
(arbitrarily scored 0-3, with 3 representing maximum IgG reaction) in a masked manner
by an investigator.

2.1.5

Enzyme-Linked Immunosorbent Assay (ELISA)

In order to measure the cytokine levels from the cell supernatants, human IL-6 and
TNF-α ELISA kits were purchased from ALPCO (Salem, NH, USA) and R&D Systems
(Minneapolis, MN, USA), respectively. Concentrations for each cytokine were first
quantified using the BCA protein assay kit (Pierce, Rockford, IL, USA) and equal
protein concentrations were used for each ELISA (100 µg) according to the
manufacturer’s instructions. For the IL-6 chemiluminescence assay, the SpectraMax M5
(Molecular Devices, California, USA) was used to detect luminescence. Whereas, for
the TNF-α Quantikine ELISA kit, the optical density for each well was determined at
450 nm and corrected at 568 nm using the Multiskan FC Microplate Photometer
(Thermo Fisher Scientific, Massachusetts, USA).

2.1.6

SiRNA Transfection

HRECs were transfected with either pre-designed siRNAs targeting human MALAT1
(ID

numbers:

n272231

[si1-MALAT1]

and

n272233

[si2-MALAT1],

Life

Technologies), DNMT1 (ID number: s4216 [siDNMT1], Life Technologies) or
scrambled siRNA (ID number: AM4635, Life Technologies) using Lipofectamine 2000
(Invitrogen, Burlington, ON, Canada) and Opti-MEM (Life Technologies). A
lipofectamine-mediated transfection protocol has been indicated in our earlier studies
[12, 58]. Briefly, 100 nM of siMALAT1, siDNMT1, or scrambled siRNA was used to
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transfect the cells for 4 hours and subsequently recovered in full medium overnight. The
following morning, cells were serum starved for 21 hours and were then incubated with
specific glucose concentrations (5 mM or 25 mM) for 48 hours. MALAT1 and DNMT1
knockdown were confirmed using RT-qPCR. Following verification of knockdown,
both siMALAT1s demonstrated similar knockdown activity (~75%) when compared to
scrambled controls; therefore, we decided to select si2-MALAT1 (ID: n272233) for our
subsequent experiments. Furthermore, when compared to scrambled HG controls,
siDNMT1 (ID: s4216) demonstrated a ~72% reduction in DNMT1 RNA expression in
HG-treated HRECs.

2.1.7

3-Deazaneplanocin

A

(DZNep),

5-Aza-2’-

deoxycytidine (5-aza-dC), and Zebularine
Based on previous literature, 5 µM of DZNep (Cayman Chemical, Ann Arbor, MI), 5aza-dC (Sigma, St. Louis, USA), or zebularine (Cayman Chemical) pre-treatment was
applied to HRECs for 1 hour prior to the addition of D-glucose [44, 58, 62, 67]. DZNep,
5-aza-dC, or zebularine-treated HRECs and their respective controls were collected at
48 hours for further analyses.

2.1.8

CpG Island Methylome Analysis

Whether a differential methylation pattern exists in a diabetic environment remains
entirely elusive, therefore we investigated the CpG island methylation status in the
promoter of the MALAT1 gene in NG or HG-treated HRECs. At the 48-hour mark after
glucose treatment, HRECs were collected and 1 µg of genomic DNA was used for
bisulfite conversion using the EZ DNA Methylation Kit (Zymo Research, Irvine,
California, USA). The bisulfite-converted DNA was then hybridized to the Illumina
Infinium MethylationEPIC BeadChip array (Illumina, San Diego, California, USA)
following the manufacturer’s protocol. To achieve the readout from the array, we used
the HiScan System (Illumina, San Diego, California, USA) and subsequently imported
the methylated and unmethylated signal intensity data into R 3.4.0 for analyses. The
methylation intensity was normalized using the Illumina normalization method with
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background correction using the minfi package. Probes with a detection P-value > 0.01
were excluded from the downstream analyses. Further, probes known to contain SNPs
at the single nucleotide extension, or the CpG interrogation, were removed. The beta
value (β-value) was used to represent the methylation intensity for each CpG locus and
was calculated from the ratio of unmethylated probe to methylated probe, ranging
between 0 (no methylation) and 1 (full methylation). Three independent samples were
used per group.

2.1.9

RNA Immunoprecipitation (RIP)

At the 48-hour mark, cell lysates from NG and HG-treated HRECs were collected for
immunoprecipitation using the Magna RIP RNA-Binding Protein Immunoprecipitation
Kit (Millipore, Etobicoke, ON, Canada) following the manufacturer’s instruction [44].
Anti-IgG (control) and anti-EZH2 antibodies (Millipore) were used to co-precipitate the
RNA-binding proteins of interest. The extracted RNAs were then analyzed by RTqPCR.

2.1.10 Western Blotting
In order to evaluate the protein expression of EZH2 after siMALAT1 and HG
treatments, western blotting was performed. As previously described [58], cell lysates
were obtained from HRECs following 48 hours of NG or HG culture with scrambled or
MALAT1 siRNA. The Bicinconinic acid assay (Thermo Fisher Scientific, IL, USA) was
used to determine protein concentration, in which 20 µg of protein was used for western
blotting. Primary antibody incubation was performed overnight using monoclonal antiEZH2 (1:500; Millipore) or for 1 hour using polyclonal anti-β-actin (1:10000; Abcam,
Toronto, ON, Canada). While, secondary antibody incubation was conducted using antimouse IgG (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-rabbit
IgG (1:5000; Bio-Rad, Hercules, CA, USA) horseradish peroxidase conjugated
secondary

antibodies.

Antigenic

detection

was

performed

using

enhanced

chemiluminescence following the manufacturer’s instruction (GE Healthcare Life
Sciences, QC, Canada).
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2.1.11

RNA

Isolation

and

Quantitative

Real-Time

Polymerase Chain Reaction (RT-qPCR)
Total RNA was extracted using TRIzol reagent (Invitrogen, Burlington, ON) as
described [12, 44, 58-61]. After isolation, RNA concentrations were quantified using a
spectrophotometer (260 nm; Gene Quant, Pharmacia Biotech, USA) and 1 µg of total
RNA was reverse transcribed to complementary DNA (cDNA) using a high-capacity
cDNA reverse-transcription kit (Applied Biosystems, Burlington, ON, Canada). In order
to detect RNA expression, cDNA was amplified in the LightCycler 96 System (Roche
Diagnostics, Laval, QC, Canada) using SYBR-green master mix (Clontech, Mountain
View, CA, USA) and specific primers for the genes of interest (Sigma; Appendix A,
Table S1). We analyzed results using the LightCycler 96 SW 1.1 software (Roche) and
we calculated expression levels by the relative standard curve method using β-actin as
an internal control for sample normalization.

2.1.12

Cell Viability Assay

As previously described [58], the cytotoxicity of glucose treatments (5 mM and 25 mM)
in HRECs were determined using the WST-1 Cell Viability Assay (Roche). Viability
was assessed at various durations of incubation (0, 24, and 48 hours). Absorbances were
first measured at 450 nm, with the Multiskan FC Microplate Photometer (Thermo
Fisher Scientific), and then corrected using 690 nm as the reference wavelength.

2.1.13

Statistical Analysis

Data are expressed as mean ± SEM, unless specified. To determine statistical
significance, GraphPad Prism 7 was used to perform Student’s t tests when comparing 2
conditions or 1-way ANOVA followed by Tukey’s post hoc test for multiple
comparisons. While, for the clinical samples, non-parametric statistical measures
(Mann-Whitney U test) were applied. As well, two-sided Pearson Correlations were
performed to determine a linear association between RNA expressions of MALAT1 and
PRC2 components, or EZH2 and inflammatory cytokines in HRECs cultured with HG

62

and siMALAT1. Differences below P<0.05 were considered statistically significant.

2.2 Results
2.2.1

MALAT1 is upregulated in HRECs exposed to high

glucose
Retinal ECs are a fundamental cell type in the retinal microvasculature [20]. Retinal
ECs are also one of the earliest cells to undergo glucose-induced damage as a
consequence of DR [21]. Hence, we used HRECs for our in vitro experiments. Of note,
we have previously reported HG-induced increases in the expression of MALAT1 in
large vessel ECs [12]. In order to investigate the differential expression patterns of
MALAT1 and inflammatory markers, we cultured HRECs in HG and examined
MALAT1, IL-6, TNF-α, MCP-1 and IL-1β RNA expressions at 12, 24, 48, and 72 hours.
RT-qPCR analyses demonstrated that expressions of MALAT1 and inflammatory
markers in HRECs peaked at 48 hours following HG incubation (see Appendix A,
Figures S1A-S1E). Furthermore, no significant differences for MALAT1, IL-6, TNF-α,
MCP-1 and IL-1β expressions were observed osmotic controls (data not shown).
Following our findings, we decided to use the 48-hour time point for our subsequent in
vitro experiments.

2.2.2

MALAT1 knockdown prevents augmented

production

of

inflammatory

cytokines

and

PRC2

components in vitro
After observing upregulation of MALAT1 at 48 hours in vitro, we wanted to delineate
the functional importance of the MALAT1 transcript in inflammation and the role of
PRC2 complex expression in HRECs. We, therefore, employed a siRNA-mediated
knockdown approach targeting MALAT1. RT-qPCR analyses confirmed a ~75%
reduction in total MALAT1 RNA after siRNA treatments when compared to scrambled
controls (Fig. 2.1A). MALAT1 silencing in HG-treated HRECs dramatically reduced the
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overall expression of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) by a
~74% and a ~93% reduction, respectively, when compared to scrambled controls (Figs.
2.1B and 2.1C). Similarly, IL-1β and MCP-1 RNA expressions were also significantly
reduced following siMALAT1 treatment (Appendix A, Figs. S2A and S2B). We
further expanded our investigation to include the effects on inflammatory proteins after
siMALAT1 treatment and findings from the ELISAs revealed that after knocking down
MALAT1 in a HG environment, IL-6 and TNF-α protein levels significantly decreased
when compared to scrambled HG controls (Figs. 2.1G and 2.1H). The trends observed
from these experiments are consistent with our previous findings of decreased
expressions for IL-6 and TNF-α after siMALAT1 transfection in HUVECs [12].
To examine whether MALAT1 knockdown can affect the components of PRC2, we
analyzed EZH2, SUZ12, and EED RNA levels in HRECs following siMALAT1
transfection. As compared with scrambled controls, we found significantly reduced
EZH2, EED, and SUZ12 RNA levels in HG-treated HRECs transfected with MALAT1
siRNA (Figs. 2.1D-F). Moreover, to demonstrate MALAT1’s ability to impact PRC2 at
the protein level, we performed western blotting and examined EZH2 expression after
MALAT1 knockdown. Our western blot analyses confirmed that EZH2 protein
expressions were reduced in HRECs transfected with siMALAT1 (Appendix A, Fig.
S2C). In addition to our western blot data, we performed RNA immunoprecipitation and
confirmed MALAT1 binding with EZH2. In fact, MALAT1 RNA was significantly
enriched in the EZH2-antibody precipitated RNA fraction from HG-treated HRECs
compared to controls (Appendix A, Fig. S2D).
Furthermore, extending our knockdown analyses, we observed significant positive
correlations between MALAT1 RNA expression and the RNA expressions of PRC2
components in HRECs subjected to HG and siMALAT1 treatments (two-sided Pearson
correlation; Appendix A, Figs. S3A-S3C). As well, positive correlations existed
between EZH2 RNA expression and the RNA expressions of inflammatory markers, IL6 and TNF-α, in the siMALAT1+ HG group (Appendix A, Figs. S3D and S3E).
Collectively, our findings from the knockdown experiment indicate that MALAT1 RNA

64

levels play an important role in influencing glucose-induced upregulation of
inflammatory cytokines and components of PRC2 in HRECs.

Figure 2.1. MALAT1 regulates glucose-induced production of inflammatory cytokines and
PRC2 components in vitro. RT-qPCR analyses indicating HG-induced upregulation of A)
MALAT1 transcript, B, C) proinflammatory transcripts (TNF-α, IL-6), and D, E, F) PRC2
components (EZH2, SUZ12, and EED) in HRECs. SiMALAT1 transfections caused significant
reductions in glucose-induced upregulation of these transcripts. G, H) ELISAs for protein levels
of IL-6 and TNF-α (expressed as pg/mL) demonstrated prevention of glucose-induced increases
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of these peptides following siRNA transfection (data expressed as a ratio to β-actin (mean ±
SEM); normalized to SCR NG; *=P<0.05, **=P<0.01, ***=P<0.001, and ****=P<0.0001,
compared to SCR NG or SCR HG; n= 6 from three independent experiments and performed in
triplicates; SCR= scrambled siRNA; NG= 5 mM D-glucose; HG= 25 mM D-glucose; si1MALAT1 (MALAT1 siRNA 1, ID: n272231); and si2-MALAT1 (MALAT1 siRNA 2, ID:
n272233)).

2.2.3

Malat1 knockout alleviates diabetes-induced retinal

inflammatory cytokines and elevated PRC2 expression
With the genetic ablation of the Malat1 gene not contributing to noticeable
developmental effects in mice under basal homeostatic conditions [22, 23, 24], we
decided to use a diabetic Malat1 KO mice model in order to evaluate the direct function
of the Malat1 gene on inflammation and PRC2 expression in retinal tissues. Malat1 KO
mice with STZ-induced diabetes and age-and sex-matched controls were monitored for
2 months. WT-diabetic (WT-D) mice showed hyperglycemia and reduced body weight
gain (Appendix A, Table S2). Polyuria and glucosuria were also observed in diabetic
mice (data not shown). Nevertheless, no effects on these parameters were seen
following Malat1 nullification.
Our analyses demonstrated that MALAT1 RNA expression was significantly elevated
(more than ~0.46-fold) in WT-D mice retinas (Fig. 2.2A) compared to WT non-diabetic
control mice (WT-C). MALAT1 RNA expressions were nearly non-existent in both
Malat1 KO animal groups (M1 KO-C and M1 KO-D), confirming that MALAT1
transcripts are depleted in the retinal tissues of this global knockout model (Fig. 2.2A).
Moreover, our initial findings of MALAT1 upregulation in WT-D mice retinas are
consistent with previous trends of increased MALAT1 expression in retinas of diabetic
rats [25, 26].
Intriguingly, upon Malat1 gene inactivation, significant RNA expression changes were
observed among IL-6, TNF-α, IL-1β, MCP-1, EZH2, EED, and SUZ12 in retinal tissues
of diabetic mice (Figs. 2.2B-F; Appendix A, S4A and S4B). When compared to WT-D
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animals, all inflammatory transcripts were significantly downregulated (>50%) in
Malat1 KO diabetic animals (Figs. 2.2B-C; Appendix A, S4A and S4B). These
changes were associated with downregulation of transcripts of PRC2 components in
Malat1 KO diabetic animals (Figs. 2.2D-F). Together, our data suggests that presence
of the Malat1 gene is important in regulating diabetes-induced inflammation and PRC2
components in retinal tissues.

Figure 2.2. Malat1 knockout alleviates diabetes-induced retinal inflammatory cytokines,
elevated PRC2 expression, and IgG leakage in vivo. RT-qPCR analyses of the retinas from
animals, following two months of poorly controlled diabetes showed increased expressions of
A) MALAT1, B, C) inflammatory transcripts (TNF-α, IL-6), and D, E, F) PRC2 components
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(EZH2, SUZ12, and EED) in WT-D retinas compared to WT-C retinas. Malat1 KO prevented
such increases in the M1 KO-D group (data expressed as a ratio to β-actin (mean ± SEM);
normalized to WT-C; *=P<0.05, **=P<0.01, ***=P<0.001, and ****=P<0.0001, compared to
WT-C or WT-D; n= 6/group). H, I, J, K) IgG staining shows elevated IgG leakage in I) WT-D
retinas (score 3) and reduced leakage in the K) M1 KO-D retinas (score 1). No changes in IgG
leakage were observed between H) WT-C (score 0) and J) M1 KO-C (score= 1) animals (scale
bar= 10 µM). WT-C= Wild-type control; WT-D= Wild-type diabetic; M1 KO-C= Malat1 KO
control; and M1 KO-D= Malat1 KO diabetic.

2.2.4

Malat1 knockout diminishes vascular leakage in

the diabetic retina
Damage to the blood-retinal barrier (BRB) becomes imminent during the severe stages
of DR, which can consequently lead to irreparable vision damage [27]. In fact, risk for
developing vision-threatening complications heightens when a chronic hyperglycemic
environment allows for increased extravasation of large plasma proteins into the neural
retina [27, 28]. Therefore, to examine functional alterations in our diabetic animal
model, we used IgG staining on retinal tissues (Figs. 2.2H-K). Both in WT-C and M1
KO mice, IgG was mostly limited within the capillaries without any significant staining
of retinal tissues (scores 0-1; Figs. 2.2H and 2.2J). In contrast, diffuse staining of retinal
tissues (score 3) were seen in WT-D animals (Fig. 2.2I). Such changes were prevented
in M1 KO-D mice (score 1; Fig. 2.2K). Taken together, these findings support the
theory that MALAT1 is implicated in advancing BRB breakdown.

2.2.5

MALAT1 is upregulated and associated with

increased inflammatory markers in the vitreous of diabetic
patients
Alteration in the VH composition ultimately reflects the retinal environment [29]. In
individuals with late stage DR, there are increased concentrations of proinflammatory
cytokines and soluble growth factors in the VH that mediate retinal neovascularization
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within the eye [30, 31, 32]. Therefore, we decided to examine RNA levels of MALAT1
and its potential downstream molecules, IL-6 and TNF-α in the diabetic VH. RT-qPCR
analyses revealed that MALAT1 expression was significantly upregulated in the vitreous
of PDR patients than that of non-diabetic patients (Fig. 2.3A). PDR patients also
demonstrated significant upregulations of TNF-α and IL-6 in the VH when compared to
the vitreous of non-diabetic patients without retinopathy (Figs. 2.3B and 2.3C). In
summary, our findings suggest that MALAT1 upregulation in the diabetic vitreous is
associated with a pathogenetic state.

Figure 2.3. MALAT1 upregulation is associated with increased inflammatory markers in
the vitreous of diabetic patients. RT-qPCR analyses of the vitreous humors indicate that
diabetic patients have elevated expressions of A) MALAT1, B) TNF-α, and C) IL-6 transcripts
(data expressed as a ratio to β-actin (mean± SD); *=P<0.05 and **=P<0.01, compared to
control vitreous).
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2.2.6

Histone methylation impacts MALAT1 and some

of its downstream targets
With epigenetic reprogramming by pharmacological intervention receiving critical
recognition and showing considerable promise in cancer trials [33, 34], we decided to
explore the function of DZNep on HRECs and elucidate the effects of inhibiting
histone methyltransferases on MALAT1 and inflammation in a diabetic environment.
Following HG incubation, DZNep-treated HRECs demonstrated significant reductions
in the RNA expressions of EZH2, EED, and SUZ12, compared to HG-treated HRECs
(Figs. 2.4D-F). Accompanying the reduction of PRC2 components, HRECs in HG
following DZNep treatment showed significant reductions in MALAT1 and TNF-α
RNA expressions when compared to control HG-treated HRECs (Figs. 2.4A-B).
However, this is in stark contrast to the trends observed for IL-6, IL-1β, and MCP-1; in
which, the RNA expressions of these transcripts were significantly upregulated after
DZNep treatment in both NG-and HG-treated HRECs, as compared to control HGtreated HRECs (Figs. 2.4C; Appendix A, S4C and S4D).
In order to further verify this surprising observation of IL-6, IL-1β, and MCP-1
upregulation and to determine whether the same trends observed in the RNA
expressions exist at the protein level, we selected IL-6 and TNF-α for subsequent
ELISA assays. Following the addition of both DZNep and HG treatments, HRECs
demonstrated a significant induction of IL-6 compared to HG-treated HRECs (Fig.
2.4G), suggesting a positive correlation with the RNA expressions observed in Figure
2.4C. On the other hand, TNF-α protein levels were significantly decreased in the
presence of DZNep + HG, as compared to HG-treated HRECs, which is in parallel to
the trends observed with TNF-α RNA levels (Fig. 2.4H). Our DZNep findings
demonstrate that PRC2 activity may have an important role in impacting MALAT1,
TNF-α, IL-6, IL-1β, and MCP-1 expressions. However, of note, the effect of PRC2
depletion on the expression of IL-6, IL-1β and MCP-1 may also result from an indirect
effect of decreased TNF-α levels, which needs further exploration.
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Figure 2.4. Global methylation inhibitor (DZNep) prevents glucose-induced upregulation
of MALAT1, TNF-α, and PRC2 expressions. RT-qPCR findings indicate HG-induced
elevations of A) MALAT1, B, C) inflammatory transcripts (TNF-α, IL-6), and D, E, F) PRC2
components (EZH2, SUZ12, and EED) compared to NG at 48 hours. Such upregulations were
prevented (except IL-6) following DZNep treatment. Protein levels of G) IL-6 and H) TNF-α
showed similar patterns (RNA data expressed as a ratio to β-actin (mean ± SEM); normalized
to NG; *=P<0.05, **=P<0.01, ***=P<0.001, and ****=P<0.0001, compared to NG or HG;
n= 6 from three independent experiments and performed in triplicates; and protein data are
expressed as pg/mL).
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2.2.7

Transient HG treatment does not alter methylation

status of the CpG island in MALAT1 promoter
To address whether differential methylation patterns exist in the MALAT1 promoter in
hyperglycemia, we cultured HRECs in NG and HG conditions and performed a
genome-wide methylation analysis. Following detection of genome-wide methylation
(over 830,000 methylation sites), we filtered to specifically examine the sites that
spanned across the MALAT1 gene, which amounted to 21 probes (Data File S1, doi:
10.1038/s41598-018-24907-w). We found that the average methylation intensity was
generally lower across the ‘Shore’, ‘Island’, and ‘Shelf” regions in both NG and HGtreated HRECs (β-values<0.2) compared to the ‘Open Sea’ region, (β-values= ~0.49,
Fig. 2.5C). Furthermore, in both NG and HG conditions, HRECs demonstrated the
lowest degree of methylation in the CpG islands compared to the other regions (βvalues<0.074, Fig. 2.5C). Although eight probe sites indicated a slight reduction in
methylation after HG treatment (Fig. 2.5B), no comparable differences in methylation
were demonstrated overall between HRECs in NG and HG conditions (Fig. 2.5C).
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Figure 2.5. Transient HG treatment does not alter methylation status of CpG island in
MALAT1 promoter; however, DNA methylation inhibition augments glucose-induced
upregulations of MALAT1, TNF-α, and IL-6 expressions. A) Information on the human
MALAT1 gene according to the UCSC database. The MALAT1 gene is 8,707 nucleotides in
length (nucleotide positions in chromosome 11.q13.1: 65,265,233 to 65,273,939) and contains
a CpG island in its promoter region that is located from positions 65,264,958 to 65,265,398
(441 nucleotides in size)63. B) An intensity map depicting the β-values of CpG sites across
the MALAT1 gene, generated by the Illumina methylation array. A β-value of 0 indicates no
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methylation, while a value of 1 indicates complete methylation at the interrogated site (the
‘*’ demonstrates a reduction in methylation following HG treatment). C) A bar graph
illustrating the β-values separated by regions relative to the CpG island in the MALAT1
promoter. These regions are defined as ‘Island’ (an area of at least 500 base-pairs that
contains an observed-to-expected CpG ratio greater than 60%), ‘Shore’ (areas 2 kilo-bases
on either side of an island), ‘Shelf’ (areas 2 kilo-bases on either side of a shore), or ‘Open
Sea’ (areas outside of the shelf). No significant differences were observed in methylation
between NG and HG conditions in these regions (data expressed as average β-value per
region; n=3 independent samples for each NG or HG group). Glucose-induced elevations
of D) MALAT1, E) IL-6, and F) TNF-α transcripts were further increased following 5-aza-dC
treatment (data expressed as a ratio to β-actin (mean ± SEM); normalized to NG; *=P<0.05,
**=P<0.01, ***=P<0.001, ****=P<0.0001, and n.s.= not significant, compared to NG or HG;
n= 6 from three independent experiments and performed in triplicates).

2.2.8

Inhibition of DNA methyltransferases (DNMTs)

increases expression of MALAT1

and

inflammatory

cytokines
We then examined the effects of inhibiting genome-wide DNA methylation on
MALAT1, TNF-α, IL-6, IL-1β, and MCP-1 RNA expressions. To produce such an
environment in vitro, we administered the pan-DNMT inhibitors 5-aza-dC or
zebularine to HRECs prior to glucose treatment and analyzed the effects of
methylation loss on RNA expressions using RT-qPCR. Following these treatments, we
confirmed the reductions of DNMT1, DNMT3A, and DNMT3B (Appendix A, Figs.
S6A-C and S6F-H). Interestingly, inhibiting the activity of DNMTs in NG and HG
conditions evoked further increases in MALAT1, IL-6, TNF-α, IL-1β, and MCP-1 RNA
expressions when compared to control NG and HG-treated HRECs (Figs. 2.5D-F;
Appendix A, S6D-E and S6I-M). Among the markers analyzed, TNF-α and IL-1β
demonstrated the greatest upregulations in 5-aza-dC or zebularine-treated HRECs
(Fig. 2.5F and Appendix A, S4E). The findings implicate that although transient HG
treatment on HRECs may not generate considerable DNA methylation alterations
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across the MALAT1 gene region, globally inhibiting the activity of DNMTs impacts
the expression of MALAT1 and inflammatory transcripts. Therefore, we speculate that
DNMTs may have a potential role in regulating MALAT1 and inflammatory RNA
expressions, which needs further characterization.
To confirm the findings from our pan-DNMT inhibitors, we selected DNMT1, a
constitutively expressed DNMT, for subsequent siRNA-mediated knockdown
(Appendix A, Fig. S7A). After silencing DNMT1, we observed overall increases in
MALAT1, TNF-α, IL-6, IL-1β and MCP-1 RNA expressions in both NG and HGtreated HRECs (Appendix A, Figs. S7B-F).
Based on our findings, we propose a diagram for MALAT1 in potentially regulating
inflammation through independent and dependent pathways in DR (summarized in
Fig. 2.6). In the independent pathways, DNA methylation may be capable of
regulating the transcriptional status of MALAT1 and if the actions of DNMTs are
hindered, MALAT1 RNA expressions could increase. Following upregulation,
MALAT1 may recruit PRC2 to the promoters of anti-inflammatory genes and
epigenetically repress these targets, which might subsequently allow for heightened
transcription of inflammatory genes. On the contrary, in the dependent pathway, the
MALAT1 transcript and MALAT1 gene may directly interact with inflammatory
transcripts and inflammatory genes to ultimately provoke a greater inflammatory
response.
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Figure 2.6. A schematic depicting the potential involvement of MALAT1 in regulating
inflammation through epigenetic mechanisms in diabetic retinopathy. Based on our
findings, we present a diagram for MALAT1 in potentially regulating inflammation by
independent and dependent pathways in DR. In the independent pathways, indicated by ‘1.’,
DNA methylation regulates the transcriptional status of MALAT1 and if the actions of DNA
methyltransferases are hindered, MALAT1 RNA expressions will increase. Following
upregulation, MALAT1 can recruit PRC2 to the promoters of anti-inflammatory genes and
epigenetically repress these targets, which will subsequently allow for heightened transcription
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of inflammatory genes. On the contrary, in the dependent pathway (indicated by ‘2.’), the
MALAT1 transcript and MALAT1 gene may directly interact with inflammatory transcripts and
inflammatory genes, respectively, to ultimately provoke a greater inflammatory response
(Me= methylation; EZH2 + SUZ12 + EED + RBAP48= PRC2 complex components; (+) and
(-)= feedback loop; 1. = Indirect effect of MALAT1 on inflammation via DNA methylation and
PRC2 pathways; and 2. = Direct effect of MALAT1 gene activity on inflammation and vice
versa). Reproduced from MALAT1: An Epigenetic Regulator of Inflammation in Diabetic
Retinopathy (p. 9) by S. Biswas, A. Thomas, S. Chen, E. Aref-Eshghi, B. Feng, J. Gonder, B.
Sadikovic, and S. Chakrabarti, 2018, Scientific Reports.

2.3 Discussion
When metabolic memory was first described [3, 4], it became clear that understanding
the processes implicated in this phenomenon are of utmost importance. Epigenetic
modifications, which can alter the expression of genes without altering the underlying
DNA sequence, are critical players in metabolic memory [35] and characterizing these
modifications will help us learn about the intricacies of epigenetic regulation in
diseases. Recently, the advancements in experimental genome-wide approaches have
allowed for the identification of lncRNAs, which play various roles in cellular
physiology and are heavily involved in epigenetic regulation [35, 36]. Further insight
into the functions of lncRNAs and their association with other epigenetic mechanisms
in diseases will help with the development of better-targeted therapeutics. Here, not
only do we show for the first time that the lncRNA MALAT1 is present in the VH of
diabetic patients, but we present through a series of well-designed in vitro and in vivo
experiments, a novel epigenetic paradigm for MALAT1 in the pathogenesis of DR.
MALAT1 was originally discovered in patients with non-small cell lung carcinoma and
shortly after its discovery, MALAT1 has also been reported in various pathologies such
as heart disease and diabetes [10-13, 25, 26, 37]. Located on human Chr.11q13.1, the
MALAT1 gene produces a well-conserved non-coding transcript that is ~8000+
nucleotides in length and is further processed by RNAses P and Z, which ultimately
results in the production of two transcripts: a mature MALAT1 transcript and a ~61-
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nucleotide MALAT1-associated small cytoplasmic RNA (mascRNA) [11, 22]. The
mature MALAT1 transcript is primarily localized to the nucleus, while the mascRNA is
exported to the cytoplasm [22, 23, 24, 38].
The stability of the mature MALAT1 transcript differs across cell-types, where
MALAT1 has been reported to have a half-life of ~9 hours in human cervical cells
(HeLa Tet-off) [39], 16.5 hours in human B cells [40], and 3 hours in murine NIH 3T3
cells [40]. Of note, we have previously reported in HUVECs that MALAT1 expression
levels increase significantly at 12 hours [12]; whereas, other reports have indicated
that MALAT1 expression is highest at the 48-hour mark in RF/6A, primary retinal
ganglion, and Müller cells [10, 26]. Our current results indicate that MALAT1
expression peaks at the 48-hour mark following HG treatment in HRECs, which is in
accordance with the findings from Liu et al. and Yao et al. [10, 26]. It is likely that
MALAT1 transcripts may exhibit similar half-life patterns among specific retinal cells,
which may explain the variation in MALAT1 expression between HUVECs and
HRECs. As well, early increases of MALAT1 by HG may regulate specific pre-mRNA
splicing patterns and potentially activate a degradation mechanism that adjusts the
MALAT1 expression at later time points [64]. Nevertheless, it is important to note that
although the initial increase of MALAT1 at 48 hours may appear as a temporary event,
MALAT1 may be capable of activating persistent epigenetic changes involving its
downstream targets—despite reductions in MALAT1 expression later in the disease
course. This phenomenon is best explained by the concept of metabolic memory,
which has been previously demonstrated with epigenetic changes occurring in the NFκB promoter following transient hyperglycemia [65].
Knocking down lncRNAs using siRNA-mediated approaches has allowed for critical
discussion on the efficiency and specificity of these particular knockdowns. Despite
the notion that siRNAs operate mainly in the cytoplasm, several studies have
demonstrated that siRNA-programmed RNA-induced silencing complexes (RISCs)
exist in the nucleus, where siRNAs can still be used to target nuclear lncRNAs [41, 42,
43]. In fact, previous studies have demonstrated efficient MALAT1 knockdown using
siRNA-mediated transfections [13-19, 25, 26, 38]. As indicated by our prior work, the
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selective targeting of MALAT1 via siRNAs resulted in a subsequent reduction of IL-6
and TNF-α mRNA and protein levels in HUVECs [12], which also resembles similar
patterns observed in this study. A reduction in MALAT1 with concomitant decreases in
inflammatory transcripts suggests that MALAT1 promotes an inflammatory phenotype
in DR. Furthermore, in the context of PRC2, we recently demonstrated that knocking
down lncRNA ANRIL downregulates the RNA expressions of PRC2 components in
HG-treated HRECs [44]. Since we observed similar trends in PRC2 expressions after
siMALAT1 treatment, our findings collectively support the notion that certain
lncRNAs, such as ANRIL and MALAT1, may act as scaffolds to chromatin-associated
complexes in order to further modulate the expression of genes in DR [45].
Under normal physiological conditions, the Malat1 KO mice do not display a
noticeable phenotype [22, 23, 24]. However, whether Malat1 KO mice will reveal a
disease-specific phenotype, when subjected to certain pathological conditions, remains
of great interest. With respect to our in vivo diabetic animal model, our initial findings
of MALAT1 upregulation in the WT-D mice retinas at 2 months are consistent with
previous demonstrations of increased MALAT1 expression in the retinas of diabetic
rats [25, 26]. However, of note, the relative MALAT1 expressions documented from
these studies were upregulated up to >3-fold at the aforementioned time points [25,
26]; whereas in our study, the relative MALAT1 RNA expression significantly
increased to ~1.46-fold in the WT-D retinas at 2 months. We believe the differences
observed in MALAT1 expressions may be accounted for potential species-specific or
other unidentified variations [46, 47]. Since we also observed statistically significant
reductions in the expressions of IL-6, TNF-α, IL-1β, MCP-1, EZH2, SUZ12, and EED
in the diabetic Malat1 KO retinas, we infer that MALAT1 may be functionally capable
of controlling the expressions of PRC2 components, through which it may regulate
inflammation in DR. To further elaborate on the potential transcriptional capabilities
of MALAT1, intergenic lncRNA transcripts have been previously shown to modulate
the expression of protein-coding genes in cis by reducing the recruitment of
transcription factors in the promoter regions of protein-coding genes and subsequently
activating histone modification cascades to silence gene transcription- also known as
transcriptional interference [48, 49, 50]. It is also likely possible that prolonged
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diabetic conditions can enable MALAT1 to act in trans by directly impacting RNA
polymerase II activity, which could impact the transcription of nearby antiinflammatory genes [51]. Moreover, confirming the immunohistochemistry findings
from our in vivo animal model, previous work by Michalik et al. demonstrated that
MALAT1 is capable of regulating and enhancing angiogenesis in the neonatal mice
retina, suggesting a proangiogenic role for MALAT1 during retinal neovascularization
[13]. Although the main focus of our manuscript has been on MALAT1 and its
epigenetic role in inflammation, future experiments should elucidate the underlying
epigenetic mechanisms implicated in the complex crosstalk between inflammation and
angiogenesis—as both of these processes converge and synergistically influence the
progression of DR [68].
The close proximity of the VH to the lens and retina make it an ideal location to
administer therapeutic agents to target ocular pathologies [29]. Yao et al. have
previously indicated that MALAT1 expression levels were significantly downregulated
in the aqueous humor of patients with primary open-angle glaucoma [26]. However, in
patients with Alzheimer’s Disease or glioma, the cerebrospinal fluid and the tumor
itself, respectively, showed MALAT1 upregulation [26]. In contrast, Yan and
colleagues have reported increased MALAT1 expression in the fibrovascular
membranes and aqueous humors of diabetic patients [10]. Previous studies have also
shown that MALAT1 upregulation contributes to epiretinal membrane formation in
patients with proliferative vitreoretinopathy [52, 53]. In keeping with previous data,
intraocular administration of MALAT1 shRNA alleviates vascular leakage and
dampens the inflammatory response in the diabetic rat retina through reduced protein
expressions of TNF-α, intracellular adhesion molecule-1 (ICAM-1), and vascular
endothelial growth factor (VEGF) [25]. To our knowledge, this is the first study to
directly identify MALAT1 RNA from the VH of PDR patients. Although much is
unknown about the specific mechanisms of lncRNAs in diabetic complications, our
novel finding suggests the possibility of therapeutically targeting MALAT1 in PDR
patients. Taken together, a prolonged diabetic environment can ultimately allow for
increased MALAT1 expression at various locations in the eye, which may associate
with increased inflammation and subsequent cellular damage [10, 13, 25, 32].
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Although interactions between lncRNAs and chromatin modification complexes have
been studied in cancers [66], such studies have not been undertaken in the context of
DR. MALAT1 has been shown to directly bind to EZH2 in renal cell carcinoma [14],
mantle cell lymphoma [17], prostate cancer [15], osteosarcoma [16], and gastric
cancer [54], suggesting an important regulatory relationship between the two
components. Of particular interest, Wang et al. revealed that MALAT1 could facilitate
the targeting capabilities of EZH2 and further augment histone 3 lysine 27
trimethylation (H3K27me3) levels at the target gene loci of EZH2 in prostate cancer
cell lines [15]. These findings allude to the many pathogenetic capabilities of
MALAT1. Moreover, our RIP findings demonstrate heightened MALAT1 binding with
EZH2 in HG-treated HRECs and we have also previously shown similar binding of
EZH2 to ANRIL in HRECs cultured with HG [44]—suggesting a potential overlap in
functional mechanism. Therefore, despite observing the expected reductions in
MALAT1, TNF-α, EZH2, EED, and SUZ12 expression levels after DZNep treatment,
it was surprising to see an increase in IL-6, IL-1β, and MCP-1 expressions in HRECs
following DZNep treatment. These data are in keeping with Serresi and colleagues,
who indicated previously that Polycomb-mediated repression exists on the IL-6 gene
in NSCLC by H3K27me3 [55]. Furthermore, a similar observation by Lee et al.
demonstrated that the depletion of EZH2 or estrogen receptor (ER) in ER-positive
breast cancer cell lines (T47D and MCF7) produced a significant upregulation of IL-6
and IL-8 expressions at basal levels [56]. In ER-negative breast cancer, EZH2 acts as a
coactivator for RelA and RelB and this in turn activates a positive feedback loop
through NF-κB signalling pathways to enhance the expressions of NF-κB targeted
genes, such as IL-6 [56]. Lee and colleagues concluded that EZH2 is capable of
context-specific regulation on the expression of NF-κB target genes [56]. These
findings are supportive of our data. However, since DZNep inhibits global histone
methylation and is not completely selective [57], further research is warranted on
elucidating the cellular-specific mechanisms of DZNep treatment in diabetic
complications.
Although we did not observe significant methylation changes in CpG sites across the

81

MALAT1 gene after HG treatment, we did notice increased expressions of MALAT1,
IL-6, TNF-α, IL-1β, and MCP-1 after 5-aza-dC or zebularine treatments in both basal
and HG conditions. Consistent with the findings from our methylation array, Hu et al.
reported no effects of CpG island methylation status on MALAT1 expression in
esophageal squamous cell carcinoma (ESCC) cells [19]. On the other hand, Guo et al.
analyzed the CpG island methylation patterns in the MALAT1 promoter of lung cancer
cells (A549) and observed a reduction of methylated sites in lung cancer cells [18].
They also demonstrated that a methyl donor could reduce MALAT1 expression in these
cells—implying that DNA methylation can regulate MALAT1 expression [18]. Taken
together, the diverse findings documented from previous DNA methylation reports,
and from our study, imply that disease-and cell-specific responses may exist after
inhibiting the activity of DNMTs. Despite our observations from this pharmacological
experiment, it still remains to be determined whether the inhibition of genome-wide
DNA methylation alters neighbouring (or distal) genes, which in turn may
substantially impact the transcriptional activity of MALAT1. Future studies should
include targeted genome editing techniques such as CRISPR-Cas9, to eliminate any
potential off-targeting effects observed from our 5-aza-dC, zebularine, or siDNMT1
experiments.
Overall, our findings collectively demonstrate that MALAT1 is capable of impacting
the expressions of inflammatory transcripts through its association with epigenetic
mediators, such as histone and DNMTs. It is important to note that the findings
described in this manuscript are simply a starting point for future investigations to
build and develop a more definitive model for lncRNAs in DR. Establishing such an
all-encompassing model, which includes the interplay of miRNAs and additional
epigenetic modifications, will enable the development of better-targeted treatment
strategies.
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2.5 Appendix A: MALAT1: An Epigenetic Regulator of
Inflammation in Diabetic Retinopathy

Figure S1: MALAT1 and inflammatory transcripts are upregulated in HRECs following
high glucose treatment. RT-qPCR analyses of A) MALAT1, B) IL-6, C) TNF-α, D) MCP-1 and
E) IL-1β expressions in HRECs exposed to 25mM (HG) or 5mM (NG) glucose over a time
course of 72 hours. MALAT1, IL-6, TNF-α, MCP-1 and IL-1β are upregulated in HG-treated
HRECs at 48 hours compared to NG (*=P<0.05, **=P<0.01, ***=P<0.001, and
****=P<0.0001 compared to NG; data expressed as mean ± SEM; n=6/group; normalized to βactin, and data represented as a fold change of NG).
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Figure S2: MALAT1 influences MCP-1, IL-1β, and EZH2 expressions and strongly binds
with EZH2 in HG-treated HRECs. RT-qPCR analyses indicating reduced RNA expressions
of A) IL-1β and B) MCP-1 following siMALAT1 treatment in HG-treated HRECs (data
expressed as a ratio to β-actin (mean ± SEM); normalized to SCR NG; *=P<0.05, **=P<0.01,
***=P<0.001, and ****=P<0.0001, compared to SCR NG or SCR HG; n= 6 from three
independent experiments and performed in triplicates). C) Representative Western blot image
showing EZH2 expressions, with β-actin as a control, in NG or HG-treated HRECs transfected
with scrambled controls or siMALAT1. Western blots presented (in C) were cropped from the
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same membrane and were cropped to improve clarity. The bands within the range of the
molecular marker were retained in this figure and the full-length blots are presented in
Supplementary Figure S5. D) RNA immunoprecipitation, using an IgG control or EZH2
antibody, demonstrating elevated MALAT1 binding to EZH2 following HG treatment in
HRECs. MALAT1 expression was determined by RT-qPCR (****P<0.0001 and n.s.= not
significant compared to IgG controls; data expressed as mean ± SEM; n=3/group, and results
are from one experiment that is representative of three independent experiments). SCR=
scrambled siRNA; NG= 5 mM D-glucose; HG= 25 mM D-glucose; SiM1= siMALAT1
treatment.

Figure S3: Positive correlations between PRC2 components and MALAT1 expression, and
between EZH2 and inflammatory transcripts after MALAT1 knockdown in HG-treated
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HRECs. Pearson correlations between RNA expressions of A-C) MALAT1 and the PRC2
components, and between D-E) EZH2 and the inflammatory cytokines in HRECs following
siMALAT1+HG treatments. RNA expressions were normalized to β-actin and n=6 in the
HG+siMALAT group.

Figure S4: IL-1β and MCP-1 transcript expressions are impacted by Malat1 knockout and
histone methyltransferases. RT-qPCR analyses of the retinas from animals, following two
months of poorly controlled diabetes showed increased expressions of A) IL-1β and B) MCP-1
inflammatory transcripts in WT-D retinas compared to WT-C retinas. Malat1 KO prevented
such increases in the M1 KO-D group (data expressed as a ratio to β-actin (mean ± SEM);
normalized to WT-C; *=P<0.05, **=P<0.01, ***=P<0.001, and ****=P<0.0001, compared to
WT-C or WT-D; n= 6/group). Following DZNep and HG treatments, RT-qPCR findings
indicate elevations of C) IL-1β and D) MCP-1 RNA expressions compared to NG at 48 hours
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(data expressed as a ratio to β-actin (mean ± SEM); normalized to NG; *=P<0.05 and
**=P<0.01 compared to NG or HG; n= 6 from three independent experiments and performed in
triplicates). WT-C= Wild-type control; WT-D= Wild-type diabetic; M1 KO-C= Malat1 KO
control; and M1 KO-D= Malat1 KO diabetic.

Figure S5: Full length blots of Figure S2C. Red dotted lines indicating the cropping locations.
A) β-actin was detected first prior to measuring EZH2 expressions, which were detected the
following day. B) Blot reveals EZH2 expressions, as well as residual β-actin expressions from
the first imaging run.
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Figure S6: Global inhibition of DNMTs significantly elevates the RNA expressions of
MALAT1, TNF-α, IL-6, MCP-1 and IL-1β. HRECs pre-treated with 5-aza-dC demonstrated
overall reductions in A) DNMT1, B) DNMT3A, and C) DNMT3B transcripts. While, glucoseinduced elevations of D) IL-1β and E) MCP-1 transcripts were further increased following 5aza-dC treatment. HRECs were also incubated with zebularine (another pan-DNMT inhibitor)
and demonstrated similar trends. Reductions in F) DNMT1, G) DNMT3A, and H) DNMT3B
transcripts were observed; whereas, I) MALAT1, J) TNF-α, and K) IL-6, L) IL-1β, and M)
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MCP-1 RNA expressions increased following zebularine treatment (*=P<0.05, **=P<0.01,
***=P<0.001, ****=P<0.0001, and n.s.= not significant compared to NG or HG controls; data
expressed as mean ± SEM; n=6/group; normalized to β-actin, and data represented as a fold
change of NG). ZEB= Zebularine.

Figure S7: DNMT1 knockdown impacts MALAT1, TNF-α, IL-6, MCP-1 and IL-1β
transcripts. HRECs transfected with siDNMT1 demonstrated significantly decreased A)
DNMT1 transcript expression and increased RNA expressions of B) MALAT1, C) TNF-α, D) IL-
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6, E) IL-1β, and F) MCP-1 compared to scrambled controls (*=P<0.05, **=P<0.01,
***=P<0.001, ****=P<0.0001, and n.s.= not significant compared to SCR controls; data
expressed as mean ± SEM; n=6/group; normalized to β-actin, and data represented as a fold
change of NG). HRECs were also incubated with 5 µM Zebularine (a DNA methylation
inhibitor) and demonstrated similar increases in D) MALAT1, E) TNF-α, and F) IL-6 RNA
compared to controls (*=P<0.05, **=P<0.01, ***=P<0.001, and ****=P<0.0001 compared to
SCR NG or SCR HG; data expressed as mean ± SEM; n=6/group; normalized to β-actin, and
data represented as a fold change of NG). SiDNMT1= siDNMT1 treatment.
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Figure S8: Cell viability of retinal endothelial cells following glucose treatments across
various durations of incubation. WST assay showing no significant differences in human
retinal endothelial cell viability between the two groups following various durations of
incubation (data presented as mean± SD; n.s.= no significance compared to NG; and
n=6/group). Legend: NG= normal glucose, HG= high glucose.
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Table S1: Specific oligonucleotide sequences used for RT-qPCR.
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Table S2: Body weights and blood glucose levels for the mice at 2 months. Legend: WTcontrol=WT-C, WT-diabetic= WT-D, Malat1 KO-control= Malat1 KO-C, and Malat1 KOdiabetic= Malat1 KO-D [data expressed as mean ± SEM; n=6/group; and ‘*’=significantly
different from WT-C].
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Chapter 3 iii

3

The long non-coding RNA HOTAIR is a critical

epigenetic mediator of angiogenesis in diabetic retinopathy
With diabetes mellitus (DM) projected to impact over 600 million people globally in
the next 20 years [1], the subsequent risk of acquiring micro- and macrovascular
complications remain a serious concern. DM is a degenerative metabolic disease that
is primarily characterized by chronic hyperglycemia, where sustained hyperglycemic
insults can evoke alterations in biochemical and metabolic pathways that ultimately
contribute to vascular damage and the pathogenesis of chronic diabetic
complications [2-4]. Among these complications, diabetic retinopathy (DR) is a
debilitating microvascular complication of DM and is also one of the leading causes
of blindness worldwide [5]. Although there are different severity stages for DR, DR
can be mainly categorized as non-proliferative DR (NPDR) and proliferative DR
(PDR), where the latter may lead to imminent vision loss due to the presence of
ocular pathological neovascularization [6].
As a result of long-term diabetes, pathological angiogenesis occurs and continuously
activates various signal transduction cascades that promote the expressions of
several pro-angiogenic genes, leading to increased concentrations of angiogenic
factors than angiostatic factors [7-10]. Following upregulation, these angiogenic
factors act synergistically to mediate the migration and proliferation of retinal
endothelial cells in pre-existing blood vessels, which ultimately leads to the
formation of new, abnormal blood vessels that are susceptible to bleeding, leakage,
fibrosis and contraction [11,12]. Among the regulatory angiogenic molecules,
vascular endothelial growth factor (VEGF) is a potent angiogenic factor expressed
by ECs and non-ECs and has been studied extensively in DR. Several pathological
processes, such as hypoxia [13], oxidative stress [14], advanced glycation end
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products [15], and inflammation [16], can stimulate VEGF expressions through a
transcriptional regulation involving a complex milieu of transcription factors [17],
mediator complexes [18] and non-coding RNAs [19,20]. Indeed, due to VEGF’s
critical role in DR, the standard first-line therapy for patients with diabetic macular
edema and PDR consists of intravitreal injections of anti-VEGF and/or steroid
compounds, which temporarily delay the progression of severe retinopathy.
However, the use of such therapies comes at a cost to patients, where frequent
intraocular injections are required, local or systemic adverse effects are associated
with anti-VEGF compounds [21,22], and 40-50% of eyes with diabetic macular
edema (another complication of diabetes) can not fully respond to anti-VEGF
treatments [23]. Undoubtedly, in order to mitigate the effects of DR, a sense of
urgency is warranted for diabetes research, as exploratory studies will provide novel
insights into our understanding of ocular angiogenesis and open new avenues for
better diagnosis and targeted therapies.
Within the last two decades, the rapid advent of genomic technologies has identified
long non-coding RNAs (lncRNAs) as a fundamental class of RNA transcripts that
are larger than 200 base-pairs and possess limited protein-coding capacities.
LncRNAs are dynamically regulated and present with distinct functionalities that
facilitate chromatin remodelling and/or help govern the expression of genes involved
in a multitude of biological and pathological processes, including development [24],
cancer [25], neurodegeneration [26] and even DR [27,28]. Despite the breadth of
literature available regarding lncRNAs, limited studies have comprehensively
characterized the functions of certain lncRNAs in mediating angiogenesis in the
context of DR.
Here, we used microarray screening to identify glucose-induced expressions of the
lncRNA HOTAIR (HOX transcript antisense RNA) in human retinal ECs and then
investigated its functional implications in the pathogenesis of DR. Examination of
retinal tissues from diabetic animals and vitreous and serum samples from patients
with PDR showed that the lncRNA HOTAIR is specifically upregulated in
hyperglycemic environments. Further mechanistic studies revealed that HOTAIR
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directly mediates angiogenesis and other glucose-induced aberrations in ECs (such
as mitochondrial and DNA damage) through its involvement in related epigenetic
pathways, including histone methylation, histone acetylation, and DNA methylation.
Collectively, our data highlights the complex regulatory nature of HOTAIR in the
context of DR and identifies HOTAIR as a potential diagnostic marker and
therapeutic target for angiogenesis in DR.

3.1 Materials and Methods
3.1.1

Cell culture

Human retinal microvascular endothelial cells (HRECs; Cell Systems, Kirkland,
WA, USA; catalog number ACBRI 181), mouse retinal microvascular endothelial
cells (MRECs; Applied Biological Materials Inc., Richmond, BC, CAN), and
primary lung endothelial cells (MLECs) from C57BL/6J mice were cultured in
endothelial basal media-2 (EBM-2, Lonza, Walkersville, MD, USA) containing
endothelial growth media-2 (EGM-2) SingleQuots (Lonza). All cells were grown in
75 cm2 culture flasks and maintained in a humidified incubator containing 5% CO2
at 37°C. As described previously [19,27,31], in order to reduce variability for
experimentation, cells were used between passages three and six and the cellular
densities were determined accordingly based on the type of culture plates used for
each experiment. Generally, once 80% confluence was obtained post-seeding, ECs
were cultured in serum and growth factor-free medium overnight before exposure to
different D-glucose levels (final glucose concentrations of 5 mmol/L, mimicking
normoglycemia [NG], and 25 mmol/L, mimicking hyperglycemia [HG]) for various
durations; the selected glucose levels are based on a large volume of previous
experiments [9,19,20,27,28,31,38,85,86]. All in vitro or ex vivo experiments were
independently repeated at least three times and performed with six replicates, unless
specified.

3.1.2

siRNA transfections

HRECs were transfected using scrambled siRNAs (ID number: AM4635 [SCR],
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Thermo Fisher Scientific) or pre-designed siRNAs targeting human HOTAIR (ID:
n272221 [si1-HOTAIR], Thermo Fisher Scientific; n272222 [si2-HOTAIR], Thermo
Fisher

Scientific;

R-187951-00-0005

[SMARTpool

siHOTAIR],

Horizon

Discovery), EZH2 (ID: M-004218-03-0005 [SMARTpool si-EZH2], Horizon
Discovery), CTCF (ID: M-020165-02-0005 [SMARTpool siCTCF], Horizon
Discovery), DNMT1 (ID: s4216 [siDNMT1], Thermo Fisher Scientific) or mouse
Hotair (ID: R-173526-00-0005 [SMARTpool siHOTAIR], Horizon Discovery)
using Lipofectamine 2000 (Invitrogen, Burlington, ON, Canada) and Opti-MEM
reduced serum media (Thermo Fisher Scientific). As documented previously by us
[19,20,27,28,31,38], cells were transfected with 100 nM of each siRNA for 3-4
hours and subsequently recovered in complete EBM-2 overnight. Cells were then
serum starved the following morning, between 18-24 hours, and then incubated with
specific glucose concentrations (5 mmol/L or 25 mmol/L) for 48 hours. Knockdown
of the target genes were then confirmed using RT-qPCR.

3.1.3

Enzyme-linked immunosorbent assay (ELISA)

Human VEGF-A (R&D Systems, Minnesota, USA) and mouse Vegf-a (Invitrogen)
ELISA kits were used to measure the cytokine levels from HREC supernatants and
mice retinal tissues, respectively. Cytokine concentrations were quantified using the
BCA protein assay kit (Pierce, Rockford, IL, USA) and 100 µg protein
concentrations were used for each ELISA kit according to the manufacturer’s
instructions. The optical density for each well was determined at 450 nm and
corrected at 568 nm using the Multiskan FC Microplate Photometer (Thermo Fisher
Scientific, Massachusetts, USA).

3.1.4

Endothelial tube formation assay

When performing the tube formation assay, ~1.5x104 HRECs (pre-treated with either
SCR siRNA or siHOTAIR) were seeded into a 96-well plate containing 100 µL of
BD Phenol red-free matrigel matrix (BD Biosciences, Bedford, MA, USA) per well.
In the presence of growth medium, cells were allowed to attach for one hour in a
humidified incubator with 5% CO2 at 37°C. Following one-hour incubation, the
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growth medium was replaced with serum-free medium containing appropriate
glucose concentrations (5 mM or 25 mM) and/or exogenous VEGF-A protein
concentrations (50 ng/mL). At the six-hour mark, images were taken at a 40x
magnification using the Nikon Diaphot microscope (Nikon Canada, Mississauga,
ON, CAN) with a PixeLINK camera (PixeLINK, Ottawa, ON, CAN) and images
were captured from at least two field views per well (n= 8 independent
samples/group). In order to assess the total number of tubules and branching points
in the images, the WimTube Image analyzer software (Wimasis) was used and these
results were plotted graphically.

3.1.5

RNA fluorescence in situ hybridization (RNA-

FISH)
As previously described [20,27,86], HRECs were seeded at 75% confluency on glass
cover slips in 12-well plates, serum starved over night, and treated with various
glucose concentrations (NG or HG) for 48 hours. RNA fluorescence in situ
hybridization (FISH) was performed according to the manufacturer’s protocol for
adherent cells (https://www.biosearchtech.com/support/resources/stellaris-protocols)
and Stellaris FISH probes for Human HOTAIR with Quasar 570 dye (5 nmol;
Biosearch Technologies, Petaluma, CA, USA) were used for hybridization. HRECs
were also counterstained with 4´,6-diamidino-2-phenylindole (DAPI; Vector
Laboratories, Burlingame, CA, USA) and mounted with Vectashield mounting
medium (Vector Laboratories). Images were captured with the Cytation 5 Cell
Imaging Multi-Mode Reader (BioTek, Winooski, VT, USA), at a magnification of
20X, by researchers blinded to the experimental groups. Yellow fluorescent protein
(YFP), DAPI, and phase contrast filters were used and images were subsequently
analyzed using ImageJ software (NIH, Bethesda, MD, USA).

3.1.6

RNA immunoprecipitation (RIP)

Cell lysates from HRECs cultured in NG or HG were collected for
immunoprecipitation at the 48-hour mark using the Magna RIP RNA-binding protein
immunoprecipitation kit (Millipore, Etobicoke, ON, CAN) [20,28], following the
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manufacturer’s

instructions.

Anti-IgG

(control)

and

anti-EZH2

antibodies

(Millipore) were used to co-precipitate the RNA-binding proteins of interest. The
extracted RNAs were then reversed transcribed to cDNA, analyzed by RT-qPCR and
normalized to the levels of B-actin mRNA (encoding a housekeeping protein).

3.1.7

3-Deazaneplanocin

A

(DZNep),

5-Aza-2’-

deoxycytidine (5-aza-dC) and 2-deoxy-D-glucose (2-DG)
treatments
Following the concentrations documented in previous studies, DZNep (Cayman
Chemical, Ann Arbor, MI, USA; 5 µM), 5-aza-dC (Sigma, St. Louis, USA; 5 µM) or
2-DG (Sigma; 0.6 mM and 5 mM) pre-treatment was applied to HRECs for 1 hour
prior to the addition of D-glucose [19,28,31,45]. DZNep, 5-aza-dC or 2-DG-treated
HRECs and their respective controls were collected at 48 hours for further analyses.

3.1.8

JC-1 assay

In order to assess mitochondrial health and functional status, the JC-1 assay was
employed [38]. Briefly, HRECs were treated with either SCR siRNA or siHOTAIR
prior to glucose culture and at the 48-hour mark, cells were subsequently incubated
for 10 minutes with 10 µM of the JC-1 dye (5,5´,6,6´-tetrachloro-1,1´,3,3´tetraethylbenzimi-dazolylcarbocyanine iodide; Abcam, Toronto, ON, CAN).
Following the manufacturer’s instructions, HRECs were then washed three times
using the JC-1 dilution buffer. In order to stain the nuclear regions, DAPI (Vector
Laboratories) was used following JC-1 staining. Fluorescence images were captured
at 20X magnification using the Zeiss LSM 410 inverted laser-scanning microscope
(Carl Zeiss Canada, North York, ON, CAN) and images were analyzed using
ImageJ.

3.1.9

8-OH-dG staining

Following siRNA pre-treatment, HRECs were plated in eight-chamber tissue culture
slides and incubated for 48 hours after glucose challenge (NG or HG) [38,85].
Following the manufacturer’s instructions, cells were fixed with methanol and then
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stained for 8-hydroxy-2′-deoxyguanosine (an oxidative DNA damage marker; 8OHdG; 1:50, Santa Cruz Biotechnology, Dallas, TX, USA). Nuclear staining was
also performed using DAPI (Vector Laboratories). Microscopy was performed by a
blinded examiner, who was unaware of the identity of the samples, using a Zeiss
LSM 410 inverted laser scan microscope (Carl Zeiss Canada) and the images were
captured at a 20X magnification and subsequently analyzed using ImageJ.

3.1.10 Chromatin immunopreciation-qPCR (ChIP-qPCR)
ChIP assays (Milipore, Temecula, CA, USA) were carried out as previously
described by us [19]. Briefly, HRECs were pre-treated with either SCR siRNA or
siHOTAIR and subsequently cultured in NG or HG for 48 hours. Cells were then
fixed with 1% formaldehyde, incubated for 10 minutes at 37°C, and then lysed and
sonicated to shear DNA. ChIP assays were performed using anti-trimethyl-Histone
H3 (Lys27; H3k27me3; Millipore), anti-RNA polymerase II (Millipore), anti-IgG
(Millipore) and anti-acetyl-Histone H3 (K9, K14, K18, K23, K27; Abcam)
antibodies. Anti-mouse IgG was used as a negative control. The immunoprecipitated
DNA was detected by RT-qPCR using promoter-specific primers for VEGF-A: distal
promoter region (forward: 5’-GTAGTCCCAGGGTGCAACAC-3’, reverse: 5’GACTGGCTAGAATGGGCATC-3’, location relative to transcriptional start site
[TSS]:

-4896

bp)

and

proximal

promoter

CGGTGCTGGAATTTGATATTCATTGAT-3’,

region

(forward:

reverse:

5’5’-

TTCAAGTGGGGAATGGCAAGC-3’, location relative to TSS: -189 bp) [87].

3.1.11

WST-1 cell viability & proliferation assay

Following glucose and siHOTAIR treatments, the viability of HRECs was
determined using the WST-1 Cell Viability Assay (Roche) at 48 hours. Using the
Multiskan FC Microplate Photometer (Thermo Fisher Scientific), absorbances were
first measured at 450 nm and then corrected using 690 nm as the reference
wavelength.
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3.1.12

Electron microscopy

Following the transfection of HRECs on coverslips, the inserts with attached cells
were fixed in 2.5% glutaraldehyde in phosphate buffer and processed for EPON
embedding as previously described [92]. Ultra-thin sections on 200 mesh nickel
grids were stained with uranyl acetate and lead citrate and examined
electronmicroscopically (Phillips EM-420 TEM).

3.1.13 Methylation analysis of CpG sites across HOTAIR
Differential methylation patterns of CpG sites across the HOTAIR gene were
identified in HRECs, incubated in NG or HG environments for 2 days (48 hours) or
7 days (168 hours), using the Illumina Infinium MethylationEPIC BeadChip array
(Illumina, CA, USA). At each respective time-point, genomic DNA was extracted
from these cells and 1 µg of DNA was used for bisulfite conversion using the Blood
& Cell Culture DNA Mini Kit (Qiagen, Toronto, ON, CAN). The HiScan System
(Illumina, CA, USA) was used to obtain the array readout and the methylated and
unmethylated signal intensity data were then imported into R 3.5.2 for analysis.
Following our previously published protocols [55], normalization was performed
using the Illumina normalization method with background correction using the minfi
package. Probes with detection p-value >0.01 were excluded from the downstream
analysis. In addition, probes known to contain single nucleotide polymorphisms
(SNPs) at the CpG interrogation or the single nucleotide extension were removed.
Methylation level for each probe was measured as a beta value (β-value), calculated
from the ratio of the methylated signals versus the total sum of unmethylated and
methylated signals, ranging between 0 (no methylation) and 1 (full methylation).
Three independent samples were used per group.

3.1.14

Diabetic animal models

The Western University Council for Animal Care Committee approved all animal
models used in this study and experiments were performed in accordance with The
Guide for the Care and Use of Laboratory Animals (NIH Publication 85-23, revised
in 1996). Beginning with our initial two-month in vivo model, male rats (Sprague-
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Dawley; ~175 g, 6 weeks old) or male mice (C57/BL6 background; ~25 g, 8 weeks
old) were obtained (Charles River, Wilmington, MA, USA) and randomly divided
into control and diabetic groups. Streptozotocin (STZ) was used to generate a type 1
diabetic animal model and methods of diabetes induction and monitoring have been
previously described [9,20,27,28,85,86,88]. At two months following diabetes
induction, animals were euthanized (n= 8 for both mice groups; n= 5 for control rats
and n=9 for diabetic rats) and retinal tissues were collected for RNA extraction and
Hotair RNA levels were assessed using RT-qPCR.
For our short-term therapeutic in vivo model (4-week duration), wild-type mice were
obtained (Charles River; C57BL/6J background; ~25 g, 8 weeks old) and randomly
divided into four groups (n= 6/group): control mice administered intravitreal
injections of SCR siRNA (negative control) or siHOTAIR, and diabetic mice
administered intravitreal injections of SCR siRNA or siHOTAIR. Prior to
administering intravitreal injections, STZ-induced diabetes was first confirmed in
diabetic animals (>20 mmol/L blood glucose levels) using the above methodologies.
After the onset of diabetes, a 1 µl solution (100 nmol/L) containing either SCR
siRNA or siHOTAIR with Lipofectamine 2000 (Invitrogen) was injected into the
vitreous chamber of the diabetic mice eye once every week for up to three weeks.
Control mice were also injected similarly with the same volume of SCR siRNA or
siHOTAIR with Lipofectamine. All mice were anaesthetized using isoflurane
(2.25% mixed with 900 mL/min O2) and intravitreal injections were performed with
a 33-gauge needle attached to a 10 µl glass syringe (Hamilton, Reno, USA). Surgical
positioning of the needle and the general duration of each intravitreal injection have
been described previously [89]. No post-surgical ocular complications occurred
throughout the 4-week study.

3.1.15

Toxicity and Histopathological Analyses

To determine potential adverse effects of siHOTAIR in mice, toxicity analyses were
performed in addition to the regular monitoring of mice (C57/BL6 background) [85].
Age-matched mice were divided into four groups: SCR siRNA group (negative
control; 100 nmol/L; n=3), siHOTAIR low-dose group (25 nmol/L; n=3), siHOTAIR
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middle-dose group (50 nmol/L; n=3) and siHOTAIR high-dose group (100 nmol/L;
n=3). SCR siRNA or siHOTAIR were intravitreally injected once, as a single-dose,
and mice were followed-up for 7 consecutive days. Following this time-point, organs
were excised, fixed in 10% buffered formalin solution and embedded, and sectioned
into 5 µm thick sections. The tissue sections were then stained with hematoxylin and
eosin (H&E) for routine histology. A blinded pathologist evaluated the
histopathological damage using a light microscope and the images were captured
(Nikon, Japan). Of note, in order to examine long-term toxicity of siHOTAIR, we
had also performed H&E staining for the mice tissues obtained from our 4-week
therapeutic model (n= 3/group).

3.1.16

Clinical sample collection

The Western Research Ethics Board and Lawson Health Research Institute at the
University of Western Ontario (London, ON, CAN) approved the clinical component
of this study. Patients provided informed consent prior to the procurement of
specimens and all of the samples were handled in accordance with the Declaration of
Helsinki. Both serum and undiluted vitreous humor (VH) were collected from
patients undergoing a pars plana vitrectomy by an experienced vitreoretinal surgeon.
Both specimens were categorized into two groups: control and diabetic retinopathy
(DR). The DR group comprised of patients diagnosed with advanced stages of DR,
including proliferative DR (PDR; n= 11; mean age ± SD= 60.9 ± 10.43 years; 10
males and 1 female), while the control group consisted of patients that had no
previous history of diabetes mellitus and were diagnosed with idiopathic macular
hole or a separate non-diabetic ocular condition (n= 10; mean age ± SD= 69.2 ± 8.87
years; 2 males and 8 females). PDR was defined as the presence of
neovascularization or fibrous proliferation of the disc or elsewhere on the retina. As
previously described [27,28], total RNA was extracted from 500 µL of VH samples
and 200 µL of serum samples using the TRIzol reagent (Invitrogen) and a serum
RNA extraction kit (Bio Basic Inc., Markham, ON, CAN) following the
manufacturer’s protocol. After conversion to cDNA, RT-qPCR was used to evaluate
the expression of HOTAIR in these samples.
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3.1.17

RNA

isolation

and

quantitative

real-time

polymerase chain reaction (RT-qPCR)
As extensively described by us [9,19,20,27,28,31,38,85,86], total RNA was
extracted using the TRIzol reagent (Invitrogen). Once total RNA was obtained, a
spectrophotometer (260 nm; Gene Quant, Pharmacia Biotech, USA) was used to
quantify RNA concentrations in which 1-2 µg of total RNA was reverse transcribed
to complementary DNA (cDNA) using a high-capacity cDNA reverse-transcription
kit (Applied Biosystems/Thermo Fisher Scientific). cDNA was then amplified in the
LightCycler 96 System (Roche Diagnostics, Laval, QC, CAN) using the SYBRgreen master mix (Takara Bio, Mountain View, CA, USA) and specific primers for
the genes of interest (Sigma; Appendix B, Supplementary Tables 1 and 2). RTqPCR results were analyzed using the LightCycler 96 SW 1.1 software (Roche) and
expression levels were calculated by the relative standard curve method using β-actin
as an internal control for sample normalization.

3.1.18

Statistical analyses

Statistical differences were evaluated between groups using GraphPad Prism 7 (La
Jolla, CA, USA). Data were considered statistically significant if the P value was
less than 0.05. All quantitative data for the in vitro experiments are presented as
mean ± SEM, while all in vivo data are presented as mean ± SD. Experiments were
performed in triplicate (n= 6 per group), unless specified. Statistical significance for
samples with non-parametric distribution was identified using the Mann-Whitney U
test, while two-tailed Student’s t-test (when comparing two conditions) or one-way
ANOVA (for multiple comparisons; followed by Tukey’s post hoc test) was applied
for parametric variables.

3.2 Results
3.2.1

HOTAIR RNA expressions are glucose-dependent

and appear to follow oscillating patterns with significant
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elevations at the 48-hour time-point
Using microarray analyses, we previously explored the global expression profiles of
lncRNAs in HRECs cultured with NG or HG for 48 hours (Gene Expression Omnibus
[GEO] ID: GSE122189). Interestingly, following stringent filtering criteria (fold
change ≤ or ≥ 2 and an adjusted p-value <0.05), thousands of lncRNAs were
differentially expressed after HG glucose culture; in particular, when examining
between replicates, 2669-3518 lncRNAs were found to be upregulated and 890-1991
lncRNAs were found to be downregulated in HRECs challenged with HG (Appendix
B, Supplemental Figures 1A-C). Among the upregulated lncRNAs, the lncRNA
HOTAIR was increased by 2.67-fold in HG-treated HRECs compared to NG controls
(Appendix

B,

Supplemental

Figure

1D).

Real-time

quantitative

reverse

transcription-PCR (RT-qPCR) further confirmed the elevated expressions of HOTAIR
following 48 hours of HG culture in HRECs (Figure 3.1A), which were also
associated with augmented expressions of VEGF-A and ET-1 transcripts (Figure
3.1C-D). Since lncRNAs have been reported to demonstrate differential expression
patterns across various time-points [28-30], we investigated HOTAIR RNA
expressions at 6, 12, 24, 48, and 72 hours. Intriguingly, when compared to their
respective NG controls, HOTAIR demonstrated significant HG-induced elevations
only at the 48-hour (Figure 3.1C; p=0.0014). Furthermore, to determine whether
specific glucose concentrations can influence HOTAIR expressions, we cultured
HRECs in the presence of 5, 10, 15, 20, and 25 mmol/L (mM) D-glucose for 48 hours.
As demonstrated by RT-qPCR, HOTAIR RNA expressions peaked significantly
following 25 mM glucose culture (mimicking hyperglycemia) compared to cells
cultured with 5 mM glucose (mimicking euglycemia) (p=0.0077; Figure 3.1D).
Therefore, based on the present findings and our previously published studies
[19,20,27,28,31], the 48-hour time-point and 5 mM and 25 mM glucose concentrations
were used for our subsequent in vitro experiments. Of note, for the above experiments,
no significant differences in HOTAIR expressions were observed when using an
osmotic control (25 mM L-glucose; data not shown).
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Figure 3.1. HOTAIR RNA expressions are associated with increased expressions of
angiogenic markers in HRECs cultured with high glucose (HG) and appear to be
glucose-dependent with significant elevations at 48 hours. RT-qPCR analyses
demonstrating HG-induced increases of (A) HOTAIR, (B) VEGF-A, and (C) ET-1 in HRECs
compared to HRECs cultured in basal glucose levels at 48 hours (normal glucose; NG). (D)
Expressions of HOTAIR across various time-points. (E) Relative HOTAIR RNA levels
following different glucose concentrations following 48 hours of culture. β-actin was used as
an internal control. Statistical significance was assessed using two-tailed Student’s t-test when
comparing two conditions or one-way ANOVA for multiple comparisons followed by Tukey’s
post hoc test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not significant). Data
represents

the

mean

±

SEM

of

3

independent

experiments

(n=6/group).

To delineate the sub-cellular localization of HOTAIR in HRECs, we performed RNA
fluorescence in situ hybridization (RNA FISH). RNA FISH showed that HOTAIR can
be present in both nuclear and cytoplasmic compartments of HRECs, with a
predominant localization in the perinuclear/cytosolic region (Figure 3.2A). Moreover,
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further confirming our microarray and RT-qPCR findings, RNA FISH analyses
demonstrated that HG significantly promotes elevated expressions of HOTAIR when
compared to NG controls (Figure 3.2B; p<0.0001). Taken together, these data reveal
that HG is an inducer of HOTAIR expressions and additionally imply an endothelialspecific role for HOTAIR during HG stress, where HOTAIR may be involved in the
regulation of nuclear and cytoplasmic processes.

Figure 3.2. High glucose promotes HOTAIR expressions and HOTAIR can be localized
in the nucleus and cytoplasm of retinal endothelial cells. (A) Visualization of HOTAIR
localization in HRECs at 48 hours as indicated by RNA fluorescence in situ hybridization
using Stellaris FISH probes for human HOTAIR with Qasar 570 dye. Cells were also
counterstained with DAPI to visualize the nuclei. Original magnification, 20X; scale bars,
100 µm. (B) Mean integrated densities of HOTAIR expressions calculated using ImageJ.
Statistical significance was assessed using two-tailed Student’s t-test (****p<0.0001). Data
represents the mean ± SEM of 50 cells captured per sample (n=4-5 independent
samples/group).
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3.2.2

HOTAIR directly mediates angiogenesis in vitro

With previous reports documenting the pro-angiogenic capabilities of HOTAIR in
nasopharyngeal carcinoma [32] and glioma cells [33], we wanted to examine whether
HOTAIR

can

mediate

angiogenesis

in

hyperglycemic

environments,

since

angiogenesis is a major pathological process in patients with proliferative diabetic
retinopathy (PDR). Therefore, in order to determine HOTAIR’s angiogenic role, we
used HRECs and performed an endothelial cell tube formation assay, which is a
widely used in vitro assay that models the reorganization stage of angiogenesis and is
a rapid method that can determine genes or pathways involved in angiogenesis [34].
As evident by the images in Figure 3.3, at the 6-hour mark, cells pre-treated with
scrambled siRNAs (denoted as ‘SCR’) and cultured in the presence of HG have an
elevated presence of capillary-like structures (tubules) compared to pre-treated SCR
cells incubated in NG. However, when cells were treated with siHOTAIR, the degree
of branching and total number of tubules significantly decreased in both NG and HG
conditions at 6 hours (Figure 3.3B and 3.3C; p<0.0001). Even more intriguing at the
6-hour mark, when HRECs were pre-treated with siHOTAIR, the presence of both
exogenous VEGF proteins and HG were not able to completely recover the degree of
branching and number of tubules compared to HG controls, which implies that the
knockdown of HOTAIR may be further desensitizing ECs to other external
angiogenesis-causing factors in HG. These findings encouraged us to explore other
angiogenic factors [35], such as angiopoietin-like 4 (ANGPTL4), placental growth
factor (PGF), hypoxia-inducible factor (HIF), interleukin-1 beta (IL-1β), and diabetesrelated molecules including poly [ADP-ribose]-polymerase 1 (PARP1) [36],
Cytochrome B [37,38], and several additional epigenetic mediators in the next set of
experiments below.
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Figure 3.3. HOTAIR directly mediates angiogenesis in vitro. (A) Images captured from the
endothelial tube formation assay at the 6-hour mark for HRECs treated with scrambled
siRNAs (SCR), siHOTAIR or exogenous VEGF proteins and cultured in NG or HG
conditions. The WimTube Image analyzer software was used to calculate (B) the number of
tubules and (C) the total branching points in each group. Statistical significance was assessed
using one-way ANOVA for multiple comparisons, followed by Tukey’s post hoc test
(****p<0.0001). Data represents the mean ± SEM of 3 independent experiments (n=8/group)
and images were captured from at least two field views per well. Original magnification, 40X.

3.2.3

HOTAIR knockdown can prevent the induction of

several angiogenic factors and diabetes-related molecules
in vitro
To determine the direct regulatory capabilities of HOTAIR on the aforesaid molecules
of pathogenetic significance in DR in vitro, we carried out a loss-of-function
experiment that involved siRNA-mediated knockdown of HOTAIR in HRECs.
Amongst the three siRNAs tested and albeit significant decreased HOTAIR
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expressions were observed across all siRNA treatments, the ‘SMARTpool siHOTAIR’
evoked the largest reduction of HOTAIR RNA levels (by ~91%, p<0.0001) in HGcultured HRECs compared to HG SCR controls (Appendix B, Supplemental Figure
2). Therefore, as such, we selected the ‘SMARTpool’ siRNA for our subsequent
downstream analyses.
Accompanying the reduced HOTAIR levels in siHOTAIR-treated HRECs challenged
with HG, significantly decreased expressions of various RNA transcripts implicated in
angiogenesis (VEGF-A, ET-1, ANGPTL4, PGF, HIF-1α; Figure 3.4), DNA and
oxidative damage (PARP-1 and Cytochrome B; Figure 3.4), and epigenetic regulation
(EZH2, SUZ12, DNMT1, DNMT3A, DNMT3B, CTCF, and P300; Appendix B,
Supplemental Figure 3) were also evident when compared to HG controls. These
findings indicate that the lncRNA HOTAIR is directly implicated in the transcriptional
regulation of several DR-related molecules. To determine whether these molecular
changes are also reflected at the protein level, we selected one of the angiogenic
markers (VEGF-A) for further follow-up via ELISA. In parallel to our RNA results,
the knockdown of HOTAIR can significantly prevent glucose-induced upregulations of
VEGF-A proteins in HRECs (Appendix B, Supplemental Figure 4A; p<0.0001).
Extending our findings, we had additionally examined the expressions of HOXD3 and
HOXD10, since HOTAIR has been implicated in the transcriptional repression of
HOXD loci [39]. Indeed, the knockdown of HOTAIR in HRECs cultured with HG can
induce significant upregulations of HOXD3 (p=0.0473) and HOXD10 (p=0.0001)
compared to SCR HG controls (Appendix B, Supplementary Figures 4B and 4C).
We had also investigated the viability of HRECs following siHOTAIR treatment and
as evidenced by our WST-1 findings, siRNA-mediated knockdown of HOTAIR can
significantly improve cellular viability compared to SCR controls (Appendix B,
Supplemental Figure 4D; p<0.0001). Collectively, these results suggest that HOTAIR
is a critical regulator of glucose-induced EC dysfunction in vitro.
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Figure 3.4. HOTAIR knockdown can prevent the induction of several angiogenic factors
and diabetes-related molecules in vitro. RT-qPCR analyses of (A) HOTAIR, (B) VEGF-A,
(C) ET-1, (D) ANGPTL4, (E) PGF, (F) IL-1β, (G) HIF-1α, (H) PARP1, and (I) Cytochrome b
expressions following the administration of SCR siRNA or siHOTAIR in HRECs subjected to
48 hours of NG or HG culture. β-actin was used as an internal control. Statistical significance
was assessed using one-way ANOVA for multiple comparisons, followed by Tukey’s post hoc
test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not significant). Data represents
the mean ± SEM of 3 independent experiments (n=6/group).

3.2.4

Hotair is significantly elevated in the retinas of

diabetic mice and rats at 2 months
Following our in vitro findings, we wanted to confirm in vivo whether HOTAIR had a
similar pathogenetic phenotype in the retina in diabetes. As such, we employed a
streptozotocin (STZ)-induced diabetic animal model involving both C57/BL6 mice
and Sprague-Dawley rats and subsequently extracted retinal tissues after 2 months of
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diabetes. Diabetic animals showed hyperglycemia and glucosuria (data not shown), as
well as reduced body weight gain and hyperglycemia (Appendix B, Supplemental
Figures 8C and 8D). In parallel to the trends observed from our in vitro experiments,
distinct patterns of Hotair RNA expressions were evident between the retinas of
control and diabetic animals, with significant upregulations of Hotair in the retinas of
both diabetic mice (p=0.0281; Appendix B, Supplemental Figure 5A) and rats
(p=0.0420; Appendix B, Supplemental Figure 5B) at 2 months, suggesting that
retinal Hotair expressions share a positive association with diabetes.
After confirming the significance of Hotair in the retina in diabetes, we sought to
evaluate the therapeutic potential for siRNA-mediated modulation of HOTAIR as a
new approach to treat DR. In order to determine this, we had first acquired a
SMARTpool siHOTAIR that specifically targeted mouse Hotair, tested this siRNA
compound on two EC-specific mouse cell lines (mouse retinal microvascular ECs
[MRECs] and primary mouse lung ECs [MLECs] (C57/BL6)), and then elucidated the
therapeutic significance of siHOTAIR using a short-term, one-month, diabetic animal
model. Beginning with our in vitro and ex vivo experiments, we found that 50 nM and
100 nM concentrations of siHOTAIR can evoke significant reductions in Hotair RNA
levels across both EC-lines cultured with HG, when compared to SCR HG controls
(Appendix B, Supplemental Figure 6). In fact, using a 50 nM concentration, ~79%
and ~53% reductions were observed in MRECs and MLECs challenged with HG,
respectively, when compared to SCR HG controls; whereas, at a 100 nM
concentration, ~80% and ~43% reductions were noted in HG-cultured MRECs and
MLECs, respectively (Appendix B, Supplemental Figure 6A and 6D). Similarly,
when compared to controls, statistically significant reductions for both Vegf-a and
Angptl4 transcripts were also found after Hotair knockdown in MRECs (at a 100 nM
concentration; Appendix B, Supplemental Figure 6B and 6C). While, conversely,
significant reductions in these angiogenic transcripts were not observed in MLECs
(Appendix B, Supplemental Figure 6E and 6F), which suggests that transfection
efficiencies may differ between EC subtypes. Nevertheless, based on the findings from
MRECs, we selected the mouse-specific siHOTAIR for our subsequent animal
experiments.
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3.2.5

Intravitreal administration of siHOTAIR is non-toxic

and prevents early DR-related retinal changes
We initially performed a toxicology study involving siHOTAIR. Wild-type C57BL/6
mice were subjected to a one-time intravitreal injection that consisted of either
scrambled siRNA control (50 nM; SCR) or siHOTAIR at varying concentrations (25
nM, 50 nM, and 100 nM) and were monitored for seven days and then euthanized for
tissue collection. No behavioral changes or ocular complications were observed in the
mice throughout the duration of the experiments. As evidenced by hematoxylin and
eosin (H&E) staining, no structural abnormalities were observed across retinal, heart,
lung, liver, and kidney tissues following intravitreal siHOTAIR injection at 25, 50, or
100 nM concentrations (Appendix B, Supplemental Figure 7). Furthermore, at the 7day mark, retinal HOTAIR expressions appeared to be the lowest following a 100 nM
dose of siHOTAIR (~50% reduction) when compared to SCR controls and other
siHOTAIR concentrations (Appendix B, Supplemental Figure 8A). Using this
information, we opted to select 100 nM as the optimal concentration of siHOTAIR for
our therapeutic animal model.
To understand the therapeutic effects of siHOTAIR, diabetes was induced in C57BL/6
mice using STZ injections. All diabetic mice showed significant hyperglycemia and a
progressive loss of body weight (Appendix B, Supplemental Figures 8B and 8C), as
well as polyuria and glucosuria (data not shown). Compared to SCR diabetic controls,
Hotair knockdown did not further affect body weight and blood glucose levels
(Appendix B, Supplemental Figures 8B and 8C). When examining the pathogenetic
molecules implicated in DR-related microvascular dysfunction, we found elevated
RNA expressions of Hotair, Vegf-a, Ctcf, Et-1, Angptl4, Mcp-1, Il-1β, Pgf, Hif-1α,
p300, polycomb repressive complex 2 [Prc2] components (Ezh2, Suz12, and Eed) and
Parp1 in the retinal tissues of diabetic mice administered SCR siRNAs (Figure 3.5).
Whereas, the knockdown of Hotair (a ~58% reduction) could significantly reduce
diabetes-induced upregulations of Hotair, Vegf-a, Et-1, Angptl4, Mcp-1, Ctcf, Hif-1α,
p300, Prc2 components (Ezh2, Suz12, and Eed), and Parp1—suggesting that HOTAIR
knockdown can alleviate early molecular aberrations induced by a diabetic milieu
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within the retina (Figure 3.5). Of note, we did not observe statistically significant
changes in retinal expressions of Hoxd3 between SCR and siHOTAIR-treated diabetic
animals (Appendix B, Supplemental Figure 8D). Furthermore, as indicated by H&E
stains and in comparison to SCR controls, we did not find any observable cellular
anomalies or toxic effects in retinal, cardiac, lung, liver, kidney, and brain tissues
following 1 month of siHOTAIR injections (Appendix B, Supplemental Figure 9).

Figure 3.5. In vivo knockdown of HOTAIR can significantly prevent early glucoseinduced elevations of angiogenic and diabetes-associated molecules in the diabetic retina.
Non-diabetic and diabetic C57BL/6J mice were administered intravitreal injections of
scrambled siRNAs (SCR) or siHOTAIR once every week for up to 3 weeks. Animals were
then euthanized at 4 weeks (1 month) and retinal tissues were isolated and extracted for RNA.
RT-qPCR was employed to analyze (A) Hotair, (B) Vegf-a, (C) Et-1, (D) Angptl4, (E) Parp1,
(F) Mcp-1, (G) Il-1β, (H) p300, (I) Ezh2, (J) Suz12, (K) Eed, (L) Pgf, (M) Hif-1α, and (N)
Ctcf expressions. β-actin was used as an internal control. Statistical significance was assessed
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using one-way ANOVA for multiple comparisons, followed by Tukey’s post hoc test
(*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not significant). Data represents the
mean ± SD (n=6/group).

3.2.6

HOTAIR is upregulated in the vitreous and serum

of diabetic patients
After establishing HOTAIR’s biological importance in diabetic animals, we wanted to
determine whether HOTAIR expressions have similar clinical importance from a
potential biomarker angle. To this extent, we examined HOTAIR expressions in the
serum and vitreous humor (VH) of patients with DR. Based on our RT-qPCR
analyses, HOTAIR expressions were distinct and significantly upregulated in the
vitreous (p<0.0001; Figure 3.6A) and serum (p=0.0021; Figure 3.6B) of patients with
PDR than that of non-diabetic patients without retinopathy. Moreover, we performed
two-sided Pearson correlations to determine whether a linear association for HOTAIR
expressions existed between the two sample types. Interestingly, statistically
significant correlations for HOTAIR were found between serum and vitreous samples,
where increased serum HOTAIR expressions positively correlated with increased
vitreous HOTAIR expressions (p=0.0005, R2=0.482; Figure 3.6C). Taken together,
our clinical findings suggest that HOTAIR expressions in the vitreous and serum are
associated with DR and may have potential to be used as a prognostic and diagnostic
biomarker for DR.
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Figure 3.6. HOTAIR is upregulated in the serum and vitreous of patients with
proliferative diabetic retinopathy (PDR). RT-qPCR analyses were used to examine
HOTAIR expressions in the (A) vitreous and (B) serum from non-PDR (control) and PDR
patients. β-actin was used as an internal control. Statistical significance was assessed using the
Mann-Whitney U test. Data represents the mean ± SD (n=10 per control group or n=11 per
DR group; **p<0.01 or ****p<0.0001). (C) Two-sided Pearson correlations determined that a
linear (positive) association for HOTAIR expressions existed between the two sample types
(***p<0.001). Legend: DR= PDR.

3.2.7

HOTAIR knockdown can partially prevent glucose-

induced DNA and mitochondrial damage, as well as
disruptions of endothelial cell junctions in vitro
We then wanted to further explore some of the molecular mechanisms for HOTAIR in
vitro. With a previous report documenting HOTAIR’s implications in mitochondrial
dysfunction in HeLa cells [40] and based on the localization of HOTAIR from our
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RNA FISH experiments and the impact of siHOTAIR on Cytochrome B RNA levels,
we first assessed the mitochondrial transmembrane potential (ΔΨM) in HRECs after
HOTAIR knockdown through the detection of JC-1 signals. As shown in Figure 3.7,
HG significantly evoked mitochondrial depolarization (indicated by more green and
less red fluorescence; low ΔΨM) compared to scrambled NG controls (p<0.0001),
suggesting that HG induces mitochondrial depolarization/dysfunction in HRECs.
Conversely, when compared to SCR NG controls, the knockdown of HOTAIR in cells
cultured with NG can markedly increase mitochondrial activity (indicated by more red
and less green fluorescence; normal to high ΔΨM; p<0.0001). As expected, HOTAIR
knockdown partially reduces HG-induced mitochondrial dysfunction/depolarization
when compared to SCR HG controls (p=0.0459). Collectively, the JC-1 results
indicate that HOTAIR contributes to mitochondrial aberrations in hyperglycemic
environments.
Since it is well documented that HG can induce abnormalities in several glucose
metabolic pathways that subsequently lead to intracellular oxidative stress and DNA
damage [3,4,41], we examined the relationship between HG, HOTAIR, and 8-hydroxy2’-deoxyguanosine (8-OHdG) levels, a biomarker for oxidative DNA damage [42].
Indeed, in comparison to SCR NG cells, HRECs in the presence of SCR siRNAs and
HG demonstrated significant expressions of 8-OHdG (increase in green fluorescence;
p<0.0001, Figure 3.8). In contrast, however, HOTAIR knockdown significantly
reduced glucose-induced increases in 8-OHdG expressions compared to SCR HG cells
(p=0.0264), which suggests that HOTAIR may be implicated in HG-induced oxidative
damage. Moreover, an essential prerequisite in the development of DR is the loss of
endothelium, which is caused by chronic hyperglycemic exposure and demonstrated
by dysregulated endothelial cell-to-cell junctions [4]. To investigate this in our cell
culture model, we examined SCR or siHOTAIR-treated HRECs in HG using electron
microscopy. As expected, HG induced disruptions of cell junctions in HRECs treated
with SCR siRNAs (Appendix B, Supplemental Figure 17A). However, conversely,
the knockdown of HOTAIR preserved EC junctional integrity following HG culture
(Appendix B, Supplemental Figure 17B). These results further suggest that HOTAIR
contributes to DR-related EC dysfunction.
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Figure 3.7. HOTAIR knockdown can partially prevent glucose-induced mitochondrial
depolarization/dysfunction. (A) Images captured from the JC-1 assay, where HRECs were
pre-treated with scrambled (SCR) siRNAs or siHOTAIR and subsequently cultured in NG or
HG for 48 hours. Mitochondrial depolarization is indicated by more green and less red
fluorescence (low ΔΨM, suggesting unhealthy/dysfunctional mitochondrial), while a polarized
mitochondrial state is indicated by more red and less green fluorescence (normal to high
ΔΨM, suggesting healthy/functional mitochondria). Cells were also counterstained with DAPI
to visualize the nuclei. Original magnification, 20X; scale bars, 100 µm. (B) JC-1 red/green
fluorescence ratio was calculated using ImageJ. Statistical significance was assessed using
one-way ANOVA for multiple comparisons, followed by Tukey’s post hoc test (*p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not significant). Data represents the mean ±
SEM of 20 cells captured per sample (n=8 independent samples/group).
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Figure 3.8. Knockdown of HOTAIR can significantly prevent glucose-induced oxidative
damage. (A) Images captured from the 8-OHdG assay, where HRECs were pre-treated with
scrambled (SCR) siRNAs or siHOTAIR and subsequently cultured in NG or HG for 48 hours.
8-OHdG is a biomarker for nuclear and mitochondrial oxidative DNA damage, where
heightened oxidative damage is indicated by strong green fluorescence. Cells were also
counterstained with DAPI to visualize the nuclei. Original magnification, 20X; scale bars, 100
µm. (B) Mean integrated densities of 8-OHdG expressions calculated using ImageJ. Statistical
significance was assessed using one-way ANOVA for multiple comparisons, followed by
Tukey’s post hoc test (*p<0.05 or ****p<0.0001). Data represents the mean ± SEM of 20 cells
captured per sample (n=8 independent samples/group).
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3.2.8

HOTAIR-induced

production

of

DR-related

molecules depends on glycolytic metabolism
To have a better understanding of the regulatory mechanisms, we sought to examine
the upstream role of glucose on HOTAIR and the expression of its target molecules.
We employed 2-deoxy-D-glucose (an inhibitor of the glycolytic pathway [43]; 2-DG)
and investigated the effects of this glucose analogue on HRECs in vitro. Accordingly,
albeit the apoptotic nature of 2-DG (~45-55% viability indicated by trypan blue
exclusion assay [data not shown]), 2-DG treatment significantly blocked HG-induced
expressions of HOTAIR, VEGF-A, ET-1, ANGPTL4, MCP-1, IL-1β, CTCF, and
Cytochrome B (Figure 3.9), which further emphasized the upstream regulatory roles
played by glucose. Furthermore, inhibiting effective glucose metabolism (at 5 mM of
2-DG) evoked significant reductions in epigenetic molecules including EZH2, SUZ12,
EED, and DNMT1, but no differences were observed for DNMT3A and DNMT3B
(Appendix B, Supplemental Figure 10). Interestingly, even at 5 mM concentrations,
2-DG treatments also did not induce significant reductions in PARP1 and P300
expressions and did not augment Cytochrome B expressions, which may suggest that
the blockade of glycolysis may continue to produce direct oxidative stress through
nuclear transport mechanisms involving PARP1 and P300 rather than contributions of
oxidative damage from the mitochondria [44]. Moreover, at 5 mM concentrations,
HOXD3 and HOXD10 expressions were significantly upregulated in 2-DG-treated
HRECs cultured with HG (Appendix B, Supplemental Figures 10H and 10I)
compared to HG controls, further highlighting the inverse relationship shared between
HOTAIR and HOXD expressions. Taken together and in keeping with previous reports
that confirm the anti-angiogenic and apoptotic effects of 2-DG on ECs [45], our data
indicates that glucose works upstream of HOTAIR and inhibiting glucose uptake can
ultimately prevent the upregulation of HOTAIR and most of its downstream targets.

124

Figure 3.9. Glucose metabolism regulates HOTAIR and most of its downstream targets in
vitro. RT-qPCR analyses of (A) HOTAIR, (B) VEGF-A, (C) ET-1, (D) ANGPTL4, (E) MCP-1,
(F) IL-1β, (G) CTCF, (H) Cytochrome B, and (I) PARP1 expressions following 2-deoxy-Dglucose treatment (0.6 or 5 mM) in HRECs subjected to 48 hours of NG (5mM D-glucose) or
HG (25 mM D-glucose) culture. 2-deoxy-D-glucose is a potent inhibitor of glycolysis. β-actin
was used as an internal control. Statistical significance was assessed using one-way ANOVA
for multiple comparisons, followed by Tukey’s post hoc test (*p<0.05, **p<0.01, ***p<0.001,
****p<0.0001, or n.s.= not significant). Data represents the mean ± SEM of 3 independent
experiments (n=6/group).
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3.2.9

Histone

methylation

epigenetically

regulates

HOTAIR and its downstream targets
As HOTAIR and PRC2 (a critical histone methyltransferase) have shown a relationship
in cancer [46,47], we decided to investigate the role of histone methylation in the
context of diabetes. Beginning with the administration of a global histone methylation
inhibitor known as 3-deazaneplanocin A (DZNep) [48], we confirmed that HRECs in
the presence of HG plus DZNep had significantly reduced expressions of PRC2
components; in particular, EZH2, SUZ12, and EED transcripts were reduced by ~72%
(p<0.0001), ~48% (p=0.0005), and ~61% (p<0.0001), respectively, when compared to
SCR HG cells (Appendix B, Supplemental Figure 11A-C). Accompanying the
reduced expressions of PRC2 components in HRECs treated with DZNep and HG,
statistically significant reductions were also evident for HOTAIR, VEGF-A,
ANGPTL4, CTCF, PARP1, P300, and Cytochrome B transcripts when compared to
SCR HG controls (Figure 3.10). On the contrary, opposite trends were observed for
ET-1, MCP-1, IL-1β, HOXD3 and HOXD10 transcripts, where DZNep pre-treatment
plus HG culture of HRECs significantly augmented the expressions of the
aforementioned molecules (Figure 3.10 and Appendix B, Supplemental Figures
11D and 11E). These dynamic observations are in keeping with our previous studies
[20,28] and could suggest that DZNep is not completely selective and as such, may be
disrupting a number of different cellular crosstalks in ECs within a hyperglycemic
environment.
To confirm and expand our experimental findings using DZNep, we selected EZH2
(the catalytic subunit of PRC2 [49]) and CTCF (a critical transcription factor that can
maintain chromosome organization and is possibly implicated in the direct regulation
of HOTAIR [50,51]) for subsequent siRNA-mediated knockdown. Following siRNA
treatments and when compared to SCR HG controls, we confirmed significant
reductions for EZH2 (~77% knockdown; Figure 3.11E) and CTCF (~55%
knockdown; Figure 3.11F). Interestingly, inhibiting the expressions of EZH2 in HG
conditions also evoked significant reductions in HOTAIR, VEGF-A, ET-1, ANGPTL4,
CTCF, SUZ12, PARP1, MCP-1, IL-1β, Cytochrome B, and DNMT1 RNA expressions,
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while significant increases were seen for P300, HOXD3 ad HOXD10 transcript levels,
compared to SCR HG controls (Figure 3.11 and Appendix B, Supplemental Figure
12D-F). No significant differences in expressions were observed for DNMT3A and
DNMT3B following siEZH2 treatment. Taken together, these findings imply that
EZH2 (the critical component of PRC2) is also directly involved in the transcriptional
regulation of HOTAIR and several other downstream genes in a hyperglycemic
environment. Of note, the differences observed between ET-1, MCP-1, and IL-1β
RNA expressions for DZNep and siEZH2 treatments may have been due to the
particular selectivity profile for each compound (i.e. siRNAs are generally more
specific in gene knockdown versus global inhibitors for histone methylation).
On the other hand, the knockdown of CTCF in HRECs cultured with HG produced
differential expressions of several genes, including significant increases in HOTAIR,
ANGPTL4, EED, IL-1β, Cytochrome B, HOXD3, and HOXD10 and significant
decreases in ET-1, EZH2, PARP1, MCP-1, DNMT1, and P300 transcripts when
compared to their respective SCR HG controls. As well, no significant differences
were observed for VEGF-A, SUZ12, DNMT3A, and DNMT3B transcripts after the
silencing of CTCF in HRECs cultured with HG (Figure 3.11 and Appendix B,
Supplemental Figure 12). Based on these results, our collective findings allude to the
diverse roles of CTCF in gene regulation, where siRNA-mediated depletion of CTCF
can either augment glucose-induced expressions of certain genes (possibly through the
inability of CTCF to block the interaction between enhancers and promoters, leading
to subsequent gene induction) or repress the expressions of select genes, which may
occur due to changes in chromatin architecture that prevent gene induction [51,52].
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Figure 3.10. Histone methylation differentially regulates HOTAIR and its downstream
targets. HRECs were pre-treated with DZNep (a global histone methylation inhibitor) prior to
NG or HG culture for 48 hours. RT-qPCR was then used to analyze the expressions of (A)
HOTAIR, (B) VEGF-A, (C) ET-1, (D) ANGPTL4, (E) CTCF, (F) PARP1, (G) MCP-1, (H) IL1β, (I) P300, and (J) Cytochrome B. β-actin was used as an internal control. Statistical
significance was assessed using one-way ANOVA for multiple comparisons, followed by
Tukey’s post hoc test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not
significant). Data represents the mean ± SEM of 3 independent experiments (n=6/group).
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Figure 3.11. EZH2 and CTCF are directly involved in the transcriptional regulation of
HOTAIR and several other downstream genes. RT-qPCR analyses of (A) HOTAIR, (B)
VEGF-A, (C) ET-1, (D) ANGPTL4, (E) EZH2, (F) CTCF, (G) SUZ12, (H) EED, (I) PARP1,
(J) MCP-1, (K) IL-1β, and (L) Cytochrome B expressions following the administration of
scrambled (SCR) siRNAs, siEZH2, or siCTCF in HRECs subjected to 48 hours of NG or HG
culture. EZH2 is the catalytic subunit of PRC2 (a critical histone methyltransferase) and CTCF
is an important epigenetic transcription factor involved in the direct regulation of genes. βactin was used as an internal control. Statistical significance was assessed using one-way
ANOVA for multiple comparisons, followed by Tukey’s post hoc test (*p<0.05, **p<0.01,
***p<0.001, ****p<0.0001, or n.s.= not significant). Data represents the mean ± SEM of 3
independent experiments (n=6/group).
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3.2.10

HOTAIR binds with histone modifying enzymes

and regulates VEGF transcription
We then examined for possible direct relationships shared between HOTAIR and
critical histone modifying enzymes in HRECs and thus, we performed a RNA
immunoprecipitation (RIP). In comparison to IgG controls, our results demonstrated
that HOTAIR RNA levels were distinctly enriched in the precipitated anti-EZH2 and
P300-antibody fractions obtained from HRECs cultured in HG (p<0.0001; Appendix
B, Supplemental Figure 13), suggesting that HG promotes strong HOTAIR binding
associations to EZH2 and P300. Our findings are in agreement with previous reports
that have documented similar relationships with HOTAIR and these epigenetic
mediators [53,54].
Next, to demonstrate the involvement of histone modifications at the genomic level,
we performed chromatin immunoprecipitation (ChIP)-qPCR using antibodies for IgG
(negative control), RNA polymerase II (indicative of transcriptional activity; Pol II),
H3K27me3 (indicative of transcriptional repression), and pan-H3K9/14/18/23/27
acetylation (indicative of transcriptional activation). We treated HRECs with
siHOTAIR and employed primers that specifically spanned across the proximal and
distal promoter regions of VEGF-A for subsequent ChIP-qPCR analyses. Accordingly,
compared to NG controls, RNA Pol II levels were significantly enriched in both the
distal (p<0.0001; Figure 3.12A) and proximal promoter (p<0.0001; Figure 3.12D)
regions of VEGF-A in HRECs cultured with HG; whereas, the knockdown of HOTAIR
can markedly reduce Pol II enrichment in these regions compared to HG controls.
Conversely, under HG stimulation, significant reductions of H3K27me3 enrichment
were observed in both VEGF-A distal (p<0.0001; Figure 3.12B) and proximal
promoter (p<0.0001; Figure 3.12E) regions and siHOTAIR treatment significantly
reversed glucose-induced reductions of H3K27me3 in the VEGF-A promoter.
Moreover, when compared to NG controls, HG conditions significantly augmented the
enrichment of H3K9/14/18/23/27 acetylation in both VEGF-A promoter regions, while
the knockdown of HOTAIR significantly prevented glucose-induced increases in panacetylation levels of H3K9/14/18/23/27 across the VEGF-A distal (p<0.0001; Figure
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3.12C) and proximal promoter (p<0.0001; Figure 3.12F) regions, compared to HG
groups. Hence, we concluded that a dynamic interplay exists between HOTAIR,
histone–modifying enzymes, and RNA Pol II in the transcriptional regulation of genes,
such that HOTAIR may have an active role in modulating the epigenome during
hyperglycemic stress. Of note, no significant differences were observed between IgG
NG and HG groups, confirming the specificity of the antibodies.

Figure 3.12. HOTAIR can govern the transcriptional status of VEGF-A in hyperglycemic
environments. ChIP-qPCR analyses examining the enrichment of (A,D) RNA polymerase II
(Pol II), (B,E) tri-methylation of lysine 27 in histone 3 (H3K27me3; a repressive histone
mark), and (C,F) acetylation of lysines 9, 14, 18, 23, and 27 in histone 3 (H3K9/14/18/23/27;
an active histone mark) in the distal (top panel) and proximal (bottom panel) regions of VEGFA. In order to determine the role of HOTAIR in transcriptional regulation, HRECs were pretreated with scrambled (SCR) siRNAs or siHOTAIR and subsequently cultured in NG or HG
for 48 hours prior to ChIP-qPCR experimentation. IgG antibodies were used as a negative
control and β-actin was used as an internal control. Statistical significance was assessed using
one-way ANOVA for multiple comparisons, followed by Tukey’s post hoc test
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(****p<0.0001 or n.s.= not significant). Data represents the mean ± SEM of 3 independent
experiments (n=3/group).

3.2.11

Duration-dependent

and

glucose-induced

alterations of CpG methylation patterns across the
HOTAIR gene were not observed in HRECs
In order to investigate glucose-induced implications of DNA methylation on HOTAIR
regulation, we incubated HRECs in NG and HG conditions for durations of 2 and 7
days and then performed a genome-wide DNA methylation experiment using Infinium
EPIC arrays and quality controls. Following the detection of >860,000 CpG sites
(probes), we exclusively selected CpG sites that spanned across the HOTAIR gene
(5kb upstream to 1kb downstream of the gene), which corresponded to 59 probes
(Figure 3.13). We found that the average methylation intensity was generally lower
for a majority of the probes (β-values < 0.3), except for 7 probes where slightly greater
methylation intensities were observed (0.2 < β-values < 0.5; these sites mainly
corresponded to North/South Shelf and North/South Shore regions; Figure 3.13).
Furthermore, when examining the methylation patterns between the various groups
across the HOTAIR genomic region (chromosome 12: 54,351,994 to 54,373,040;
Appendix B, Supplemental Figure 14A), it was interesting to observe that a stable
DNA methylation pattern persisted across all groups despite different culture durations
(2 and 7 days) and glucose concentrations (NG and HG). However, of note, although
not statistically significant, HRECs stimulated with HG at both 2 and 7 days displayed
a slight trend towards the reduction of DNA methylation intensities in the HOTAIR
promoter, compared to their respective NG controls (Appendix B, Supplemental
Figure 14B). Nevertheless, these findings may allude to the stable epigenetic nature of
DNA methylation marks in HRECs during hyperglycemic stress [55].
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Figure 3.13: DNA methylation profiling of HRECs. (A) Information on the human HOTAIR
gene according to the UCSC database, where the position of HOTAIR is located on
chromosome 12: 54,356,092-54,368,740 (hg19) and its approximate size (for transcript variant
1) is 12,649 nucleotides containing a total of 6 exons (90). (B) Unsupervised hierarchical
clustering with heatmap using all the CpGs in HRECs that span across HOTAIR, which
amounted to 59 probes. Interestingly, there are no distinctions between cells treated with
different concentrations of glucose (5 mM versus 25 mM) and the duration of culture (2 versus
7 days)—alluding to the stable epigenetic nature of DNA methylation in these cells following
glucose treatment for different durations. Rows indicated CpGs and columns show the
samples; the color scale from blue to red indicates the level of methylation from zero to one
(with zero indicating no methylation and one indicating maximum methylation; n= 3
independent samples per group indicated by the top panel colors; HR5_2= HRECs cultured in
5 mM glucose for 2 days, HR25_2= HRECs cultured in 25 mM glucose for 2 days, HR5_7=
HRECs cultured in 5 mM glucose for 7 days, and HR25_7= HRECs cultured in 25 mM
glucose for 7 days).
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3.2.12

Blockade of DNA methyltransferases differentially

regulates the expressions of HOTAIR and some of its
targets
We then wanted to examine the cause-effect relationship of genome-wide DNA
methylation on the expressions of HOTAIR and its downstream targets. Accordingly,
we pre-treated HRECs with the DNA de-methylating agent, 5-Aza-2’-deoxycytidine
(5-aza-dC) prior to NG or HG culture. Following 5-aza-dC administration and
compared to HG controls, DNMT1, DNMT3A, and DNMT3B RNA levels were
reduced by ~69%, ~58%, and ~69%, respectively (p<0.0001; Appendix B,
Supplemental Figures 15A-C). Accompanying the significantly reduced expressions
of DNMTs in 5-aza-dC-treated HRECs, we also observed significant elevations in
HOTAIR, ET-1, CTCF, Cytochrome B, MCP-1, IL-1β, HOXD3, and HOXD10
transcripts, while no significant differences were observed for ANGPTL4, P300, and
PARP1 expressions (Figure 3.14 and Appendix B, Supplemental Figure 15).
Intriguingly, however, globally inhibiting the expressions of DNMTs significantly
prevented glucose-induced increases in VEGF-A RNA expressions (p<0.0001; Figure
3.14B), which is in keeping with previous observations documented by others [56,57].
To further confirm the findings from our 5-aza-dC experiments, we specifically
silenced DNMT1 (a constitutively expressed DNMT) using a siRNA-mediated
approach. With a ~71% knockdown in DNMT1 RNA levels following the
administration of siDNMT1 and HG (p<0.0001; Appendix B, Supplemental Figure
16A), DNMT3A and DNMT3B also exhibited significant reductions in transcript
expressions by ~43% (p=0.0005; Appendix B, Supplemental Figure 16B) and ~51%
(p<0.0001; Appendix B, Supplemental Figure 16C), respectively.

In parallel,

significant increases in RNA expressions were observed for HOTAIR, ET-1, CTCF,
Cytochrome B, PARP1, IL-1β, HOXD3, and HOXD10 after the knockdown of DNMT1
in HG-cultured cells, relative to SCR HG controls (Figure 3.15 and Appendix B,
Supplemental Figure 16). Although no significant differences were observed for
ANGPTL4, P300, and MCP-1 transcripts after knockdown in HG conditions,
significant reductions in VEGF-A transcripts still remained in siDNMT1-treated
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HRECs cultured with HG (p<0.0001; Figure 3.15B), confirming the observations
from our 5-aza-dC experiments. Indeed, it may be possible that depending on the
genomic location, the inhibition of DNA methylation can have varying methylating
effects on distal or intragenic regulatory elements with different degrees of CpG
density, which subsequently dictate the regulation of gene expression [58].
Nevertheless, our findings suggest that DNA methylation is critically implicated in the
regulation of HOTAIR and its target molecules in hyperglycemic environments.

Figure 3.14. Global inhibition of DNA methyltransferases (DNMTs) can differentially
regulate the expressions of HOTAIR and its targets. HRECs were pre-treated with 5-aza-dC
(a pan-DNMT inhibitor) prior to NG or HG culture for 48 hours. RT-qPCR was then used to
analyze the expressions of (A) HOTAIR, (B) VEGF-A, (C) ET-1, (D) ANGPTL4, (E) CTCF,
(F) P300, (G) PARP1, (H) Cytochrome B, (I) MCP-1, and (J) IL-1β. β-actin was used as an
internal control. Statistical significance was assessed using one-way ANOVA for multiple
comparisons, followed by Tukey’s post hoc test (*p<0.05, **p<0.01, ***p<0.001,
****p<0.0001, or n.s.= not significant). Data represents the mean ± SEM of 3 independent
experiments (n=6/group).
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Figure 3.15. Selective knockdown of DNMT1 can impact the expressions of HOTAIR and
some of its downstream targets in vitro. RT-qPCR analyses of (A) HOTAIR, (B) VEGF-A,
(C) ET-1, (D) ANGPTL4, (E) CTCF, (F) P300, (G) Cytochrome B, (H) PARP1, (I) MCP-1,
and (J) IL-1β expressions following the administration of scrambled (SCR) siRNAs or
siDNMT1 in HRECs subjected to 48 hours of NG or HG culture. DNMT1 is a constitutively
expressed DNA methyltransferase. β-actin was used as an internal control. Statistical
significance was assessed using one-way ANOVA for multiple comparisons, followed by
Tukey’s post hoc test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not
significant). Data represents the mean ± SEM of 3 independent experiments (n=6/group).

3.3 Discussion
The process of physiological angiogenesis is critical for vascular homeostasis, since
the formation of new blood vessels from pre-existing vasculature provides sufficient
blood flow, oxygen, and nutrients to metabolically active tissues [59]. A delicate
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balance between angiogenic and angiostatic factors regulates angiogenesis and any
shifts in this balance will ultimately dictate the activity of the vascular network.
However, in disease states such as DR, chronic hyperglycemia drastically alters the
spatial and temporal kinetics of numerous biochemical and metabolic pathways that
promote active pathological angiogenesis in the eye, subsequently leading to visionthreatening complications [4,7-10]. Although it is well-established that pathological
angiogenesis, as well as macular edema early in the disease progression, is primarily
mediated by VEGF-A in DR [60], limitations in current anti-VEGF therapies suggest
that our understanding of the molecular networks underlying the pathobiology of
ocular angiogenesis remains far from complete. As such, deciphering and exploring
novel molecular mediators in this network may allow for the development of bettertargeted therapies and diagnostic biomarkers. In recent years, lncRNAs have garnered
considerable attention due to their critical regulatory capabilities in a number of
diseases, particularly in cancer. In the context of DR however, several lncRNAs have
been identified in the diabetic retina but very few lncRNAs have been
comprehensively characterized.
In the present study, we provide for the first time direct evidence that the lncRNA
HOTAIR mediates angiogenesis in DR through a complex web of epigenetic
mechanisms involving histone methylation, histone acetylation, DNA methylation and
the CTCF transcription factor. Using cell culture and animal models of diabetes, the
targeted knockdown of HOTAIR via siRNAs made it evident that the inhibition of this
lncRNA significantly prevented glucose-induced increases of several angiogenic
factors,

diabetes-associated

molecules,

and

critical

epigenetic

mediators.

Mechanistically, HOTAIR can contribute to glucose-induced mitochondrial and DNA
damage and this lncRNA can also facilitate the epigenetic activation of VEGF-A by
recruiting RNA polymerase II and acetylation writers (such as P300) to the promoter
regions of VEGF-A, resulting in heightened VEGF-A expressions and subsequent
angiogenesis.

As well, HOTAIR and its target molecules can be differentially

regulated through histone and DNA methyltransferases and CTCF. Collectively, our
findings provide in-depth mechanistic insights into the epigenetic paradigm behind
HOTAIR’s regulatory capabilities in DR and based on its clinical implications,
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HOTAIR may also serve as a novel diagnostic biomarker and therapeutic target for
DR.
LncRNAs can exhibit a wide range of stability profiles that are comparable to proteincoding transcripts. In fact, using genome-wide microarrays, lncRNA half-lives
(ranging from t1/2< 2 hours to t1/2> 16 hours) were shown to correlate with several
lncRNA features, including genomic location, splicing, GC percentage, and
subcellular localization [30]. LncRNAs that were either spliced, localized in the
cytoplasm, classified as intergenic or cis-antisense, or contained high GC percentage
were considered more stable than those lncRNAs that were unspliced, classified as
intronic, nuclear-retained, or contained low GC percentage. Interestingly, the degree of
stability is critical for regulating lncRNA function, where lncRNAs (particularly those
residing in the nucleus) with short half-lives have demonstrated rapid turnover in order
to contribute to the dynamic processes that they regulate [30,61]. Published studies
have made it evident that cell-specific variations exist for the half-life of HOTAIR, in
which trophoblasts can exhibit a t1/2 of ~7.7 hours [62], while HeLA cells demonstrate
a t1/2 of ~1.3 hours [63]. In the present study, although we did not examine HOTAIR
stability in HRECs, we instead investigated HOTAIR expression levels across various
time-points and observed oscillating HOTAIR patterns, with significant glucoseinduced elevations at the 48-hour mark. Intriguingly, our results are in keeping with
similar expression patterns observed for another lncRNA, MALAT1, in HRECs [28],
which suggests that HREC-derived lncRNAs may have distinct and overlapping
expression profiles compared to other cell types. Furthermore, based on a previous
report documenting the long-lasting, activating, epigenetic changes that occur in the
NF-ΚB-p65 promoter region following transient hyperglycemia [64], it may be
plausible that initial glucose-induced spikes of HOTAIR expressions could similarly
induce persisting epigenetic changes that involve altered gene expressions of its
downstream targets, despite reduced HOTAIR expressions at later time-points.
Nevertheless, future research is warranted to further validate HOTAIR’s role in
metabolic memory.
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The subcellular localization of lncRNAs can provide insights into their potential
functions. For example, lncRNAs localized in the cytoplasm are typically implicated
in post-transcriptional modifications that govern mRNA stability and translation [65],
while nuclear-retained lncRNAs can be involved in transcriptional regulation [66],
organization of nuclear architecture [67], and alternative splicing [68]. On the other
hand, certain lncRNAs can also be found in both the nucleus and cytoplasm [69],
where these versatile RNA molecules shape the epigenome, regulate organelle
formation and function, and influence transcription and translational processes [70]. In
order to elucidate the subcellular localization of HOTAIR in ECs and develop potential
insights into its regulatory capabilities, we performed RNA FISH and found that
HOTAIR is present in both nuclear and cytoplasmic compartments. Our findings are in
keeping with previous studies that depict the dual localization patterns for HOTAIR in
other cells, such as cutaneous squamous cell carcinoma [71] and fibroblasts [72].
Extending our RNA FISH findings and on the basis of our mechanistic-based in vitro
experiments, it quickly became evident that HOTAIR can regulate the expressions of
several angiogenic and diabetes-associated genes, while simultaneously targeting
enzymes involved in histone modification and DNA methylation processes. Lending
further credence to our observations, earlier reports have demonstrated that HOTAIR is
directly involved in PRC2-mediated silencing of the chromatin, where HOTAIR
depletion in fibroblasts can lead to a loss of HOXD silencing and H3K27me3 by PRC2
[53]; while, HOTAIR overexpression in breast cancer cells can promote cellular
invasiveness through selective, genome-wide re-targeting of PRC2 and H3K27me3,
which ultimately enables the expression of genes that are conducive to cancer invasion
[47]. Indeed, additional reports have suggested that HOTAIR may function as a
molecular scaffold in order to regulate gene expressions through its direct interactions
with epigenetic mediators, including PRC2 [73] and histone demethylases (LSD1)
[39]. Based on these findings and the reciprocal relationships documented between
this lncRNA and other epigenetic mechanisms in cancer (such as DNA methylation
[74] and histone acetylation [75]), our findings imply that HOTAIR also possesses a
similar regulatory profile as a critical epigenomic modulator in the pathogenesis of
DR.
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In addition to its role as a transcriptional regulator, we demonstrated that HOTAIR
could also pathogenetically contribute to glucose-induced mitochondrial and oxidative
DNA damage in ECs, which further highlight the dynamism of HOTAIR in diabetes.
Although these roles of HOTAIR have not been previously investigated in the context
of DR, other studies have shown that HOTAIR can mediate DNA damage response in
ovarian cancer cells, through the regulation of NF-kB activation [76], and maintain
mitochondrial function in HeLa cells [40]. Intriguingly, the findings by Zheng et al
further demonstrate that HOTAIR knockdown in HeLA cells is accompanied with
several mitochondrial aberrations, including dysregulations of 32 proteins associated
with mitochondrial function, decreased Ubiquinol-Cytochrome C Reductase Complex
III Subunit VII expressions, elevated mitochondrial swelling, reduced glucose uptake,
and decreased ΔΨM [40]. In contrast to these findings, we observed that HOTAIR
knockdown in HRECs could protect the mitochondria in NG and HG environments as
evidenced by higher ΔΨMs and decreased Cytochrome b expressions (a fundamental
component for the assembly and function of complex III [77]), compared to SCR HG
controls. Although it is likely that cell-specific regulations may exist for HOTAIR,
another possible explanation for our results could be attributed to certain stressinduced mechanisms involving mitophagy and autophagy. More precisely, prolonged
hyperglycemia has been reported to evoke significant mitochondrial oxidative stress
and membrane depolarization in Müller cells, consequently leading to mitochondrial
fragmentation [78]. Following the induction of mitochondrial dysfunction and
fragmentation, increased levels of reduced Cytochrome b, along with specific
mitophagy factors (including autophagy-related genes, ATG11 and ATG32) have been
shown to trigger non-specific autophagy [79]. Interestingly, a recent study has also
demonstrated that HOTAIR can promote autophagy by upregulating the expressions of
ATG7 in pancreatic cancer cells [80], which warrants further research into the
mechanisms revolving around HOTAIR and mitophagy in diabetes.
Aberrations in the microvasculature represent one of the earliest pathological
manifestations of DR. In fact, chronic hyperglycemic exposure can compromise the
function of ECs and the integrity of the endothelium in the retinal microvasculature,
which consequently leads to the extravasation of plasma constituents into the retina
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due to blood-retinal barrier damage [4]. Coupled with chronic ischemic regions in the
retina (known as capillary non-perfusion), endothelium damage and the heightened
activation of glucose-induced biochemical pathways further stimulate retinal cells to
release inflammatory cytokines and vasoactive factors that cause increased vascular
permeability and lay the foundation for pathological angiogenesis in DR [4,81]. For
these reasons, we specifically examined retinal ECs in our experiments. Accordingly,
glucose can directly induce the expressions of HOTAIR and numerous angiogenic
factors in ECs and diabetic retinas, while the subsequent knockdown of HOTAIR can
preserve endothelial cell junctions in HG environments and significantly alleviate
early glucose-induced upregulations of angiogenic factors in both in vitro and in vivo
models. Our observations on the pro-angiogenic capabilities of HOTAIR are consistent
with previous reports in cancer, where HOTAIR has been shown to enhance
angiogenesis by directly targeting the VEGF-A promoter in nasopharyngeal carcinoma
cells [32] or through transmission of glioma cell-derived extracellular vesicles into
ECs [33]. Hence, based on these findings, it is no surprise that HOTAIR is involved in
the pathogenesis of DR, possibly through its role in EC dysfunction.
With HOTAIR exhibiting pro-oncogenic functions [32,33,46,47,54,71,74-76,80] and
potential involvement in diabetic kidney disease [91], several emerging studies are
beginning to address the clinical utility of HOTAIR as a lncRNA biomarker [82]. We
wanted to delineate the clinical significance of this lncRNA in the context of DR. As
such, we decided to examine the presence of HOTAIR in VH and serum samples
because the vitreous fluid can be used to indirectly assess the pathophysiological
events that take place in the diabetic retina [83] and circulating serum non-coding
RNAs have been previously associated with the pathogenesis of DR [84]. When
compared to controls, we found that HOTAIR expression levels are significantly
upregulated in the VH and serum samples of PDR patients, implying a pathogenetic
association between HOTAIR and DR. These results are in keeping with our
previously published findings for another pathogenetic lncRNA, MALAT1, in DR
[28]—alluding to the potential overlapping patterns shared between pathogenetic
lncRNAs in certain disease states. Furthermore, to the best of our knowledge, this is
the first study to identify positive correlations in HOTAIR RNA levels between serum
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and VH of PDR patients, which raise the possibility of using HOTAIR as a potential
serum-based biomarker for DR. Although the complete clinical validation of HOTAIR
as a potential prognostic or diagnostic marker for DR will require larger sample sizes
with appropriate power calculations, stringent cut-off criteria and determination of
clinically meaningful endpoints, our results simply provide a proof of principle for the
pathological significance of HOTAIR in DR and further large-scale investigations are
undoubtedly warranted.
In summary, this report establishes for the first time that the lncRNA HOTAIR is a
critical epigenetic regulator of angiogenesis in DR. Mechanistic experiments
confirmed HOTAIR’s ability to directly regulate the transcriptional expressions of
multiple angiogenic factors and DR-associated molecules in vitro and in vivo, possibly
through a complex epigenetic axis involving PRC2/P300/DNMTs/CTCF. In addition
to transcriptional regulation, HOTAIR may also have implications in other organelle
functions, since the knockdown of HOTAIR can partially prevent glucose-induced
oxidative mitochondrial and DNA damage. We further highlight the clinical
significance of HOTAIR, where HOTAIR RNA expressions in the vitreous fluid and
serum strongly correlate with PDR. Taken together, these findings allude to HOTAIR’s
potential as a possible diagnostic and therapeutic target in DR.
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3.5 Appendix B: The long non-coding RNA HOTAIR is a
critical epigenetic mediator of angiogenesis in diabetic
retinopathy

Supplemental Figure 1. LncRNA microarray findings from HRECs cultured in NG or HG
for 48 hours (GEO: GSE122189). (A) Scatter plot demonstrates lncRNA expressions between
normal glucose (NG) and high glucose (HG) replicates. In general, the scatter plot is a
visualization method used for assessing the lncRNA expression variation (or reproducibility)
between the two compared samples (or groups). The values of X and Y axes in the scatter plot
are the normalized signal values (log2 scaled) of two samples or the averaged normalized signal
values (log2 scaled) for two groups. The green lines are fold change lines (the default fold
change value given is 2.0). The lncRNAs above the top green line and below the bottom green
line indicates more than 2.0 fold change of lncRNAs between the two compared groups or
samples. (B) Hierarchical clustering for the lncRNAs in all sample groups. “Red” indicates high
relative expression, and “blue” indicates low relative expression. (C) Venn diagrams depicting
the total number of lncRNAs that were upregulated (top) or downregulated (bottom) between
NG and HG replicates. (D) Specific microarray readout for HOTAIR.
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Supplemental Figure 2. HOTAIR knockdown using three different siRNAs. HRECs were
pre-treated with scrambled (SCR) siRNAs or specific siRNAs targeting HOTAIR prior to NG or
HG culture for 48 hours. RT-qPCR was then used to analyze the expressions of HOTAIR. βactin was used as an internal control. Statistical significance was assessed using one-way
ANOVA for multiple comparisons, followed by Tukey’s post hoc test (****p<0.0001). Data
represents the mean ± SEM of 3 independent experiments (n=6/group).
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Supplemental Figure 3. HOTAIR knockdown can prevent the induction of several
epigenetic mediators in hyperglycemic environments. RT-qPCR analyses of (A) EZH2, (B)
SUZ12, (C) EED, (D) DNMT1, (E) DNMT3A, (F) DNMT3B, (G) CTCF, and (H) P300
expressions following the administration of SCR siRNA or siHOTAIR in HRECs subjected to
48 hours of NG or HG culture. β-actin was used as an internal control. Statistical significance
was assessed using one-way ANOVA for multiple comparisons, followed by Tukey’s post hoc
test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not significant). Data represents
the mean ± SEM of 3 independent experiments (n=6/group).
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Supplemental Figure 4. HOTAIR knockdown can reduce VEGF-A proteins, improve
cellular viability, and prevent glucose-induced decreases of HOXD loci in HRECs. (A)
VEGF-A ELISA results (expressed as pg/mL) from HRECs that were pre-treated with SCR
siRNA or siHOTAIR and subjected to NG or HG culture for 48 hours. (B,C) RT-qPCR analyses
of HOXD3 and HOXD10 expressions following HOTAIR knockdown. β-actin was used as an
internal control. (D) WST-1 findings for SCR or siHOTAIR-treated HRECs. Statistical
significance was assessed using one-way ANOVA for multiple comparisons, followed by
Tukey’s post hoc test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not significant).
Data represents the mean ± SEM of 3 independent experiments (n=6/group).
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Supplemental Figure 5. HOTAIR is significantly elevated in the retinas of diabetic animals
at 2 months. Non-diabetic (control) and streptozotocin-induced diabetic C57BL/6J mice or
Sprague-Dawley rats were followed for 2 months. Retinal tissues were isolated and extracted for
RNA. RT-qPCR was employed to analyze retinal Hotair expressions in (A) mice and (B) rats.
β-actin was used as an internal control. Statistical significance was assessed using the MannWhitney U test. Data represents the mean ± SD (n=8 per control or diabetic mice group, n=5 per
control rat group or n=9 per diabetic rat group; *p<0.05).
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Supplemental Figure 6. SiRNA-mediated knockdown of mus Hotair and its impact on
angiogenic markers in mouse retinal and lung endothelial cells. RT-qPCR analyses of (A,D)
Hotair, (B,E) Vegf-a, and (C,F) Angptl4 expressions following the administration of SCR
siRNA or siHOTAIR in mouse retinal endothelial cells (top panel) and primary mouse lung
endothelial cells (bottom panel) subjected to 48 hours of NG or HG culture. β-actin was used as
an internal control. Statistical significance was assessed using one-way ANOVA for multiple
comparisons, followed by Tukey’s post hoc test (*p<0.05, **p<0.01, ***p<0.001,
****p<0.0001, or n.s.= not significant). Data represents the mean ± SEM of 3 independent
experiments (n=6/group).
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Supplemental Figure 7. Hematoxylin and eosin (H&E) staining of various mouse tissues
following siHOTAIR toxicology experiments. Wild-type C57BL/6 mice were subjected to a
one-time intravitreal injection that consisted of either scrambled siRNA control (50 nM; SCR)
or siHOTAIR at varying concentrations (25 nM, 50 nM, and 100 nM) and were monitored for
seven days and then euthanized for tissue collection (n=3 per group). No behavioural changes or
ocular complications were observed in the mice throughout the duration of the experiment and
as evidenced by H&E staining, no cellular abnormalities were also observed across (A) retinal,
(B) heart, (C) lung, (D) liver, and (E) kidney tissues following the one-time intravitreal
siHOTAIR injection at 25, 50 or 100 nM concentrations (images not shown for 25 nM).
Original magnification, 40X; scale bar= 5 microns.
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Supplemental Figure 8. In vivo results following the knockdown of Hotair. (A) Relative
Hotair knockdown expressions, as indicated by RT-qPCR, in the retinal tissues of C57BL/6J
mice from our toxicology experiments involving different siHOTAIR concentrations (n=3 per
group). β-actin was used as an internal control. (B,C) Body weights and blood glucose levels of
all C57BL/6J mice involved in our short-term, one-month therapeutic model, where intravitreal
injections of scrambled (SCR; 50 nM) siRNAs or siHOTAIR (100 nM) were administered to
non-diabetic and diabetic mice eyes once every week for up to three weeks. (D) RT-qPCR
analysis of retinal Hoxd3 expressions at 1 month following siHOTAIR treatment. β-actin was
used as an internal control. Statistical significance was assessed using one-way ANOVA for
multiple comparisons, followed by Tukey’s post hoc test (****p<0.0001 or n.s.= not
significant). Data represents the mean ± SD (n=6/group).
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Supplemental Figure 9. Hematoxylin and eosin (H&E) staining of various mouse tissues
following our short-term, 1-month therapeutic animal model involving siHOTAIR. Nondiabetic (control) and diabetic C57BL/6 mice were subjected to intravitreal injections of
scrambled (SCR; 50 nM) siRNAs or siHOTAIR (100 nM) once every week for up to three
weeks. Mice were monitored throughout the duration of the experiment and subsequently
euthanized for tissue collection at 4 weeks (n=3 per group). Similar to our initial toxicology
experiments, no behavioural changes or ocular complications were observed in the mice and as
evidenced by H&E staining, no cellular abnormalities were also observed across (A) retinal, (B)
heart, (C) lung, (D) liver, (E) kidney, (F) cortical, and (G) hippocampal tissues following
multiple intravitreal siHOTAIR injections at 1 month. Original magnification, 40X; scale bar= 5
microns.
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Supplemental Figure 10. Glycolytic inhibition can impact certain epigenetic molecules and
may also influence nuclear transport molecules involved in oxidative stress, independent
of the mitochondria. RT-qPCR analyses of (A) EZH2, (B) SUZ12, (C) EED, (D) P300, (E)
DNMT1, (F) DNMT3A, (G) DNMT3B, (H) HOXD3, and (I) HOXD10 expressions following 2deoxy-D-glucose treatment (0.6 or 5 mM) in HRECs subjected to 48 hours of NG (5mM Dglucose) or HG (25 mM D-glucose) culture. 2-deoxy-D-glucose is a potent inhibitor of
glycolysis. β-actin was used as an internal control. Statistical significance was assessed using
one-way ANOVA for multiple comparisons, followed by Tukey’s post hoc test (*p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not significant). Data represents the mean ±
SEM of 3 independent experiments (n=6/group).
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Supplemental Figure 11. DZNep pre-treatment reduces the expression of PRC2
components and stimulates the transcription of HOXD loci. HRECs were pre-treated with
DZNep (a global histone methylation inhibitor) prior to NG or HG culture for 48 hours. RTqPCR was then used to analyze the expressions of (A) EZH2, (B) SUZ12, (C) EED, (D)
HOXD3, and (E) HOXD10. β-actin was used as an internal control. Statistical significance was
assessed using one-way ANOVA for multiple comparisons, followed by Tukey’s post hoc test
(*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not significant). Data represents the
mean ± SEM of 3 independent experiments (n=6/group).
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Supplemental Figure 12. The knockdown of EZH2 and CTCF can alter glucose-induced
expressions of certain epigenetic molecules. RT-qPCR analyses of (A) DNMT1, (B)
DNMT3A, (C) DNMT3B, (D) P300, (E) HOXD3, and (F) HOXD10 expressions following the
administration of scrambled (SCR) siRNAs, siEZH2, or siCTCF in HRECs subjected to 48
hours of NG or HG culture. EZH2 is the catalytic subunit of PRC2 (a critical histone
methyltransferase) and CTCF is an important epigenetic transcription factor involved in the
direct regulation of genes. β-actin was used as an internal control. Statistical significance was
assessed using one-way ANOVA for multiple comparisons, followed by Tukey’s post hoc test
(*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not significant). Data represents the
mean ± SEM of 3 independent experiments (n=6/group).
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Supplemental Figure 13. High glucose promotes strong binding associations between
HOTAIR and epigenetic enzymes. RNA immunoprecipitation (RIP) experiments were
conducted using anti-IgG, anti-EZH2 (catalytic subunit of the histone methyltransferase, PRC2),
or anti-P300 (a histone acetyltransferase) antibodies on HRECs cultured with NG or HG for 48
hours. RT-qPCR was then used to determine the fold enrichment of HOTAIR following IgG, (A)
EZH2 and (B) P300 pulldown. IgG antibodies were used as a negative control and β-actin was
used as an internal control. Statistical significance was assessed using one-way ANOVA for
multiple comparisons, followed by Tukey’s post hoc test (****p<0.0001 or n.s.= not
significant). Data represents the mean ± SEM of 3 independent experiments (n=3/group).
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Supplemental Figure 14. DNA methylation profiling of HRECs. (A) Panel that depicts the
stable DNA methylation patterns across the HOTAIR genomic regions shared between HRECs
cultured with NG or HG for various durations (2 or 7 days). (B) Differential methylation
patterns in the HOTAIR promoter region. The box plots represent the distribution of median
methylation values across all of the probes mapping to this region as stratified by glucose
concentration and culture duration. Center line: median of regional methylation levels across
samples; lower and upper bounds: first and third quartiles; whiskers: interquartile ranges (n= 3
independent samples per group).

161

Supplemental Figure 15. 5-aza-dC can decrease the expressions of DNMTs, while
promoting HOXD3 and HOXD10 gene expressions. HRECs were pre-treated with 5-aza-dC
(a pan-DNMT inhibitor) prior to NG or HG culture for 48 hours. RT-qPCR was then used to
analyze the expressions of (A) DNMT1, (B) DNMT3A, (C) DNMT3B, (D) HOXD3, and (E)
HOXD10. β-actin was used as an internal control. Statistical significance was assessed using
one-way ANOVA for multiple comparisons, followed by Tukey’s post hoc test (*p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001, or n.s.= not significant). Data represents the mean ±
SEM of 3 independent experiments (n=6/group).
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Supplemental Figure 16. SiRNA-mediated knockdown of DNMT1 can influence glucoseinduced expressions of DNMTs and HOXD loci. RT-qPCR analyses of (A) DNMT1, (B)
DNMT3A, (C) DNMT3B, (D) HOXD3, and (E) HOXD10 expressions following the
administration of scrambled (SCR) siRNAs or siDNMT1 in HRECs subjected to 48 hours of
NG or HG culture. DNMT1 is a constitutively expressed DNA methyltransferase. β-actin was
used as an internal control. Statistical significance was assessed using one-way ANOVA for
multiple comparisons, followed by Tukey’s post hoc test (*p<0.05, **p<0.01, ***p<0.001,
****p<0.0001, or n.s.= not significant). Data represents the mean ± SEM of 3 independent
experiments (n=6/group).
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Supplemental Figure 17. HOTAIR knockdown can prevent glucose-induced disruptions of
endothelial cell junctions in vitro. Representative images, by electron microscopy, of (A)
scrambled siRNA (SCR) or (B) siHOTAIR-transfected HRECs after high glucose culture (n=3
samples per group). Disruptions of endothelial cell junctions can be visualized in SCR plus HG
cells compared to preservation of junctions in siHOTAIR plus HG cells (a higher magnification
was inserted in B showing the intact junctions [indicated by the black arrows]). Direct
magnification, 1950X; scale bar= 2 microns; ‘N’= nucleus.
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Supplemental Table 1. qPCR primers for human-specific genes.

Supplemental Table 2. qPCR primers for mouse-specific genes.
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4

Endothelin-1 regulation is entangled in a complex
web of epigenetic mechanisms in diabetes
With the continuous global rise in diabetes [21], the risk for developing glucoseinduced injuries to the microvasculature also remains high. As a consequence of
hyperglycemia, microvascular damage gives rise to debilitating complications
affecting the eyes, kidneys, and peripheral nerves [15]. To minimize the risk of
subsequent diabetes-induced vessel damage, current therapeutic modalities are
comprised of lifestyle changes and pharmaceutical intervention [5, 15]. Although these
therapies may be effective in impeding some progression of late stage diabetic
complications, the presence of ‘metabolic memory’ contributes to unique molecular
alterations that may alter an individual’s response to treatments [36]. Epigenetic
mechanisms comprise the ‘metabolic memory’ phenomenon and identification of
these mechanisms would expand current therapeutic modalities, allowing for the
development of targeted treatment strategies.
Modifications to the epigenome influence gene expression without changing the
underlying nucleotide sequence [45]. DNA methylation, histone modifications, and the
activity of non-coding RNAs are examples of such epigenetic mechanisms that are
involved in metabolic memory [2]. The identification of these processes have been
made evident by high throughput genomic technologies, however new questions arise
with respect to our current understanding of the documented mechanistic properties
for pro-inflammatory markers.
Endothelin-1 (ET-1) is a prominent peptide in diabetes that has been well documented
within the last three decades. As previously demonstrated by our laboratory and
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others, aberrations in metabolic pathways can heighten the production of ET-1 and
subsequently allow for an increased pathologic state in various diabetic complications
[4, 6, 42]. Using such knowledge and information from ligand-binding studies, drugs
were developed to target the ET-1 receptors, in order to mitigate cellular dysfunction
and other effects in diabetic complications [25, 38]. Despite the promising results for
endothelin receptor antagonists in animal models, investigators discovered that there
were adverse, undesirable and heterogeneous responses present among numerous
patients using these drugs—suggesting that there are alternative mechanisms
implicated in ET-1 regulation [34]. As the mechanistic impact of epigenetic machinery
on ET-1 production still remains unclear, further characterization is warranted to
understand such a process.
In this study, we examined the roles of DNA methylation, histone methylation, and
long non-coding RNAs (lncRNAs) on ET-1 regulation in retinal microvascular
endothelial cells (HRECs). We performed a DNA methylation array to identify
whether unique methylation patterns exist across the ET-1 gene (EDN1) after high
glucose (HG) incubation. To further follow-up our findings from the methylation
array, we employed a global DNA methylation inhibitor in HRECs to determine the
impact of DNA methyltransferases on ET-1 regulation. Next, we subjected HRECs to
a

histone

methylation

inhibitor

to

understand

the

influence

of

histone

methyltransferases on ET-1 mRNA production. Moreover, based on our previous
lncRNA microarray analysis [43], we selected three prominent HG-induced
upregulated lncRNAs and silenced these lncRNAs to determine the effects on ET-1.
We then collated our previous and current findings to present an all-inclusive
epigenetic paradigm for ET-1 regulation.

4.1 Research Design and Methods
4.1.1

Cell culture

Endothelial dysfunction is one of the earliest pathological features during chronic
hyperglycemia [1]. Hence, we used HRECs (Olaf Pharmaceuticals, Worchester, MA)
for our experiments. Such experimental conditions have been previously described
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[24, 32, 35, 43] and all cell culture reagents were purchased from Sigma (Oakville,
Ontario, Canada). Based on our previous findings, the 48-hour time point was selected
for our in vitro experiments. All experiments were independently repeated at least
three times and performed with six replicates, unless specified.

4.1.2

EDN1 CpG DNA methylation analysis

The Illumina Infinium MethylationEPIC BeadChip array (Illumina, CA, USA) was
used to identify differential methylation patterns of CpG sites across the EDN1 gene in
HRECs incubated in 5 mM glucose (NG, mimicking euglycemia) and in 25 mM
glucose (HG, mimicking hyperglycemia). Genomic DNA was extracted from HRECs
after 48 hours of glucose culture and 1 µg of DNA was used for bisulfite conversion
using the EZ DNA Methylation Kit (Zymo Research, CA, USA). The HiScan System
(Illumina, CA, USA) was used to obtain the array readout and the methylated and
unmethylated signal intensity data were then imported into R 3.4.0 for analysis.
Normalization was performed using Illumina normalization method with background
correction using the minfi package. Probes with detection P-value > 0.01 were
excluded from the downstream analyses. In addition, probes known to contain SNPs at
the CpG interrogation or the single nucleotide extension were removed. Methylation
level for each probe was measured as a beta value (β-value), calculated from the ratio
of the methylated signals versus the total sum of unmethylated and methylated signals,
ranging between 0 (no methylation) and 1 (full methylation). Three independent
samples were used per group.

4.1.3

3-Deazaneplanocin

A

(DZNep)

and

5-Aza-2’-

deoxycytidine (5-aza-dC)
In order to understand the impact of histone and DNA methylation inhibition on ET-1,
we used pharmacological inhibitors that globally blocked the methylation process.
Therefore, based on previous literature, 1 hour pre-treatment of either 5 µM of DZNep
(Cayman Chemical, Ann Arbor, MI) or 5-aza-dC (Sigma, St. Louis, USA) was applied
to HRECs prior to addition of D-glucose [35, 43, 46]. DZNep or 5-aza-dC-treated
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HRECs, and their respective controls, were collected at 48 hours for further analyses.

4.1.4

SiRNA-mediated transfection

The lncRNA array analysis from our earlier study identified several upregulated
lncRNAs in HG-treated HRECs [43]. Therefore, in this study, we selected the three
most upregulated lncRNAs, which potentially target ET-1, and silenced each of these
lncRNAs to determine the impact on ET-1 regulation. HRECs were initially
transfected with either two pre-designed siRNAs targeting human ANRIL (antisense
RNA to INK4 locus), MALAT1 (metastasis-associated lung adenocarcinoma transcript
1), or ZFAS1 (zinc finger antisense 1), or scrambled siRNA (catalog number:
AM4635, Life Technologies, CA, USA) using Lipofectamine 2000 (Invitrogen, ON,
CA) and Opti-MEM (Life Technologies, CA, USA). Details regarding the
lipofectamine-mediated transfection protocol can be found in our previous studies [36,
44]. Following confirmation of knockdown by RT-qPCR, the siRNA sequences with
the best knockdown were selected for this study: ANRIL (Lincode CDKN2B-AS1;
catalog number: R-188105-00-0005, Dharmacon, IL, USA), MALAT1 (catalog
number: n272233, Life Technologies, CA, USA), and ZFAS1 (catalog number:
n271357, Life Technologies, CA, USA).

4.1.5

RNA

Isolation

and

Quantitative

Real-Time

Polymerase Chain Reaction (RT-qPCR)
As previously described, the TRIzol reagent (Invitrogen, Burlington, ON) was used to
extract total RNA and a spectrophotometer (260 nm; Gene Quant, Pharmacia Biotech,
USA) was utilized to quantify RNA concentrations [24, 32, 35, 43]. A high-capacity
complementary DNA (cDNA) kit (Applied Biosystems, Burlington, ON) was then
employed to reverse transcribe 1 µg of total RNA to cDNA. Next, in combination with
SYBR-green master mix (Clontech, Mountain View, CA, USA) and specific target
gene primers (Sigma; Appendix C, Table S1), cDNA was amplified in the
LightCycler 96 System (Roche Diagnostics, QC, CA) to detect RNA expression.
Expression levels were further calculated by the relative standard curve method using
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β-actin as internal control for normalization.

4.1.6

Statistical analysis

All statistical tests were performed using GraphPad Prism 7 (GraphPad, CA, USA).
Data are expressed as mean ± SEM. Student’s t-test or 1-way ANOVA, followed by
Tukey’s post hoc test, were used as appropriate. Differences with a P value below 0.05
were considered significant.

4.2 Results
4.2.1

Transient HG treatment results in hypomethylation

of CpG sites in the proximal promoter regions of EDN1
Technological advancements in next-generation sequencing have allowed for the
identification of genome-wide DNA methylation patterns, which have critical
implications in disease pathogenesis. Following our methylation profiling of NG and
HG-treated HRECs, we exclusively selected the CpG sites that spanned across EDN1,
which corresponded to 12 probes (File S1, doi: 10.33549/physiolres.933836). All of
the probes were placed in the ‘Open Sea’ category, since the array did not detect a
CpG island (defined as regions that have a GC content greater than 50% and are
greater than 200 base pairs in length [16]) in the EDN1 region—which was also
confirmed by the UCSC Human Genome Browser (University of California, Santa
Cruz, CA, USA; Figure 4.1A). Using annotations derived by Illumina, we further
categorized the probes based on functional location relative to the gene region:
TSS1500 (region that is -200 to -1500 nucleotides upstream from the transcription
start site), TSS200 (the region from -200 nucleotides upstream to the transcription start
site itself), 5’ UTR (can include the region through the first exon), gene body, and 3’
UTR. Analyzing the EDN1 regions, there were four probes for TSS1500, five probes
for TSS200, one probe for 5’ UTR, one probe for gene body, and one probe for 3’
UTR. According to our array readout, nearly 58% of CpG sites were hypomethylated
following 48 hours of HG treatment (Figure 4.1B). In addition, a substantial number
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of these hypomethylated CpG sites were predominantly located in the TSS200 region
of EDN1, while a hypomethylated CpG site was also detected in both TSS1500 and 5’
UTR regions (Figure 4.1C). Despite the overall methylation intensities between the
NG and HG groups being low for each gene region (0≤ β-value≥0.119; a value of 0
indicates no methylation, while a value of 1 indicates maximal methylation), the
percentage of methylation further reduced at CpG sites in the proximal promoter and
promoter regions of EDN1 following high glucose treatment.

Figure 4.1. CpG sites in specific regions of EDN1 are hypomethylated following high
glucose treatment in vitro. A) Information on the human EDN1 gene annotated from the
UCSC database. EDN1 is located on chromosome 6 and spans from the nucleotide positions
12, 289, 311 to 12, 296, 209 (6899 nucleotides in size [23]). B) A heat map depicting the
methylation intensity (in ß-values) of specific CpG dinucleotides across EDN1 in HRECs
following 48 hours of NG or HG culture. The Illumina methylation array indicates that a ß-
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value of 1 suggests complete methylation at the interrogated site, while a value of 0 indicates
no methylation. C) A bar graph categorizing the methylation intensities of probes based on
gene region. The proximal promoter and 5’ UTR/first exon regions demonstrated CpG
hypomethylation following HG treatment (data expressed as average ß-value per region; N= 3
independent samples for each NG or HG group). Legend: ‘*’ demonstrates a significant
reduction in methylation following HG treatment.

4.2.2

Global inhibition of DNA methyltransferases

increases ET-1 expression
To further investigate the impact of DNA methylation on EDN1 regulation, we
administered a DNA demethylating agent in HRECs prior to glucose treatment.
Following the global inhibition of DNA methyltransferases, we subsequently analyzed
ET-1 mRNA expression (the main product of EDN1 transcription) using RT-qPCR.
Interestingly, 5’-aza-dC administration significantly augmented ET-1 expressions in
both NG and HG-treated HRECs compared to controls (Figure 4.2A). Among the
groups analyzed, HRECs that were cultured with NG and 5’-aza-dC demonstrated
comparable ET-1 expression levels to HRECs cultured solely in HG—suggesting the
importance of DNA methyltransferases in governing the transcriptional activity of
EDN1. Collectively, both of our DNA methylation experiments indicate that
hyperglycemic environments can greatly impact DNA methylation patterns in EDN1
and its transcriptional products.
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Figure 4.2. Global inhibition of DNA or histone methylation significantly increases ET-1
mRNA expressions in HRECs. RT-qPCR findings indicate that A) 5-aza-dC treatment
increases ET-1 expressions in NG or HG-treated HRECs, B) DZNep treatments also showed
similar patterns of ET-1 upregulation (data expressed as a ratio to β-actin (mean ± SEM);
normalized to NG; *=P<0.05, ***=P<0.001, and ****=P<0.0001 compared to NG or HG; and
N= 6 from three independent experiments and performed in triplicates).

4.2.3

Histone methylation is important in ET-1 regulation

Following demonstration of DNA methylation’s impact on ET-1, we investigated the
role of histone methylation on ET-1 mRNA expression. Therefore, prior to glucose
treatment, we subjected HRECs to a global histone methylation inhibitor and
subsequently analyzed ET-1 mRNA. Similar to the trends observed in our 5’-aza-dC
experiment, DZNep pre-treatment significantly upregulated ET-1 in both NG and HGtreated HRECs (Figure 4.2B). Following pharmacologic inhibition of histone
methylation, the sharp induction of ET-1 expression in both NG and HG-treated
HRECs alludes to the regulatory capabilities of histone methyltransferases on ET-1
transcription.
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4.2.4 lncRNAs regulate ET-1 expression in hyperglycemia
With lncRNAs gaining widespread recognition as important epigenetic mediators, we
examined the impact of lncRNAs on ET-1 regulation. Based on the lncRNA array
analysis from our previous study [43], we selected the top three upregulated lncRNAs
in HG-treated HRECs for silencing in this investigation: ANRIL, MALAT1, and
ZFAS1. Compared to scrambled controls, approximately 70%, 75%, and 90%
knockdown activity was observed in HRECs following siANRIL, siMALAT1, and
siZFAS1 treatments, respectively (data not shown). Interestingly, the siRNA-directed
inhibition of ANRIL, MALAT1, or ZFAS1 also significantly reduced ET-1 mRNA in
HG-treated HRECs (Figure 4.3). More specifically, when compared to scrambled
controls, ANRIL knockdown contributed to the greatest reduction of ET-1 expression
in HG-treated HRECs (~75%; Figure 4.3A); while, siMALAT1 (Figure 4.3B) and
siZFAS1 (Figure 4.3C) demonstrated comparable levels of ET-1 mRNA reduction
(~37-42%) in HG-treated HRECs. Taken together, the findings observed from our
knockdown experiments suggest that pathogenetic lncRNAs can also influence
glucose-induced upregulation of ET-1 in microvascular endothelial cells (ECs).
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Figure 4.3. ANRIL, MALAT1, and ZFAS1 regulates glucose-induced production of ET-1
mRNA in vitro. RT-qPCR analyses indicating that A) siANRIL, B) siMALAT1, and C)
siZFAS1 caused significant reductions in the glucose-induced upregulation of ET-1 transcripts
(data expressed as a ratio to β-actin (mean ± SEM); normalized to SCR NG; *=P<0.05,
**=P<0.01, ***=P<0.001, and n.s.= not significant compared to SCR NG or SCR HG; and N=
6 from three independent experiments and performed in triplicates).

4.3 Discussion
When a chronic hyperglycemic environment jeopardizes the integrity of the
endothelium, the risk of advancement to severe diabetic microvascular complications
dramatically heightens. ECs are one of the earliest cells to undergo dysfunction in
diabetes, contributing to disease progression [17]. During the development of
endothelial dysfunction, one well-documented characteristic is the heightened
production and activity of ET-1 [20, 39].
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With the biologically active form being only 21 amino acids in length, the mature ET1 peptide can elicit a potent proinflammatory and vasoactive response [31]. ET-1,
belonging to the group of endothelin peptides, mediates its response through Gprotein-coupled receptor subtypes, ETA and ETB [37]. In the vasculature, ECs
predominantly express the ETB receptors, while both receptor subtypes can be found
on vascular smooth muscle cells [31]. Furthermore, the vascular response is
characterized by the fine balance between the concentrations of ET-1 and its receptor
subtypes. When this balance becomes disrupted in various pathologies such as
atherosclerosis and diabetes, enhanced activities of vasoconstriction, inflammation,
and mitogenesis can subsequently follow [37]. In order to truly understand the
conundrum behind aberrant activation of the ET-1 axis, the transcriptional regulatory
features behind ET-1 production must be thoroughly examined.
Located on chromosome 6, the human EDN1 generates a 2.8-kb transcript that
encodes for the pre-pro-ET-1 protein [48]. Once pre-pro-ET-1 is generated, the 212amino-acid protein then undergoes a series of proteolytic modifications to ultimately
produce the mature ET-1 peptide [48]. Although post-translational mechanisms are
moderating ET-1 processing, large bodies of scientific reports indicate that ET-1
bioavailability is mainly directed by transcriptional regulation [4, 7, 19, 30, 41]. In
fact, the 6.8-kb spanning mammalian EDN1 can be transcriptionally governed by a
plethora of transcription factors, which can include hypoxia inducible factor-1, NF-κB,
activator protein-1, GATA-2, and c-Myc [22, 33, 40, 47]. Despite the welldocumented literature on the various stimuli driving EDN1 transcription, recognizing
and incorporating novel regulatory mechanisms, such as epigenetic regulation, into the
current ET-1 signalling paradigm will allow for improved understanding and
exploration of innovative therapeutics.
Based on our DNA methylation array, we were able to develop significant insights
into the glucose-induced methylation patterns present in the regulatory regions of
EDN1. Specifically, in HRECs, transient high glucose exposure sufficiently evoked
hypomethylation in the proximal promoter and 5’ UTR/first exon regions of EDN1. In
association, HG-treated HRECs also demonstrated a significant upregulation of ET-1
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mRNA at the 48-hour mark. Our findings, together with previous reports by Han et al
[18] and Feinberg and Vogelstein [11], highlight the importance of reduced
methylation at CpG dinucleotides in the regulatory regions of actively transcribed
genes. In fact, hypomethylated CpG sites in the promoter regions of an active gene
provide a greater degree of accessibility for transcription factors, which will then
facilitate transcription [9, 10]. Moreover, Vallender and Lahn [44] have previously
indicated that hypermethylation of CpG regions near intron 1 in Edn1 blocks the
binding site for the Sp1 transcription factor, which may contribute to Edn1 silencing in
mice fibroblasts [44].
Despite the presence of differential CpG methylation patterns across EDN1 between
NG and HG-treated HRECs, the administration of a global DNA demethylating agent
resulted in a significant induction of ET-1 mRNA in both HREC groups. This data is
in keeping with past reports in which similar trends for ET-1 mRNA were observed in
fibroblasts [44] and 1833-bone metastatic cells [27] following the complete inhibition
of DNA methylation. These findings, along with our study, suggest that DNA
methyltransferases have a critical role in regulating the transcriptional status of EDN1
and that pathological stimuli may be capable of altering the DNA methylating
properties of these enzymes in the EDN1 region.
In the context of histone modifications, globally inhibiting histone methylation
provoked a significant elevation of ET-1 mRNA in HRECs cultured with NG and HG.
The profound influence of histone methylation on EDN1 transcriptional activity has
been previously documented in renal epithelial cells, where aldosterone treatment
induced specific histone conformation changes that maintained active transcription in
the EDN1 promoter [41]. Although chronic hyperglycemic environments can facilitate
chromatin remodeling by histone methylation, histone acetylation can also
significantly contribute to chromatin state dynamics. Former studies from our
laboratory have indicated that the upregulation of histone acetyltransferase P300 can
cause increased EDN1 promoter activity [7], reduced expression of the class II histone
deacetylase SIRT1 [29], and increased expressions of ET-1 transcripts, extracellular
matrix (ECM) proteins and vasoactive factors [7, 14]. Collectively, our past and
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current findings demonstrate that pathologies like diabetes can cause unique
alterations in histone modification patterns, which may ultimately enhance EDN1
transcriptional activity and contribute to elevated ET-1 protein levels.
With lncRNAs greatly influencing the epigenetic landscape, we knocked down three
pathogenetic glucose-induced lncRNAs in HRECs in order to determine the impact of
lncRNAs on ET-1 transcript expression. Following siRNA-mediated knockdown of
ANRIL, MALAT1, and ZFAS1, significant reductions in ET-1 mRNA levels were
observed. These findings are consistent with the notion that lncRNAs can alter mRNA
transcription by controlling chromatin structure, transcription factors, nuclear
organization, or specific protein complexes [26]. To further support these notions, we
have previously shown that ANRIL can regulate VEGF (vascular endothelial growth
factor) through its direct interactions with P300 and PRC2 (polycomb repressive
complex 2; a histone methyltransferase) in HRECs [43]. Such a mechanistic study is
warranted for ET-1, so that the direct relationship between epigenetic mediator
proteins and EDN1 can be confirmed in a diabetic context. Moreover, we have
previously demonstrated the importance of microRNAs (miRNAs) 1 and 320 in ET-1
regulation [12, 13], miR-200b in mediating PRC2 and P300 activities [28, 35], and
miR-146a impacting ECM proteins [14], inflammatory cytokines [8], and endothelialto-mesenchymal transitioning [3]. Therefore, based on our past and current findings,
we collated the pertinent information and developed an epigenetic paradigm for ET-1
regulation (Figure 4.4).
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Figure 4.4. An illustration depicting the proposed epigenetic paradigm underlying ET-1
regulation in microvascular endothelial cells in diabetes. Based on our previous and current
findings, we propose this epigenetic model in which histone modifications, DNA methylation,
miRNAs, and lncRNAs can possibly influence EDN1 transcriptional activity and ultimately
ET-1 RNA and protein levels. Legend: GDP= guanosine diphosphate; GTP= guanosine
triphosphate; lncRNA= long non-coding RNA; miRs= microRNAs; P300= histone
acetyltransferase, H2A-H4= histones; RNA Pol. II= RNA polymerase II; and

=

acetylation. Reproduced from Endothelin-1 Regulation Is Entangled in a Complex Web of
Epigenetic Mechanisms in Diabetes (p. 8) by S. Biswas, B. Feng, A. Thomas, S. Chen, E.
Aref-Eshghi,

B.

Sadikovic,

and

S.

Chakrabarti,

2018,

Physiological

Research.

Incorporation of the emerging regulatory mechanisms into the previously understood
paradigm of ET-1 signalling becomes imperative in the development of novel ET-1based therapeutics. Although the findings from our study shed novel insights into the
epigenetic influence on ET-1 regulation, further mechanistic studies are necessary to
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elucidate the direct relationship between epigenetic mediator proteins and ET-1 in the
diabetes context.
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4.5 Appendix C: Endothelin-1 regulation is entangled in a
complex web of epigenetic mechanisms in diabetes
Supplemental Table 1. qPCR primers for human ET-1.
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Chapter 5 v

5

General Discussion

5.1 Thesis Summary
The body of work presented in this thesis describes studies of lncRNAs and their
molecular mechanisms in the pathogenesis of DR. Namely, through early microarray
analyses (GEO: GSE122189) involving NG and HG-cultured retinal ECs, I selected
two of the most prominent glucose-induced lncRNAs for further follow-up: MALAT1
and HOTAIR. In Chapter 2, I specifically examined the epigenetic implications of
MALAT1 in inflammation in DR using various cell culture and diabetic animal models.
I showed that the lncRNA MALAT1 is capable of impacting the expressions of
inflammatory transcripts (including TNF-α and IL-6) through its association with
histone methylation and DNA methylation processes. Similarly, I demonstrated in vivo
that the Malat1 gene is directly involved in DR pathogenesis, as the genetic ablation of
Malat1 in diabetic animals significantly alleviated diabetes-induced upregulations of
retinal inflammatory transcripts and prevented vascular leakage, compared to the
retinas from diabetic animals with a wild-type background. Furthermore, I also alluded
to the potential clinical significance of MALAT1 in human DR, with distinct
differences for MALAT1 existing in the vitreous fluid between diabetic patients with
PDR and non-diabetic patients without diabetes.
After establishing the relationship between MALAT1 and inflammation, I wanted to
investigate whether lncRNAs are linked to other critical pathogenetic processes in DR,
such as angiogenesis. Therefore, based on our microarray findings and previous
literature in cancer [1, 2], I wanted to delineate whether the lncRNA HOTAIR can
similarly mediate angiogenic processes in DR, which was the focus of Chapter 3.
Indeed, in vitro and in vivo experiments involving siRNA-mediated knockdown of
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HOTAIR demonstrated that this lncRNA could directly impact the expressions of
several angiogenic cytokines, as well as critical epigenetic and DR-related molecules.
HOTAIR was also shown to be involved in glucose-induced mitochondrial and
oxidative DNA damage, while mechanistic-based experiments further illustrated that
HOTAIR may be regulating the transcriptional status of certain angiogenic genes
through its association with epigenetic RNA-binding proteins, including histone
methyltransferases, histone acetyltransferases and RNA polymerase II. Moreover, I
established that DNA methylation mechanisms are also implicated in the regulation of
HOTAIR and its downstream targets. Extending my in vitro findings, I discovered that
HOTAIR RNA levels are specifically elevated in the vitreous fluid and serum of
diabetic patients with PDR, which further allude to the biological significance of
lncRNAs in human DR.
In Chapter 4, I examined the interrelationships shared between epigenetic mechanisms
and specific molecular alterations in DR. As such, using HRECs, I explored the
implications of DNA methylation, histone methylation, and lncRNAs in the regulation
of endothelin-1 (ET-1), a well-documented molecule that is dysregulated in diabetic
complications. My findings indicated that HG environments could induce
hypomethylation patterns in the promoter regions of ET-1 (EDN1), while global
blockade of DNA or histone methyltransferases could further augment glucoseinduced elevations of ET-1. In addition to our findings, siRNA-mediated knockdown
of certain pathogenetic lncRNAs also altered the expressions of ET-1 transcripts,
which ultimately confirmed the presence of an epigenetic axis in the regulation of ET1.
Taken together, this work has uncovered a novel epigenetic paradigm involving an
intricate web of epigenetic mechanisms that regulate glucose-induced transcription of
DR-associated molecules in important pathological processes (inflammation and
angiogenesis).
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5.2 LncRNAs: Missing Pieces of the Epigenetic Puzzle in
DR?
There is no doubt that the existing molecular network is complex. We know that under
homeostatic conditions, cellular mechanisms are carried out in a very coordinated
manner. However, in the event of chronic hyperglycemia, the activities of several
genes go awry, which significantly alter the spatial and temporal kinetics of various
signalling pathways and consequently promote damaging cellular processes.
Interestingly, several studies have made it evident that damaging cellular events (such
as the generation of oxidative stress) can still mediate the persistence of diabetic
vascular complications even after glucose normalization—this is known as ‘metabolic
memory’ [3-8]. Epigenetics, which refer to mechanisms that modify the expression of
genes without changing the underlying nucleotide composition, is an attractive field of
study underlying metabolic memory, since these mechanisms have been critically
implicated in diabetes [9-11]. Epigenetic mechanisms include histone modifications,
DNA methylation, and the activity of non-coding RNAs and as discussed before,
several lncRNAs can exert their functionalities through these epigenetic mechanisms
in various pathologies. Considering the diverse types of epigenetic mechanisms
present, very few studies exist that take into consideration the complex crosstalk
between lncRNAs and other epigenetic mechanisms in the pathogenesis of DR.
Therefore, in my work, several experimental approaches were carried out in order to
provide some insights into this dynamic epigenetic network and these findings, along
with observations from current literature, will be discussed below.

5.2.1 Crosstalk between lncRNAs and DNA methylation
Considered one of the earliest discovered epigenetic mechanisms [12], DNA
methylation involves the interactions between two opposing enzymes that facilitate the
methylation status of cytosine residues in CpG dinucleotides: either through the
addition (via DNA methyltransferases; DNMTs) or removal (via DNA demethylases)
of methyl groups [13]. Furthermore, genomic regions that contain a high frequency of
CpG dinucleotides are known as CpG islands (CGIs), which reside in the
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regulatory/promoter regions of genes, and the CGIs can ultimately determine the
transcriptional activity of a gene based on its degree of methylation [13, 14]. For
instance, promoter CGIs that are hypermethylated are associated with gene silencing,
while conversely hypomethylation is associated with gene activation [13, 14]. Indeed,
in recent years, the impact of DNA methylation has been documented in DR, where
previous reports suggest that hyperglycemia can evoke distinct methylation patterns in
the promoters of miRNAs [15] and several DR-related genes (such as TNF and MMP9) [16-18], which further the progression of DR. Adding to these results, findings from
my MALAT1 and HOTAIR studies demonstrate for the first time that reciprocal
relationships exist between lncRNAs and DNMTs in the regulation of specific
inflammatory and angiogenic mediators during DR pathogenesis (Chapters 2 [19] and
3). In fact, the knockdown of MALAT1 or HOTAIR prevented glucose-induced
elevations of DNMTs in HRECs, while blocking the actions of DNMTs (through
siDNMT1

or

pan-DNMT

inhibitors)

exacerbated

glucose-induced

lncRNA

expressions and also evoked differential expressions of various downstream targets of
HOTAIR and MALAT1. These results suggest that both DNMTs and lncRNAs actively
participate in the transcriptional regulation of several genes under hyperglycemic
environments. In support of our notion, previous reports in colon cancer [20],
myogenesis [21], and neural differentiation [22] have revealed that certain lncRNAs
can regulate gene expressions and DNA methylation in biological or pathological
processes through their potential association with DNMTs. For example, using ChiRPSeq (Chromatin Isolation by RNA purification), Merry et al [20] demonstrated that the
induction of the lncRNA DACOR1 (DNMT1-associated Colon Cancer Repressed
lncRNA 1) could enhance DNA methylation at multiple loci without affecting
DNMT1 protein levels in colon cancer cells [20]. Following additional mechanisticbased experiments, the authors concluded that DACOR1 could indirectly regulate the
methylome through its influence on DNMT1 genomic occupancy and/or its ability to
govern the levels of certain substrates (Cystathionine β-synthase) that are required for
the generation of key methyl donors utilized by DNMTs. Nevertheless, similar
mechanistic studies are warranted to further solidify the role(s) of DNMT-associated
lncRNAs in the context of DR. As well, it still remains to be determined whether the
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inhibition of DNA methylation through siDNMT1 or pan-DNMT inhibitors alters
neighbouring (or distal) genes, which in turn may substantially impact the
transcriptional activity of MALAT1 and HOTAIR.
We further interrogated the methylation status of individual CpG sites across
the MALAT1 and HOTAIR genes in both NG and HG-cultured HRECs using a DNA
methylation array. Interestingly, we observed that transient glucose treatments (48
hours) did not significantly alter the methylation status of several CpG sites across
the MALAT1 and HOTAIR gene. One possible explanation for this result may be
attributed to the stable epigenetic nature of DNA methylation marks during
hyperglycemic stress. For example, a previous report has documented that active
global DNA methylation changes can take place prior to the physiological elevation of
glucose levels in humans [23]. Based on this, although we conducted our DNA
methylation experiment at one particular time-point, it would be intriguing to see
whether initial hyperglycemic treatments can provoke persistent, long-lasting changes
in the methylation status of CpG sites across the MALAT1 and HOTAIR genes.
Constructing such an in vitro cell culture model involving multiple time-points and
alternating glucose treatments will provide unique insights behind metabolic memory
and the regulatory nature of DNA methylation on the biogenesis of lncRNAs during
the progression of DR.

5.2.2

The Interplay between lncRNAs and Histone

Modifications
Another fundamental epigenetic mechanism involved in the coordination of gene
expression is histone modifications. Histone-modifying enzymes, including histone
demethylases,

histone

methyltransferases,

histone

deacetylases

and

histone

acetyltransferases, coordinate their actions by chemically modifying particular amino
acid residues within histone proteins (H2A, H2B, H3, and H4), which govern the
overall conformation of the chromatin and its accessibility to transcription factors for
gene transcription at that modified region [24-28]. For example, an open configuration
(euchromatin) can be induced by histone acetyltransferases through the acetylation of
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lysine residues, which generally leads to active gene transcription [24-26]. Conversely,
depending on the degree of methylation and the specific residue, histone
methyltransferases facilitate the methylation of lysine residues that can drive gene
silencing (a heterochromatin state) or activation [27, 28]. Changes in histone
modifications have been extensively reported in multiple cancers [29] and in recent
years, several studies are also documenting the presence of aberrant histone
modifications in diabetic environments [30-36]. Despite the breadth of information
available, few studies have addressed the involvement of histone modifications on
lncRNA-mediated mechanisms in DR. In fact, presently, only studies from our
laboratory have addressed the influence of histone methylation and acetylation
processes on lncRNAs in DR, which will be the topic of discussion in the paragraphs
below.
Polycomb repressive complex 2 (PRC2) is a multimeric histone methyltransferase
complex that catalyzes the tri-methylation of lysine 27 on histone 3 (H3K27me3), a
distinct chromatin mark linked with gene repression [37]. A previous report from our
laboratory demonstrated that the core components of PRC2 (EZH2, SUZ12, and EED)
were significantly augmented in HG-cultured HRECs and retinal tissues of diabetic
rats and mice, which were also accompanied by increased VEGF expressions and
reduced miR-200b levels (a negative regulator of VEGF) [38]. Interestingly, using
ChIP-qPCR analyses, HG-cultured HRECs exhibited increased H3K27me3 and
decreased RNA polymerase 2 associations in the promoter region of miR-200b when
compared to NG controls. Furthermore, administration of DZNep significantly
prevented HG-induced reductions of miR-200b, while VEGF RNA and protein levels
were dramatically decreased in parallel—suggesting that PRC2 can negatively regulate
miR-200b, while indirectly promoting the expressions of VEGF, in hyperglycemic
environments.
Another study from our laboratory indicated for the first time that lncRNAs are closely
connected with PRC2 functions in DR. Notably, the lncRNA ANRIL (antisense RNA
to INK4 locus) was shown to exhibit a pathogenetic phenotype in DR through its
augmented expressions in HRECs and retinal tissues following hyperglycemia [39].
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Moreover, retinal tissues from Anril knockout diabetic mice revealed depressed
expressions of Ezh2 and Eed RNA levels when compared to retinas from wild-type
diabetic animals. Similar observations were also reported in HG-cultured HRECs
following ANRIL silencing—confirming ANRIL’s direct impact on the EZH2 and EED
subunits of PRC2. On the other hand, administration of DZNep in HG-cultured
HRECs dramatically reduced both ANRIL and VEGF RNA expressions, which
suggests that a highly interactive network may exist between these molecules.
Potential binding interactions between ANRIL and PRC2 were further assessed by
RNA immunoprecipitation analyses, where it was demonstrated that HG could
promote strong binding associations between EZH2 and ANRIL. Of note, ANRIL also
shared a similar relationship with P300, which is a prominent histone acetyltransferase
involved in the regulation of several glucose-related genes [40-42]. Generally, HGinduced upregulations of P300 were corrected following ANRIL silencing in HRECs
and Anril knockout diabetic mice exhibited reduced retinal p300 levels compared to
retinas from wild-type mice. Interestingly, transfection with siP300 in HG-treated
HRECs did not alter ANRIL expressions [39].
Extending our ANRIL study, I demonstrated in my thesis that two other lncRNAs
(MALAT1 and HOTAIR) can also significantly influence PRC2 and P300 regulation of
target gene expressions in DR (Chapters 2 [19] and 3). Indeed, it was evident that
siRNA-mediated silencing of MALAT1 or HOTAIR is capable of significantly
preventing diabetes-induced increases of PRC2 components and P300, while the
inhibition of PRC2 (through DZNep or siEZH2) can evoke differential expressions of
these lncRNAs and their target downstream molecules. Moreover, strong binding
associations were apparent between histone modifying enzymes (i.e. EZH2 and P300)
and these two lncRNAs in HG environments. Interestingly, the knockdown of
MALAT1 was also shown to directly reduce protein expressions of EZH2 (Appendix
A, Figure S2C) in HG, while HOTAIR knockdown was capable of governing
methylation and acetylation statuses in the VEGF-A promoters following HG culture
(Figure 3.12). These results suggest that lncRNAs may be able to govern the
expressions of certain histone modifying enzymes in addition to influencing their
functional capabilities. Supporting our observations, previous reports have shown that

189

MALAT1 and HOTAIR can share direct regulatory relationships with histone
modifying enzymes [43, 44]. For instance, MALAT1 has been shown to detach EZH2
from binding with the HIV1-long terminal repeat promoter, subsequently removing
the PRC2-mediated H3K27me3 mark in this region and relieving epigenetic silencing
of HIV-1 transcription [43]. Similarly, HOTAIR can tether distinct RNA-binding
complexes and coordinate their targeting to chromatin for coupled histone
modifications on target genes. For example, PRC2 has been shown to directly bind to
the 5’ domain of HOTAIR, while the 3’ domain of HOTAIR binds to a demethylase
that mediates enzymatic demethylation of H3K4me2 (lysine-specific demethylase 1;
LSD1) [44]. Intriguingly, the knockdown of HOTAIR in primary foreskin fibroblasts
was shown to decrease the occupancy of SUZ12 and LSD1 in the proximal promoters
of HOXD genes [44]. Taken together, these findings allude to the potential abilities of
lncRNAs to form scaffolds or act as guides with certain chromatin-modifying enzymes
in diabetic environments. Further mechanistic-based studies are undoubtedly
warranted that closely examine the relationship between lncRNAs (such as HOTAIR
and MALAT1) and other key RNA-binding proteins in mediating the pathogenesis of
DR.

5.2.3

The Relationship Between lncRNAs and miRNAs

in DR: Friend or Foe?
Emerging as critical post-transcriptional regulators of gene expression [45, 46],
miRNAs are small ncRNAs (~22 nucleotides in length) that can bind to the 3’-UTR of
their target mRNAs, subsequently leading to mRNA degradation and/or inhibition of
protein translation [47]. Within the last decade, the implications of miRNAs have been
well identified in cardiovascular disease [48], cancer [49], neurodegenerative diseases
[50], and even DR [42, 51-54]. Although I did not examine the role of miRNAs in my
experimental work, emerging studies in DR are beginning to reveal a unique
relationship shared between miRNAs and lncRNAs, which will be briefly discussed
below.

190

Beginning with the lncRNA MIAT (myocardial infarction associated transcript), Yan
et al. have shown that this lncRNA can function as a molecular sponge/decoy that
sequesters miR-150-5p, which subsequently promotes the expression of its target
mRNA (VEGF) in DR [55]. Using bioinformatics, the authors first identified predicted
binding sites for miR-150-5p on its targets, VEGF and MIAT. These predictions were
then confirmed in vitro through luciferase assays, which demonstrated that miR-1505p directly targeted VEGF and MIAT transcripts. Additional mechanistic-based
experiments involving miR-150-5p mimics and MIAT overexpressing ECs suggested
that a dynamic interplay exists between MIAT, miR-150-5p, and VEGF in the critical
functions of ECs during HG stress. Specifically, VEGF expressions were significantly
upregulated in MIAT-overexpressing cells, while VEGF expressions were markedly
reduced with increasing levels of miR-150-5p in MIAT-overexpressing cells. In a
similar manner, gradual increases in MIAT were capable of restoring miR-150-5pinduced downregulations of VEGF in miR-150-5p-overexpressing ECs, further
alluding to the regulatory crosstalk between these molecules. Other studies have also
alluded to miRNAs as potential negative regulators of lncRNAs and mRNAs. For
instance, miR-185-5p was shown to directly regulate the lncRNA RNCR3 (retinal noncoding RNA 3) and the mRNA Krüppel-like Factor 2 (KLF2) [56]. In fact, miR-1855p mimics decreased the expressions of RNCR3 and KLF2 and subsequently
contributed to reduced viability and proliferation in chorioretinal ECs. Moreover,
inverse regulatory relationships have also been documented for the lncRNA MEG3
and miR-34a in retinal epithelial cells [57]. Accordingly, HG environments were
shown to promote the upregulation of miR-34a and downregulations of MEG3 and a
histone deacetylase (SIRT1), while the overexpression of MEG3 in these cells
dramatically reversed HG-induced effects. Interestingly, using luciferase assays and
mimics and inhibitors for miR-34a, the researchers confirmed that MEG3 could
positively regulate SIRT1 by directly sponging its negative regulator, miR-34a. With
the consequent downregulation of miR-34a, MEG3 overexpression was shown to
reduce HG-induced apoptosis and inflammation. Based on these reports, future studies
should continue investigating the dynamic crosstalks shared between lncRNAs,
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miRNAs and their target mRNAs, as these findings will provide significant insights
into perturbed regulatory networks that are implicated in the pathogenesis of DR.

5.3 Limitations and Future Directions
Although the findings generated from my experiments highlight the critical regulatory
capabilities of lncRNAs in DR, one must recognize that inherent limitations oftentimes
exist in experimental models. Beginning with my in vitro experiments, HRECs were
grown in monolayers using culture flasks and plates, which constitute a twodimensional (2D) cell culture model. As such, it is likely that ECs organized in a 2D
culture system may not accurately recapitulate the bioactivities of ECs in an in vivo
environment, since differences in motion and migration, extracellular matrix
composition, and mechanical responses exist between the structure of ECs in 2D
culture and in vivo environments [58]. These differences may also contribute to
variations in gene expressions. Therefore, due to these reasons, it would be interesting
to implement novel 3D (three-dimensional) cell culture models that could accurately
model the composition of blood vessels in vivo.
Furthermore, ECs were the primary cell-type used in my experiments because these
cells are the earliest (and primary) targets of diabetes-induced tissue damage.
Considering that the retina is comprised of multiple layers of cells, simply focusing on
ECs may not provide a complete picture of the molecular events transpiring across the
retina during DR. Thus, future experiments should examine the expressions of
lncRNAs in other retinal cell types. For example, in a study by Liu et al., the
knockdown of MALAT1 was shown to prevent capillary degeneration, microvascular
leakage, retinal inflammation, as well as diabetes-induced retinal pericyte loss [59]—
alluding to potential molecular crosstalks shared between various cell types.
Interestingly,

recent

evidences

have

also

demonstrated

that

inflammatory

environments can induce cerebrovascular ECs to shed endothelial-derived exosomes,
containing bioactive molecules (i.e. miRNAs), which can subsequently modulate
pericyte responses [60]. With exosomal lncRNAs being reported in various
pathologies [61], it would be logical to explore the potential regulatory functions and
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transport pathways of these extracellular vesicles in cell-to-cell communication (i.e.
between retinal ECs and pericytes) during DR pathogenesis.
Although we examined specific subsets of diabetes-related molecules across our
studies, there is a possibility that we may have missed out on other critical molecules
regulated by these lncRNAs. As such, future experiments should continue to examine
the global transcriptome and methylome, using high-throughput sequencing methods,
after the administration of epigenetic inhibitors (from DZNep to 5-aza-dC) and/or
lncRNA-specific siRNAs in HRECs. Such findings, through ChIP-Seq, RIP-Seq or
even DNA methylation arrays, can enable researchers to further elucidate the effects of
these compounds on the epigenome in its entirety. Similarly, with the optimization of
next-generation sequencing technologies in the last few years, it would be fruitful to
perform single-cell RNA-seq using diabetic retinal tissues, as this information will
help us understand whether discrete and abundant expressions for lncRNAs exist
among individual cells.
Furthermore, in our studies, we examined very specific time-points across our cell
culture and animal models, which impose its own limitations, as we are unable to
examine the effects of metabolic memory on transcriptional regulation and the longterm consequences of inhibiting pathogenetic lncRNAs in the retina of diabetic
animals. For instance, in our diabetic animal models, the one and two-month endpoints were selected because early retinal aberrations can be detected during this time.
Of course, if graduate degrees did not possess certain time constraints, later end-points
for diabetes could have definitely been examined using the animal models presented in
Chapters 2 and 3. Regardless, future work should definitely investigate the long-term
implications of Malat1 knockout or Hotair knockdown in the retinas of diabetic
animals. Moreover, unlike Malat1, we were unable to use a global Hotair knockout
mice model because the targeted deletion of Hotair was shown to cause homeotic
transformation of the spine and malformation of metacarpal-carpal bones in mice [62].
An alternative solution to this limitation could be through the use of a Cre/loxP system
to generate a retinal tissue-specific or inducible knockout of HOTAIR [63].
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Other limitations in my studies include not examining histone and DNA demethylases,
histone deacetylases, histone phosphorylation, histone ubiquitination and other histone
modifications. Future studies should definitely investigate these mechanisms, as
potential crosstalks could exist between different histone modifications and may
uncover novel interactions shared between lncRNAs and other chromatin-modifying
complexes. Furthermore, in addition to the double-stranded siRNAs used in our
MALAT1 and HOTAIR knockdown experiments, future investigations should also
consider alternative approaches that ensure complete gene knockout or stronger
knockdowns. For example, CRISPR/Cas9 knockout strategies could be used in
HRECs to ablate the lncRNAs of interest, while other novel antisense molecules, such
as locked nucleic acids (i.e. GapmeRs), or short hairpin RNAs (shRNAs) can also be
used to target the lncRNAs of interest and obtain strong knockdowns in retinal ECs.
Lastly, in regard to our clinical experiments, further large-scale investigations are
warranted to determine the complete clinical validation of MALAT1 and HOTAIR as
potential prognostic or diagnostic markers for DR. As such, larger sample sizes with
appropriate power calculations, stringent cut-off criteria and determination of
clinically meaningful endpoints will be required to truly understand the clinical
significance of these lncRNAs in DR.

5.4 Concluding Remarks
In recent years, the rapid advent of genomic technologies has drastically improved our
capacity to survey the intricate complexities of the genomic landscape. What were
once considered ‘junk DNA’ or ‘dark matter’, lncRNAs (and other ncRNAs) are now
proving to be dynamic regulators of gene expression, as these versatile RNA
molecules can interact with different layers of regulation: epigenetic, transcriptional,
and post-transcriptional. In this thesis, I have discussed two lncRNAs and their
regulatory implications in the pathogenesis of DR.
With new, unannotated lncRNAs frequently being discovered, added efforts must be
taken to functionally characterize these lncRNAs in the field of diabetes, especially
DR. Additional mechanistic understanding of lncRNAs will allow us to appreciate the
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dynamic regulatory networks behind these RNA molecules in pathophysiological
processes, which will further create novel avenues for research and drug discovery in
DR. As well, from the lncRNAs I have examined in my thesis, it is quite evident that
these lncRNAs co-exist in a highly coordinated molecular network. Therefore, going
forward, future studies should consider implementing integrated experimental
approaches. Such approaches, and with the help of appropriate computational and
database-driven tools, will help pinpoint potential lncRNA regions in disease-specific
contexts. Once the target lncRNA is identified, subsequent gain-of-function and lossof-function experiments will further provide in-depth understanding of the lncRNA
functionalities. Nevertheless, given the pervasive nature of transcription throughout
the mammalian genome, it is not surprising that other new ncRNA groups (circular
RNAs, snoRNAs, and piwi-interacting RNAs) are also beginning to emerge as critical
players in diabetes [64-66], which truly adds new dimensions to this perplexing
transcriptional paradigm and require further consideration as well.
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